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Abstract  
Curcuminoids are highly bioactive polyketide chemicals produced in the rhizomes of the turmeric 
plant (Curcuma longa). In addition to giving turmeric powder its distinctive yellow colour and 
flavour, these molecules elicit a plethora of medicinal effects. This project aimed to biosynthesize 
curcuminoids and their derivatives using the metabolic engineering of Baker’s yeast 
(Saccharomyces cervisiae) and tobacco (Nicotiana benthamiana). Phenylpropanoids, sustainably 
derived from bio-refinery waste, were to be used as starting materials. To convert 
phenylpropanoids into curcuminoids three enzymatic steps were needed: this involved the cloning 
and expression of 4-coumarate CoA ligase 5 (4CL5) from Arabidopsis thaliana and diketide-CoA 
synthase (DCS) and curcuminoid synthase 1 (CURS1) from C. longa. Protein extract from yeast 
expressing 4CL5 was able to convert both natural and non-natural phenylpropanoids to their 
corresponding phenylpropanoyl-CoA esters. However, protein extracts from yeast transformed 
with either DCS or CURS1 did not yield the corresponding enzyme activity. Furthermore, it was 
concluded that tobacco was not an optimal chassis for curcuminoid production as both 
phenylpropanoid substrates and curcuminoid products were metabolised by endogenous enzymes 
in the leaf tissue. 
Despite their bioactivities, curcuminoids are poorly bioavailable reducing their medicinal 
potential. Regiospecific glycosylation, performed by UDP-glycosyltransferases (UGTs), is a 
known strategy to improve a molecule’s solubility. Diglucosylated curcuminoids are 10 000 times 
more soluble in water than the aglycone. Using metabolomics and 14C radiolabelling assays C. 
longa was investigated as a source of novel curcuminoid UGTs. No evidence of curcuminoid 
glycosylation or other bio- conjugation was found and it was concluded that, like the ginger plant, 
C. longa is likely to sequester curcuminoids within sesquiterpene oil droplets. Instead, CaUGT2, 
a UGT from Catharanthus roseus known to glycosylate curcuminoids, was heterologously 
expressed in S. cerevisiae. Previous work with CaUGT2 by Kaminaga et al.1, gave only a 4 % 
yield of curcumin monoglucoside in E.coli. In this project, when yeast culture expressing 
CaUGT2 was fed curcumin, both mono- and diglucosides were produced. The bioreaction was 
successfully scaled up 200 times from a shake flask to a 5 L bioreactor and was estimated to 
produce 32 mg L-1 curcumin monoglucoside (60 % yield). To date, this is the best performing 
biosynthetic production of curcumin glucosides and with optimisation is expected to surpass 
chemical methods. 
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Chapter 1. Introduction 
For thousands of years, humans across the globe have relied upon plants and the diverse range of 
chemicals they produce as part of everyday life. Not only do plants form an intrinsic part of our 
diet, clothing and building materials, but they can also act as remedies to help cure ailments when 
applied as a poultice or sipped as an infusion. In the first century AD modern pharmacology 
began; Dioscorides, a Greek physician and botanist wrote the first pharmacopeia, De Materia 
Medica, a vast encyclopaedia of the medicinal qualities of plants he encountered whilst travelling 
with the Roman army. However, there is evidence that plants have been used medicinally for 
much longer, with records indicating that Neanderthals, 60 000 years ago, used plants for their 
therapeutic properties2, derivatives of which are still used today. According to the World Health 
Organisation, 80 % of the world’s population rely upon medicines derived from plant sources 3 
and approximately a quarter of all pharmaceuticals used today are still sourced from plants 4. 
The medicinal properties of plants are mainly due to their secondary metabolite constituents. 
Kossel was the first to define these metabolites, over a century ago, as being distinct from the 
function of primary metabolites involved in basic life functions such as respiration, cell growth 
and reproduction. Secondary metabolites, or natural products, are often less than 1 % of the total 
carbon and function to allow plants to adapt to their environment, having roles in pathogen 
protection, anti-feedants, UV protection and pollinator attraction 5. They are classified into 
different types depending on the chemical structures, related starting materials and functional 
groups; these include polyphenolics, alkaloids and terpenoids 5. Humans have found many uses 
for this diverse range of bioactive chemicals, from common pain relief, such as aspirin to licit and 
illicit opioid drugs.  
For mankind to make use of the plethora of plant secondary metabolites, they need to be readily 
available; this is often limited by the small quantities synthesized and extractable from the plant. 
Furthermore, some plants originating from certain ecosystems do not readily grow in the 
environments where they are needed. Therefore, using retrosynthetic chemistry, organic chemists 
try to decipher which sequence of chemical reactions are necessary to produce such intricate and 
potent molecules. One of the most notable examples of retrosynthesis of a plant natural product 
was the total synthesis of taxol, an anticancer agent from Pacific yew (Taxus brevifolia), in which 
two research groups competed to be the first to complete the total synthesis 6,7. Although many 
total syntheses like this have been successful in producing plant natural products, they are often 
protracted, economically impractical and low yielding. An attractive alternative is to utilise the 
plant system itself, creating elite cultivars or culturing plant cells. Another alternative is to use 
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metabolic engineering to reconstruct the plant biosynthetic pathway in a chassis organism with 
the objective to develop a bio-based production system that is amenable to product extraction. 
This thesis will focus upon the bioactivity, biosynthesis and modification of plant chemicals, in 
particular, curcuminoids. 
  Biosynthesis of plant natural products 
Although organic chemistry offers a wide range of chemical conversions, and a vast array of total 
syntheses exist for many complex plant natural products, the yields are often low. Additionally, 
chemical syntheses often rely on unsustainable starting materials from petroleum and expensive, 
toxic catalysts. In comparison, enzymes can frequently use naturally derived substrates from 
waste or sustainable sources. Utilising enzymes in biosynthetic reactions also allows milder 
reaction conditions and produces fewer side products, meaning the target compound is easier to 
extract and purify. Enzymatic syntheses also allow the reduction of catalytic steps as enzymes 
often target one specific functional group, avoiding the need for protection and deprotection. 
However, enzymes can sometimes produce a mixture of isomers and epimers which compromises 
biological activity leading to a decrease in interest from pharmaceutical companies 8. 
Both endogenous and recombinant enzymes can be utilised through metabolic engineering to 
produce the desired target molecule. In 1991, James Bailey defined metabolic engineering as ‘the 
direct improvement of production, formation, or cellular properties through the modification of 
specific biochemical reactions or the introduction of new ones with the use of recombinant DNA 
technology’ 9. The Synthetic Biology Roadmap for the UK defines synthetic biology as ‘the 
design and engineering of biologically based parts, novel devices and systems as well as the 
redesign of existing, natural biological systems’ 10. There are multiple biosynthetic platforms 
which are amenable to synthetic biology and can be metabolically engineered for the production 
of natural products, including in vivo and in vitro biosynthesis in micro-organisms, plant cell 
culture and plant biotransformations. To date, substantial efforts have been made to produce 
multiple classes of natural products, their intermediates and novel analogues such as terpenes, 
flavonoids, and alkaloids in a range of host organisms 11. This project will focus upon the 
biosynthesis of pharmaceutical plant natural products using microbial and plant platforms. 
 Microbial biosynthesis of plant natural products 
Compared to field grown plants or plant cell culture, microorganisms can be grown quickly and 
are easily genetically manipulated. Microorganisms can be used in three ways to produce or 
modify plant natural products. Firstly, biotransformations can be carried out using endogenous 
enzymes. Secondly, using genetic engineering, heterologous enzymes can be expressed in the 
17 
 
microorganism, allowing previously impossible biosynthetic reactions. Thirdly, the 
microorganism can be used to produce enzymes (endogenous or heterologous) which can be 
extracted on scale and utilised in in vitro bioconversions. These three approaches will be 
considered in the context of in vivo and in vitro reactions, with emphasis upon Baker’s yeast 
(Saccharomyces cerevisiae).  
1.1.1.1 In vivo biosynthesis of natural products 
If performing in vivo biosynthesis, it is important to consider the host organism and how the 
substrates and products interact with it 12. Is the substrate taken up by the cell, is it degraded or 
utilised by an endogenous pathway, what by-products might be formed, is the product 
sequestered? Whole-cell biocatalysis contains two main categories, fermentation and 
biotransformation, depending on whether the starting material was part of native or non-native 
metabolism 13. In the early 1990s, the first industrial scale whole cell biocatalyses relied upon 
native enzymes to convert non-native substrates, such as the conversion of methyl substituted 
heteroarenes to the corresponding carboxylic acids by Pseudomonas putida 14. Another successful 
strategy relied on knocking-out certain native genes, resulting in accumulation of endogenous 
pathway intermediates such as the synthesis of long chain dicarboxylic acids from fatty acids in 
Candida yeast strains 15. Although successful, the scope of utilising native pathways is limited by 
the discovery and natural abundance of industrially relevant reactions.  
An increase in the ease of DNA manipulation and the popularity of systems and synthetic biology 
has seen a growth in de novo heterologous biotransformations. As genes from different organisms 
can be combined, it means the products are not limited by natural pathways and therefore allows 
a broader range of substrates 16. It also means retrobiosynthetic molecule design can be applied 
and longer biosynthetic pathways have been able to be explored, including the synthesis of plant 
natural products 17. There are a range of microbial hosts in which plant biosynthetic pathways 
have been heterologously expressed, however research has mainly focussed around S. cerevisiae 
and Escherichia coli due to their well-known physiology, biochemistry and ease of use in the 
laboratory. E. coli has a relatively simple metabolism, high genetic tractability and grows quickly. 
Whilst similar to E. coli, S. cerevisiae is eukaryotic offering larger cells with intracellular 
organelles, higher tolerance to pH fluctuations and the ability to perform post-translational 
modifications. Replicating complex biosynthetic pathways requires considered cloning 
approaches, with promoter and terminator strength and gene expression being finely tuned. Using 
typical cloning and transformation methods, can often prove time consuming and unproductive, 
therefore significant efforts are being made to create automated, one-pot DNA construction 
methods utilising homologous recombination in S. cerevisiae 18,19. Coupling computational and 
systems biology to metabolic engineering has allowed the production of improved strains which 
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can efficiently channel carbon flux towards the desired product. For example, the engineering of 
gene deletions and network modifications in E. coli to increase the intracellular concentration of 
the intermediate malonyl-coenzyme A (CoA), increased recombinant naringenin production by 
660 % 20. Although there are many strategies to increase production of phytochemicals in these 
recombinant microorganisms, very few have resulted in commercial processes due to low yields. 
Biosynthesis of natural products using S. cerevisiae 
Baker’s yeast has been used for centuries in traditional fermentation processes such as making 
bread, beer and wine and is now the organism of choice for synthetic biology and industry as a 
metabolically engineered ‘cell factory’. In addition to S. cerevisiae’s robustness to harsh 
conditions its GRAS (generally regarded as safe) status awarded by the FDA (U.S. Food and Drug 
Administration) has made it preferential to E. coli in the industrial fermentation arena, despite 
generally giving lower yields 21. This is why yeast is so often chosen for metabolic engineering; 
from bioethanol production 22, to synthesising secondary metabolites of greater purity than can be 
isolated naturally, such as vanillin and resveratrol 23,24. Nielsen and Hong 25 evaluate the potential 
of S. cerevisiae as a synthetic biology chassis by reviewing its extensive use in industry and the 
numerous patents that have been recently filed for the production of biofuels, proteinaceous drugs 
and bulk and fine chemicals.  
The most notable example of heterologous production of a plant biosynthetic pathway in a 
microorganism is that of the sesquiterpene lactone endoperoxide artemisinin. Artemisinin is 
produced by the Artemisia annua L. plant and exhibits excellent antimalarial activity towards the 
multi-drug-resistant parasite Plasmodium falciparum 26. As part of a large ongoing project by 
Keasling and co-workers they first used E. coli to produce artemisinin, then moved to Baker’s 
yeast as it could tolerate higher product concentrations 27,28. This required the recombinant 
expression of thirteen genes to allow the conversion of acetyl-CoA to dihydroartemisinic acid 29 
or artemisinic acid 30, but required a final photochemical reaction step to yield artemisinin 31. At 
the time, artemisinin itself could not be biosynthesized due to the last enzymatic step being 
unidentified in A. annua. Therefore, this process is a good example of a ‘hybrid’ strategy in which 
biological limitations can be overcome by chemistry. To increase yields, the mevalonate pathway 
was up-regulated in yeast and FPP consumption was down-regulated and the heterologous A. 
annua pathway was coupled to the native terpenoid metabolism via farnesyl pyrophosphate. After 
optimisation, the process could yield 25 g L-1 artemesinic acid 27. This was a fantastic 
biotechnological feat, hailed as a synthetic biology triumph, showcasing the potential of natural 
product biosynthesis 28. In combination with Amyris Biotechnologies the pharmaceutical 
company Sanofi began industrial production of artemisinin theoretically allowing the annual 
production of 50– 60 tons of artemisinin per year, a third of the global demand. However, it is 
one hurdle to produce a proof-of-principle biosynthetic pathway, it is another to be able to make 
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the procedure economically viable and competitive. The cost of the photochemical reaction 
needed to produce artemisinin resulted in the costs Sanofi’s semi-synthetic artemisinin being 
much higher than that of the naturally extracted product, $350– 400 per kilogram compared to 
$250 per kilogram 32. Therefore, in 2015, Sanofi did not produce any artemisinin and the 
manufacturing plant is now closing 32. Nonetheless, being the first effort of its kind, there is still 
much to learn and develop, and metabolic engineering and synthetic biology production of fine 
chemicals is still high upon academic and industrial interests. 
The success of production of the artemisinin precursor artemisinic acid at such high 
concentrations in yeast, spurred others on to recreate large secondary metabolic pathways in yeast. 
One recent example is the production of natural and semisynthetic opioids, by Smolke’s 
laboratory 33,34. By expressing genes from Papaver somniferum and Pseudomonas putida M10, 
and optimising co-substrate availability and gene copy number, they were able to produce opioid 
titres of up to 131 mg L-1. Nonetheless, P. somniferum is commercially grown around the world 
for approximately $250 per kilogram 35, meaning much work is needed before the biosynthesis of 
morphine can rival extraction from the plant. It is important to remember that, although such 
proof-of-concept studies have great potential, there remain challenges involving optimisation and 
scale-up before the biosynthesis of secondary metabolic chemicals become a viable bioeconomy. 
It is therefore worth noting, that whilst the above are excellent examples, microbial biosynthetic 
efforts would be more beneficial if applied to secondary metabolites that are recalcitrant to 
extraction from commercially grown plants.  
 
One way in which metabolic engineering is being used to improve biosyntheses, is the extensive 
modification of endogenous metabolism to allow an increase in endogenous intermediate 
availability and therefore an increase in final product yield 25. Nielsen 36 and others 37,38 have 
applied rational engineering to create yeast strains capable of producing high levels of important 
precursors such as acetyl-CoA and malonyl-CoA. By adopting push-pull-block systems, in which 
upstream endogenous genes are over expressed, heterologous genes are over expressed and 
downstream genes are knocked out they managed to increase the intracellular pools of these 
precursors allowing greater substrate availability for heterologous enzymes. These high 
producing precursor strains have been shown to be valuable in the production of terpenoids, such 
as α-santalene, an important constituent of sandalwood oil, and fatty acid ethyl esters increasing 
yields four and three times, respectively 37,38. 
1.1.1.2 In vitro biotransformations of natural products 
Enzymes, heterologous or endogenous, can be extracted from a host and used in in vitro 
biocatalysis or transformations. In comparison to in vivo catalysis, this allows the isolation of 
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metabolic pathways and use of non-conventional substrates which may be toxic to whole cells 17. 
It also reduces competition with endogenous reactions, incidence of side reactions and production 
of derailment products. Furthermore, enzyme subcellular localisation and transport issues of the 
substrate and product are negated. However, in vitro systems often require the production and 
purification of large quantities of stable and active enzyme, in addition to the need for expensive 
cofactors such as NADPH or CoA. 
As in vitro systems are often a single reaction step, the enzymes that lend themselves to this 
process are often tailoring enzymes which decorate the core molecular structure enhancing the 
complexity. They include transferases, halogenases, oxidoreductases and cyclases. 
Glycosyltransferases are common tailoring enzymes used for glycodiversification. An interesting 
example of in vitro chemical biosynthesis and the use of glycodiversification is exhibited by the 
one-pot synthesis of thymidine diphosphate-D-ravidosamine, a potent antitumour compound, 
using five enzymes 39. 
In vitro biosynthesis offers the opportunity to combine enzymatic reactions with chemical 
synthesis, known as cooperative catalysis. It has proven to be especially useful for the production 
of chiral chemicals where an enantioselective enzyme can be used in combination with a chemical 
reagent. Although cooperative catalysis reaction development can be difficult due to mutual 
deactivation of the catalyst and enzyme, there are examples of this being overcome. Using a 
biphasic solvent system of dioctyl phthalate and buffer, a Ru(I) cross-metathesis catalyst and a 
cytochrome P450 enzyme from Bacillus megaterium allowed the selective epoxidation of cross-
metathesis products at a greater yield than the two separate reactions 40. 
As is apparent, in vitro biosynthesis offers a great opportunity for powerfully combining chemical 
syntheses with biological reactions. It is expected that as strategies improve and knowledge is 
gained about their synergistic effects, cooperative catalysis and in vitro biosynthesis could be 
powerful tools for biotransformations, allowing diversification of natural products to produce 
novel analogues. 
 Natural product biosynthesis using plant platforms 
Plants as biosynthetic chassis have one major advantage over other systems, in that they can use 
atmospheric CO2 and sunlight as starting materials. Therefore, plant metabolic engineering is 
being exploited to a range of ends from CO2 fixation to protein production, as well as chemical 
biosynthesis. Compared to microbial chasses, plant platforms offer multiple tissue types and 
intracellular organelles. This can be advantageous, but can also complicate the localisation of 
heterologous protein expression and complicate metabolite analysis 41. This highlights the 
importance of considering transporters and membrane channels in plant metabolic engineering. 
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Compared to microbial metabolic engineering, plant metabolic engineering is still in its infancy. 
Utilising plants to produce natural products and important biochemical intermediates is being 
studied on two fronts: plant cell culture and whole plant systems.  
Plant cell culture in some aspects is analogous to producing chemicals in eukaryotic microbial 
hosts. Both involve cell suspensions within a bioreactor and both can exploit endogenous 
biosynthetic pathways or support heterologous enzymes. Plant cell cultures are generated from 
the dedifferentiation of actively dividing root, shoot or embryo tissue to generate mitotically 
reactivated cells 42. Plant cell cultures that rely on endogenous biosynthesis require the whole 
pathway to be expressed in the cultured cells, for example, the production of pharmaceuticals by 
Catharanthus roseus cell suspension 43. Although almost two decades ago, the greatest successes 
have been the production of rosmarinic acid and taxol using Rosmarinus oficinalis and Taxus 
media cells, respectively. The cell culture of Rosmarinus oficinalis was able to produce 
approximately 5 times more rosmarinic acid than the whole intact plant 44. Taxus media cells were 
able to produce 0.6 % (dry weight) taxol, when biosynthesis was stimulated by the addition of 
methyl jasmonate 45. In fact, the largest producer of taxol, Phyton Biotech, uses a 75 000 L plant 
cell culture 46. However, since then, plant cell culture production platforms have mainly focussed 
around the production of pharmaceutical proteins, such as vaccines, instead of secondary 
metabolites 47. This may be due to the fact that secondary metabolite synthesis is typically 
considered to take place when the culture enters the static growth phase. Additionally, as plant 
cell cultures do not always maintain photoauxotrophic growth, productivity has been limited 48. 
A recent breakthrough by Loake et al. 49,50 involved the isolation of cambial meristematic cells 
from the cambium tissue of plant secondary meristems. These innately undifferentiated cells 
performed better on all fronts compared to typical dedifferentiated plant cells. They aggregated 
less, showed lowering sheering damage and were able to produce secondary metabolites at a much 
higher yield. Undifferentiated Taxus cuspidata cambial meristematic cells in a 20 L bioreactor 
were shown to produce 268 mg kg-1 taxol compared to dedifferentiated T. cuspidata embryonic 
cells which didn’t produce any  49. Therefore, the use of cambial meristematic cells offers much 
potential to the field of plant cell culture biosyntheses.  
Some desired secondary metabolic pathways are not expressed in plant cell culture, requiring the 
biosynthetic pathway to be introduced by bacterial mediated transformation involving 
Agrobacterium. The transformation can be transient or stable, lasting several days until the cells 
senesce or indefinitely being passed on to descendants 51. Agrobacterium rhizogenes is used for 
creating transgenic hairy root culture 52, whereas infection with Agrobacterium tumefaciens 
allows the generation of shoot culture 48. Unlike plant cell culture, shoot and hairy root cultures 
are able to stably produce secondary metabolites concomitant with growth 53. This was 
demonstrated by Mendoza et al. 54, in which more than 500 hairy root lines from Datura 
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stramonium produced stable amounts of tropane alkaloids over 5 years. An advantage over plant 
cell suspension culture is that organ cultures are generally less sensitive to shearing forces, and 
can be made even more so by immobilising to matrix 55. To date, there is only one company, 
ROOTec using hairy root cultures on an industrial scale 11.  
Whole plants offer a simpler production process compared to plant cell cultures, with significantly 
lower production costs due to existing horticulture expertise and crop management facilities. 
Although the most obvious approach, host plants take time to grow and are often underdeveloped 
as crops. The production of natural products in whole plants currently takes two main forms: 
breeding to increase yields or the introduction of heterologous pathways. There has been much 
success in breeding improved varieties of plants with increased yields of secondary metabolites. 
Again, a notable example is that of artemisinin production. By performing in-depth transcriptome 
sequencing of A. annua, Graham et al. 56, were able to identify key genes and markers for the fast-
track breeding of high yielding lines. This allowed the creation of a hybrid (Hyb8001r) which is 
able to produce a maximum artemisinin yield of 21.8 kg per acre, significantly higher than the 
previous elite variety and much higher than Keasling’s yeast 57. Not only does studying the crop 
in such detail enable natural increases in yield, but also increases the understanding of 
biosynthetic pathways necessary for heterologous biosynthesis.  
Popular examples of heterologous biochemical synthesis in whole plants are in the production of 
natural products important in food nutrition. In 2000, Ye et al. 58, created ‘Golden rice’, an 
engineered rice variety using stable Agrobacterium mediated transformation, to produce 
provitamin A in the rice endosperm to help address the problem of vitamin A deficiency in Asia. 
The yield was increased 23 times further, to 37 µg/g, by investigating and replacing the rate 
limiting phytoene synthase enzyme 59. Another example is that of the purple tomato, in which 
tomatoes were engineered by Martin et al. 60, to accumulate health-promoting anthocyanins. 
Interestingly, in contrast to the majority of examples outlined thus far, instead of introducing 
heterologous biosynthetic enzymes, Martin et al. 60, instead introduced transcription factors, 
which in turn caused the upregulation of anthocyanin biosynthetic enzymes. Although these 
examples of heterologous secondary metabolite production are for direct consumption and not 
extraction, they illustrate the successful production of secondary metabolites in plants. 
Interestingly, a heterologous plant system offers the most recent advance in the battle for 
artemisinin production. By developing a new synthetic biology approach, which they called 
COSTREL (combinatorial supertransformation of transplastomic recipient lines), Fuentes, et al. 
61, were able to transfer the A. annua genes necessary for artemisinic acid production into the 
chloroplast of tobacco (Nicotiana tabacum). Tobacco is a high-biomass crop, having multiple 
harvests per year, which can be grown easily on a large scale. In tandem they introduced 
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‘accessory’ genes into the nuclear genome allowing for improved regulation of the heterologous 
pathway. They were able to produce tobacco which could synthesize 4.8 kg artemisinic acid per 
acre, which is impressive for bioengineering, but it is still approximately 5 times lower than that 
of Graham et al.’s A. annua hybrid Hyb8001r 56. Furthermore, the work highlighted how little is 
still known about plant synthetic biology, exemplified by the nuclear ‘accessory’ genes which 
although aided yield, functioned in a ‘largely unknown manner’. Nonetheless, the approach of 
Fuentes, et al. 61, exemplifies how developments in methods and techniques allows progression 
in synthetic biology 
When comparing whole plant, plant cell culture and micro-organism platforms for the production 
of natural products there is are many advantages and disadvantages to be considered. Depending 
on the nature of the desired product, how it is synthesized and its market demand dictates the 
efficiency of the synthesis and the economics of its production. However, at a time in which DNA 
synthesis and assembly is rapidly become automated, it is likely that we are only at the very 
beginning of an exciting age of natural product microbial biosynthesis.  
 Curcuminoid chemicals: activity, synthesis and bioavailability 
Ayurveda, from the Indian words ‘Ayar’ (life) and ‘veda’ (science) meaning the Science of Life, 
is thought to be the oldest traditional medicine, predating even Chinese traditional medicine. One 
of a plethora of Ayurvedic medicinal plants is the turmeric plant (Curcuma longa L.). Rhizomes 
of the Curcuma species have been used for centuries due to their medicinal properties, as well as 
to add colour to fabrics and flavour food. The ground up rhizomes gives rise to turmeric powder, 
which is now commonly used by industry as a flavouring, preservative, and colouring agent. 
Curcuma is the third largest genus within the Zingiberaceae family, containing around 120 species 
62. Of these, the type species C. longa L. is the best known and the main source of turmeric powder 
63. C. longa is a perennial monocotyledonous plant which grows to around a metre in height and 
is distributed throughout South and Southeast Asia, with the most diversity in India and 
Indochina. 
The potency of the C. longa rhizomes as a medicine has been attributed to the synergistic effects 
of its many secondary metabolites 64. However, one of the major bioactive constituents of the 
turmeric plant rhizomes are the curcuminoid chemicals. Curcuminoids are bis-α,β-unsaturated 
diketones which are synthesized from phenylalanine or tyrosine via the phenylpropanoid and 
polyketide pathways in the rhizomes of C. longa 65,66. There are three main curcuminoids: 
curcumin, demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC) (Figure 1) which 
make up 3-5 % of Curcuma rhizomes, with Curcuma zedoaria having the highest curcuminoid 
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content. The major curcuminoid is curcumin (~ 77 %), followed by DMC (~ 18%), then BDMC 
(~ 5 %) 67. Curcuminoids are highly conjugated molecules, which cause the characteristic yellow 
colour of the turmeric rhizomes. Under physiological conditions, curcumin exists in equilibrium 
between two tautomers, either the keto- or the enol- form (Figure 2); in acidic conditions, the 
keto- form predominates, whereas the enol- form predominates in alkaline conditions.  
 
 
Figure 1. Curcuminoids: curcumin, demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC). 
 
 
 
Figure 2. Keto-enol tautomerisation of curumin. 
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1.2.1 The health benefits and bioactivity of curcuminoids 
Curcuminoids exhibit a plethora of health benefits, with thousands of publications claiming their 
efficacy against a vast range of diseases. In 1949, curcumin was first shown to act as an 
antibacterial agent towards Staphylococcus aureus 68. Curcumin is also well known for its 
antioxidant properties which was reported in 1975 by Sharma 69. Not only can curcumin scavenge 
free radicals 70, it can reduce the production of reactive oxygen species in vivo 71. Curcumin’s 
antioxidant ability has been shown to reduce oxidised proteins in Alzheimers amyloid pathology 
in rat models 72. Cardiovascular disease, including atherosclerosis and myocardial infarction has 
also been shown to be attenuated by diets supplemented with curcumin 73. Currently, the largest 
interest in curcuminoid bioactivity is their chemotherapeutic and chemopreventative effects 
towards a range of different cancers. Signal transducer and activator of transcription 3 (STAT3) 
and nuclear factor (NF)-ĸB are both active components in the signalling of cancer cell 
development. Curcumin, and chemically synthesized analogues, have been shown to down-
regulate both of these signalling pathways 74,75. For an extensive review of the biological targets 
and effects of curcumin(oids) see Prasad et al. 76. 
As well as evaluating the pharmacological effect of natural curcuminoids, many analogues have 
also been tested for their efficacy against different diseases 77. This has allowed conclusions to be 
made about structure-activity relationships. The bioactivity of curcuminoids is believed to be due 
to the molecular ability to act as a Michael acceptor at the enone moiety, meaning they can react 
with soft nucleophiles such as thiols (e.g. glutathione) 78. There are differing bioactivities between 
the three main curcuminoids curcumin, DMC and BDMC with curcumin exhibiting the greatest 
potency suggesting the importance of the methoxy groups on the phenyl ring 79. The positioning 
of the ring substituents is also significant: molecules with an electron donating group ortho to the 
para hydroxyl group are the most efficacious 80, with the para hydroxyl being important for 
antioxidant activities 81. 
1.2.2 Curcuminoid biosynthesis 
1.2.2.1 Polyketide Synthases 
Polyketide synthases (PKSs) catalyse the decarboxylative condensation of carboxylic acids to 
produce polyketides, a class of secondary metabolite. According to their catalytic mechanism, 
structure and primary sequence, polyketide synthases are subdivided into classes: I, II and III. 
Similar to fatty acid synthases, Type I PKSs constitute a large assembly of catalytic polypeptides, 
including essential ketosynthases, acyl transferases, and acyl carrier proteins, as well as non-
essential domains such as ketoreductases, dehydratases and methyltransferases. The presence or 
absence of these domains determines the chemical structure of the polyketide that is synthesized. 
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In bacteria, the domains are normally used once, known as non-iterative polyketide synthesis, 
whereas, in fungi domains are repeated, giving iterative polyketide synthesis. Type II PKSs 
function to synthesize aromatic polyketide and are large multi-enzyme complexes, each enzyme 
having a distinct function 82. Type III PKSs are homodimers, of which the active site in each 
monomer is responsible for iterative priming, extension, and sometimes cyclisation to form 
polyketide products 82. 
Plant type III PKSs share 21–31 % amino acid sequence identity with bacterial type III PKSs and 
35- 90 % identity with one another 83. The homodimer is 40- 45 kDa in size and catalyses iterative 
decarboxylation condensations of malonyl-Coenzyme A (malonyl-CoA) with CoA activated 
substrates from the phenylpropanoid pathway. The linear chain formed is often cyclised to form 
products including chalcones and stilbenes 83. Type III PKSs share a common three-dimensional 
structure and utilise a catalytic triad of cysteine, histidine and asparagine within the active site; 
the shape and volume of which determines the enzymes selectivity 83. The cysteine residue is the 
catalytic residue functioning as a nucleophile to cleave the C–S CoA thioester bond and initiate 
the addition of a two carbon acetyl unit via C–C bond formation (Figure 3). The histidine and 
asparagine form an oxyanion hole to stabilise the tetrahedral transition state of nucleophilic attack. 
Due to the orientation in which chain elongation occurs, type III PKS condensation is commonly 
referred to act via a head-to-tail model. The CoA activated substrates range from acetyl-CoA to 
aliphatic and aromatic CoA-esters, with the number of malonyl-CoA condensations ranging from 
one to eight, although it is usually three. If cyclisation occurs it can be carried out in three ways: 
Claisen condensation-type cyclisation, which is performed by acridone synthase (ACS) 84; aldol-
type cyclisation, utilised by stilbene synthase (STS) 85 or lactonisation as carried out by 2-pyrone 
synthase (2PS) 86 (Figure 4). Other type III PKSs, such as benzalacetone synthase (BAS) does not 
perform cyclisation (Figure 4).  
The most well characterised family of type III PKSs in plants are the ubiquitous chalcone synthase 
(CHS) superfamily, which catalyse the first step of flavonoid biosynthesis. CHS catalyses the 
condensation of p-coumaroyl-CoA with three malonyl-CoA extender units to form the aromatic 
triketide naringenin (see Figure 4). Once the naringenin flavoinoid scaffold is assembled, the 
skeleton is diversified by tailoring enzymes which perform acylation, hydroxylation, prenylation, 
O-methylation and glycosylation yielding over 6 000 different flavonoids 83.  
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Figure 3. Mechanism for type III PKS chain elongation.  
Substrate loading is followed by malonyl-CoA chain extension and decarboxylation forming the diketide intermediate, 
further extension by malonyl-CoA and decarboxylation forms of the triketide product. Shown in blue are the catalytic 
triad, cysteine, histidine and asparagine in the active site; shown in green is the malonyl-CoA extender and shown in 
black is the CoA-esterified substrate. Adapted from Abe et al. 83. 
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Figure 4. Examples of type III PKS reactions. 
Type III PKS synthase reactions shown are catalysed by acridone synthase (ACS), stilbene synthase (STS), 2-pyrone 
synthase (2PS), benzalacetone synthase (BAS) and chalcone synthase (CHS). Adapted from Abe, et al. 83. 
 
1.2.2.2 Curcuminoid polyketide synthases 
In 1997, Joachim Schröder predicted that curcuminoids were synthesized by type III PKSs 87, 
based upon radio tracer study evidence 88. Despite this prediction it took ten years for the first 
candidate enzymes to be identified in C. longa. It was contested whether the methyl ethers were 
formed from cinnamoyl-CoA units, then subsequently hydroxylated and methoxylated or formed 
from already methoxylated cinnamoyl-CoAs, such as feruloyl-CoA 89.  
The first enzyme capable of producing curcuminoids was identified in rice (Oryza sativa) despite 
there being no evidence of rice producing curcuminoids. Katsuyama et al.90 discovered it by 
conducting a BLAST search in the genome of Oryza sativa which identified 30 type III PKSs. 
All 30 were recombinantly expressed in E. coli and incubated with various CoA-esters; the 
products were then analysed using mass spectrometry. From this, one of the putative type III 
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PKSs was found to synthesize curcuminoids and is now known as curcuminoid synthase (CUS). 
In vitro, CUS produces BDMC from the condensation of two molecules of p-coumaroyl-CoA and 
one malonyl-CoA (Figure 5). Interestingly however, Oryza sativa does not produce curcuminoids 
so the in vivo function of CUS remains unknown. CUS was the first example of a type III PKS to 
break the conventional head-to-tail rule of PKSs, as the β-keto acid intermediate functions as the 
extender in the next step of the reaction, as opposed to the substrate 90. Two crystal structures 
have been solved for CUS, one at 2.5 Å resolution 91 and the other at 2.0 Å resolution 92. The large 
active site discovered, was unusual for type III PKSs and was believed to allow the unusual head-
to-head condensation where the β-keto acid acted as a second extender substrate. 
 
 
Figure 5. Curcuminoid synthase (CUS) reaction scheme. 
CUS forms bisdemethoxycurcumin from p-coumaroyl-CoA and malonyl-CoA, as demonstrated by Katsuyama et al.90. 
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Two years after the discovery of CUS, Katsuyama’s group identified two type III PKSs from C. 
longa involved in curcuminoid biosynthesis: diketide CoA synthase (DCS, AB495006.1 see 
Appendix 1.1) and curcumin synthase 1 (CURS1, AB495007.1 see Appendix 1.2) 93. In contrast 
to CUS, the single enzyme from O. sativa, which converts p-coumaroyl-CoA to BDMC, DCS 
first preferentially converts feruloyl-CoA to feruloyl-diketide-CoA using AB495006.1 malonyl-
CoA as an extender substrate (Figure 6). DCS can also accept p-coumaroyl-CoA, but at a lower 
efficiency 93. The optimum pH and temperature for DCS activity were determined to be 6.5-7.5 
and 25-35 ̊ C, respectively. CURS1 was shown to produce curcuminoids when incubated with the 
chemically synthesized feruloyl-diketide-CoA mimic cinnamoyldiketide-N-acetylcysteamine and 
feruloyl-CoA. Like CUS from O. sativa, CURS1 performed an unusual head-to-head 
condensation reaction. The optimum pH and temperature for CURS1 catalysis were calculated to 
be a particularly high 9 and 50 ̊ C, respectively. The co-incubation of DCS and CURS1 with p-
coumaroyl-CoA, feruloyl-CoA and malonyl-CoA allowed the production of curcumin, DMC and 
BDMC (see Figure 6), therefore it was concluded that together these two type III PKS functioned 
to synthesize curcuminoids in C. longa. There are reports of a second isoform of DCS, DCS2, 
however it has only been mentioned in passing in the literature (unpublished data, AB535216, 
Kita et al. 94). Two additional isoforms of curcumin synthases, CURS2 and CURS3, were later 
identified that had different substrate specificity to CURS1 accounting for the mixture of 
curcuminoids found in C. longa 95. CURS2 shared 78 % amino acid homology to CURS1, whereas 
CURS3 shared 81 %. CURS2 was shown to prefer feruloyl-CoA as a substrate, whereas CURS3 
utilised feruloyl-CoA and p-coumaroyl-CoA with a similar efficiency. RT-PCR studies showed 
CURS1 and CURS2 were primarily expressed in the rhizomes, whereas CURS3 was expressed 
equally between the leaves and roots. Using an RNA-Sequencing approach, the expression of 
DCS and CURS1-3 was shown to correlate with the abundance of each of the three curcuminoids 
produced in C. longa and C. aromatica 96. Using the ArREST (Aromatic Rhizome EST) database, 
a turmeric EST database curated by David Gang's research group  97, Resmi et al. 98 identified two 
other type III PKSs in C. longa, ClPKS9 and ClPKS10, however, they have not been shown to 
participate in curcuminoid biosynthesis. Although only the PKSs have been identified in the C. 
longa curcuminoid biosynthetic pathway, biosynthesis is believed to begin with the amino acids 
tyrosine and phenylalanine (Figure 7). The amino acids are then deaminated by PAL/TAL and 
proceed through the phenylpropanoid biosynthetic pathway to produce phenylpropanoyl-CoAs, 
which are then differentially accepted by the different isoforms of DCS and CURS to produce all 
three curcuminoids (Figure 7).  
Using laser micro-dissection of C. longa rhizomes and ultra-high performance liquid 
chromatography- mass spectrometry, Jaiswal et al. 99, identified the cork and cortex of the 
rhizome to contain the highest abundance of curcuminoids. Conversely, using Direct Analysis in 
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Real Time (DART) mass spectrometry, Rahman et al. 100 concluded that the majority of the 
curcuminoids accumulate within the pith of the rhizome. Therefore, to date, there is no conclusive 
evidence suggesting the key rhizome tissue(s) involved in curcuminoid biosynthesis. There is also 
a lack of data indicating the subcellular localisation of the type III PKSs (DCS and CURS) 
involved in curcuminoid biosynthesis or how the curcuminoid products are stored within the cell. 
Plant natural products usually undergo bio-conjugation or sequestration to reduce their potent 
bioactivities within the cell. However, ginger (Zingiber officinale), a fellow member of the 
Zingiberaceae family has been shown to sequester its polyphenolic metabolites, including 6-
gingerol, within terpenoid liposomes 101. It is possible that C. longa adopts a similar strategy for 
storing curcuminoids. 
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Figure 6. Diketide CoA synthase (DCS) and curcumin synthase (CURS) reaction scheme. 
DCS and CURS synthesize curcuminoids from p-coumaroyl-CoA or feruloyl-CoA and malonyl-CoA, as demonstrated 
by Katsuyama et al. 93. 
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Figure 7. Predicted schematic of curcuminoid biosynthesis in C. longa rhizomes.  
Tyrosine or phenylalanine are deaminated by tyrosine/phenylalanine ammonium lyase (T/PAL) to form phenylpropanoic acids cinnamic acid and p-coumaric acid. Cinnamic acid is converted to 
p-coumaric acid by C-4 hlydorxylase. p-Coumaric acid can be converted to caffeic acid by C-3 hydroxylase (C3H), the meta-hydroxyl group of which can be methylated by caffeoyl-CoA O-
methyltransferase (CCoAOMT) to give ferulic acid. The phenylpropanoic acids p-coumaric acid, ferulic acid and caffeic acid are then activated by CoA esterification by a 4-coumarate CoA ligase 
(4CL). The CoA esters are then condensed with malonyl CoA by diketide-CoA synthase (DCS) to produce the diketide-CoA, which is condensed with another phenylpropanoyl-CoA to yield the 
curcuminoid products curcumin, demethoxycurcumin and bisdemethoxycurcumin.
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1.2.3 Chemical and biological production of curcuminoids 
Due to the bioactivity of curcuminoids, much work has been carried out to synthesize these 
molecules. This began in 1918 with Lampe’s five step synthesis starting from ethyl acetoacetate 
and carbomethoxyferuloyl chloride (Figure 8) 102. Other chemical routes have also been explored 
by Sabitha et al. 103 and Pabon et al. 104.  
With the discovery of the PKS enzymes involved in their synthesis, heterologous expression of 
the curcuminoid biosynthetic pathway has been used in an effort to sustainably produce 
curcuminoids. After identifying CUS in Oryza sativa, Katsuyma’s group produced an artificial 
curcuminoid biosynthetic pathway that utilised this enzyme.28 The curcuminoid pathway was 
engineered in E. coli and comprised phenylalanine ammonia-lyase (PAL) from the yeast 
Rhodotorula rubra, 4-coumarate CoA ligase (4CL) from Lithospermum erythrorhizon and CUS. 
The metabolically engineered E. coli was fed with tyrosine or phenylalanine and produced three 
different curcuminoids with the highest yield being 107 ± 18 mg L-1 of dicinnamoylmethane when 
fed with phenylalanine. However, triketide pyrone derailment products were also produced in 
quantities up to 209 ± 18 mg L-1. In an attempt to minimise this, they repeated the feeding study 
without the PAL deamination step and fed the bacteria with phenylpropanoic acids instead. This 
increased the curcuminoid yield approximately three times and reduced triketide pyrone 
production by up to 10 %. Using this rationale, Katsuyama et al. 105 adopted a precursor directed 
strategy to produce novel curcuminoids by feeding with non-natural phenylpropanoic acids. 
Le4CL and CUS were able to utilise these non-natural substrates and produce novel curcuminoid 
derivatives such as di-4-chlorocinnamoylmethane, di-2-furylacryloylmethane and di-3-
indoleaclyloylmethane (Figure 9).  
 
 
Figure 8. Chemical synthesis of curcumin. 
Scheme of curcumin synthesis as carried out by Lampe 102, using carbomethoxyferuloyl chloride and ethyl acetoacetate.  
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Figure 9. Chemical structures of three non-natural curcuminoids. 
Katsuyama et al.105 produced a range of non-natural curcuminoids, including di-4-chlorocinnamoylmethane, di-2-
furylacryloylmethane and di-3-indoleaclyloylmethane from non-natural phenylpropanoids, using the heterolgous 
expression of Le4CL and CUS in E. coli. 
 
Wang et al.106 took advantage of curcuminoids characteristic yellow colour, using CUS as part of 
a reporter assay in E. coli. By co-expressing At4CL1 and CUS with a range of PALs and feeding 
the cells phenylalanine they used the amount of curcuminoids produced (measured by colour 
intensity) to determine the PAL with the best functionality in E. coli, which could then be used in 
other heterologous polyphenolic biosyntheses.  
In 2012, at the beginning of this project, DCS and CURS1 had not been used in an effort to 
biosynthesize curcuminoids. However, in 2015, Rodrigues et al.107 used DCS and CURS1 in 
conjunction with At4CL1 to produce curcuminoids in E. coli. They compared the curcuminoid 
production using DCS and CURS1 with that of CUS and saw that DCS and CURS1 yielded 
almost thirty times more curcumin than CUS (187.9 µM titre compared to 6.7 µM titre). 
Rodrigues et al.107 also demonstrated curcuminoid production from tyrosine via caffeic acid by 
expressing tyrosine ammonia lyase (from Rhodotorula glutinis) 4-coumarate 3-hydroxylase (from 
Saccharothrix espanaensis) and caffeoyl-CoA 3-O-methyl-transferase (from Medicago sativa) in 
combination with At4CL1, DCS and CURS1, although this resulted in lower curcuminoid yields. 
1.2.4 Increasing curcuminoid bioavailability 
A significant limitation to the pharmaceutical use of curcuminoids is their susceptibility to 
hydrolytic degradation in aqueous, physiological solutions reducing their efficacy as bioactive 
compounds 108. This degradation can be minimised by maintaining the pH of the solution below 
7, however, this drastically reduces the molecules’ solubility 109. This further decreases their 
bioavailability as drug molecules as they do not meet all of the ADMET criteria 110,111. The 
ADMET criteria stipulates that to be an effective drug the molecule must be easily Absorbed into 
the body, Distributed quickly and to the correct organs, Metabolised and Excreted at an 
appropriate pace and have low Toxicity. For example, when human volunteers orally ingested 2  
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g of curcumin, after an hour only 6 ng of curcumin could be detected per ml of blood 112. 
Intravenous delivery of curcumin in rats also results in its rapid metabolism to glucuronide and 
sulphate conjugates before being excreted 113,114.   
Many different approaches have been investigated to address the poor bioavailability of 
curcuminoids including altering how they are formulated to modifying their chemical structure 
115. Co-administering curcuminoids with an adjuvant, such as piperine, showed a 2000 % increase 
in bioavailability in humans 112. Liposome formulation has also been considered as a way of 
increasing the stability of curcuminoids, encapsulating them in polymeric micelles increased their 
stability up to 500 times in physiological conditions 116. Silica coated liposomes encapsulating 
curcumin saw the gastrointestinal absorption increase even further compared to standard lipid 
micelles 117. Further formulation development utilising lipids saw production of curcumin loaded 
solid lipid nanoparticles,  prolonging the release of curcumin and increasing its stability in in vitro 
studies 118. Another way to overcome the low bioavailability of curcuminoids is to create 
molecular analogues with improved pharmacokinetic properties. This area has been extensively 
explored with a vast range of analogues being synthesized from varying the heptanoid chain 
length, changing ring substituents and altering the enone moiety 66. One focus of the current thesis 
is curcuminoid glycoside analogues. 
 Glycosyltransferases and curcuminoid glycosylation 
One way to increase the bioavailability of curcuminoids is to create a glycoconjugate via 
glycosylation. Glycosylation can be carried out enzymatically or chemically, however, enzymatic 
reactions offer greater stereospecificity and regiocontrol 119. Glycosylation of small molecules 
increases their hydrophilicity and stability, generally giving the chemicals more desirable 
pharmacokinetic properties 120. Enzymatic glycosylation is often preferable to chemical 
glycosylation as it is regiospecific and can be performed using less harsh reaction conditions 
without the need for heavy metal catalysts 119. Enzymatic glycosylation is mainly carried out using 
glycosidases or glycosyltransferases. Glycosidases reversibly catalyse the hydrolysis of 
glycosidic bonds, therefore under appropriate conditions, they can be made to produce 
glycoconjugates. Some glycosidases have been engineered to become glycosynthases by 
removing their ability to hydrolyse the glycosidic bond 121. Conversely, glycosyltransferases 
naturally evolved to perform glycosylations and catalyse the transfer of the sugar from an 
activated donor (such as the nucleotide uridine di-phosphate (UDP)) to the acceptor. Although 
glycosidases are robust enzymes, they generally exhibit lower regioselectivity and yields 
compared to the rarer and more expensive glycosyltransferases 119. 
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1.3.1 Plant glycosyltransferases 
The variety of secondary metabolites produced by plants is due to the diverse chemical skeletons 
which are decorated by tailoring enzymes to tune their activity. One example of tailoring enzymes 
are glycosyltransferases. Glycosyltransferases play an important role in modulating the plasticity 
of plant responses to their environment. Glycosylation of secondary metabolites usually functions 
to stabilise and reduce their activity meaning they can be safely stored until needed. A common 
example is that of cyanogenic glycosides which are typically stored in the vacuole. When the 
plant is under attack by herbivory, the vacuole is damaged releasing the cyanogenic glycoside and 
allowing the glycosidic bond to be hydrolysed, this releases toxic hydrogen cyanide deterring 
further feeding 122. Glycosylation can also be utilised by plants as a crucial step in detoxifying 
xenobiotics, such as herbicides, leading to their breakdown, sequestration or transport out of the 
cell 123. 
Glycosyltransferases that catalyse the transfer of a hexose sugar from an activated donor to the 
acceptor molecule are known as UDP-glycosyltransferases (UGTs). UDP-glucose is the typical 
sugar donor, but UDP- galactose, UDP- rhamnose and UDP- glucuronic acid have also been 
identified as donors 124. The acceptor site is usually a hydroxyl group (Figure 10), however, 
glycosylation can occur at many different nucleophilic functional groups such as carboxylic acids, 
amines, thiols and also at carbon atoms 124. UGTs usually function as the last biosynthetic step, 
but in some pathways, such as that which produces flavonoid glycosides, glycosylation occurs 
during the synthesis of the backbone 125. UGTs can be retaining or inverting with the anomeric 
carbon keeping the same stereochemistry or being inverted (see Figure 10).  
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Figure 10. Glucosylation reaction. 
Nucleophilic attack of acceptor (dark blue) upon sugar donor (UDP-α-D-glucose) (black) leads to the formation of a 
glycosidic bond. The reaction can either retain the configuration of anomeric carbon centre or invert it.  
 
 
 
Figure 11. Glycosylation of 3,4-dihydroxybenzoic acid.  
Three Arabidopsis UGTs, 71B1, 72B1 and 89B1 all have different regiospecificity for the glycosylation of 3,4-
dihydroxybenzoic. 
 
UGTs are made up of a large multi-gene family, comprising over 78 families 126. Family 1 UGTs 
are defined by the presence of the plant secondary product glycosyltransferases (PSPG)-box; a 44 
amino acid motif, enabling them to transfer sugars to a wide variety of secondary metabolites 127. 
The PSGP-box is C-terminally located, where amino acid residues are involved in donor binding. 
Phylogenetic analysis of the N-terminal of Family 1 UGTs, shows that this terminal is more 
diverse and has a role in determining the binding specificity of the acceptor substrates 128. Utilising 
a functional genomics approach, recombinant Arabidopsis thaliana Family 1 UGTs, were divided 
into 14 groups (A to N) 126,128, with the selectivity of the enzymes varying across the groups. UGTs 
from other plants also aligned to these 14 groups 123. UGTs are highly regiospecific as exemplified 
by the differential glycosylation of the simple molecule 3,4-dihydroxybenzoic acid by three 
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Arabidopsis UGTs: group L 75B1 glycosylates the carboxylic acid; group E 72B1 glycosylates 
the meta hydroxyl group and group B 89B1 glycosylates the ortho hydroxyl group 129 (Figure 11). 
Family 1 UGTs carry out an inverting glycosylation mechanism resulting in the β-anomer 120. 
Although more work has been carried out with microbial and mammalian GTs, work with plant 
UGTs is increasing. Family 1 UGTs have been used as biocatalysts to produce glycosides of many 
different small molecules. As with other bioconversions, they can be used in vitro as purified 
recombinant proteins or in whole plant or microbial cell systems. As Arabidopsis Family 1 UGTs 
are the most well described, these have seen the greatest attention for heterologous expression in 
microbial systems. For example, heterologous expression of UGT73B3 and UGT71C1 in E. coli 
allowed the production of a range of quercetin glycosides at a 6 L fermenter scale 130. S. cerevisiae 
has also been used as a successful host for the heterologous production of glycosides. An 
interesting example, highlighting the unpredictable and complex nature of recombinant 
bioconversions, was shown by Strucko et al., again utilising a UGT from Arabidopsis 131. They 
constructed identical heterologous vanillin glycoside biosynthetic pathways in a laboratory and 
industrial strain of yeast: surprisingly the laboratory strain produced 10 times more product, 
emphasising the importance of choosing the correct strain and host for biocatalysis. 
The use of whole cell plant systems allows endogenous enzymes to be used, negating the need 
for heterologous expression. The major advantage of utilising whole cell systems over in vitro 
catalysis is that the cells are able to regenerate the sugar donors, reducing the need for 
supplementation which is costly. Plant cells offer not just one glycosyltransferase but potentially 
multiple UGTs which may have different regioselectivities. However, due to UGTs having a role 
in detoxification, the glycosylated product may end up being targeted to and stored in the vacuole, 
making recovery and extraction more difficult. A prominent cell culture is that of Catharanthus 
roseus used for many glycosylation reactions such as the production of glycosylated capsaicin 
and Δ9-tetrahydrocannabinol 132,133.  
1.3.2 Glycosylation of curcuminoids 
Due to the highly bioactive, yet poorly bioavailable nature of curcuminoid chemicals, different 
routes to glycosylate these molecules have been investigated. The first successes were observed 
using chemical syntheses, but more recent advances have seen the use of enzymes.  
1.3.2.1 Chemical glycosylation of curcuminoids 
The first industrially relevant curcuminoid glycosylation was seen in 2001, when Hergenhahn et 
al. 134, patented their route to synthesize a range of curcumin oligosaccharides. This was an 
involved chemical reaction scheme, requiring bromination at the anomeric carbon of the sugar 
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and protection by acetylation of the other hydroxyl groups of the sugar(s) to ensure regioselective 
glycosylation when reacted with curcumin in the presence of Et3BnN+Br̄. With glycosylation, 
Hergenhahn et al. 134 observed an increase in water solubility compared to the curcumin aglycone, 
as well as the ability to reduce inflammation and act as a tumour suppressor 134. However, after 
de-protection, the yields were poor, giving only 3 % curcumin 4’,4”-O-β-D-diglucoside 
(curcumin diglucoside) (Figure 12). Utilising a different rationale, expanding on the chemical 
synthesis of Pabon et al. 104 and Whiting et al. 84, Mohri et al.109 achieved better yields  of 34 % 
curcumin diglucoside. Instead of using curcumin as a starting material, they condensed two 
already glucosylated vanillin molecules using a boron catalyst 109. Nevertheless, this reaction 
scheme still required protection and deprotection steps which lowered the overall yield. Benassi 
et al. 111, also utilised vanillin and bromoacetogluose as starting materials and a boron catalyst, 
however, they additionally carried out thorough computational analyses of the products crystal 
structures and partion co-efficients. They showed that not only did glycosylation of curcuminoids 
increase the molecules’ bioavailability, but it also increased the molecules’ ability to act as 
bidentate iron chelating agents which may be useful in iron overload therapy 111. The most recent 
and highest yielding chemical synthesis of curcumin glucosides utilised a biphasic reaction 
medium and a tetrabutylammonium bromide phase transfer catalyst under simple and ecofriendly 
conditions, yielding 71 % curcumin diglucoside 135. However, once again, a loss in yield was 
observed due to protection and deprotection to make to reaction regioselective. The curcumin 
glucoside was shown to exhibit enhanced antioxidant and antimicrobial activities 135. 
 
 
 
Figure 12. Curcumin diglucoside. 
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1.3.2.2 Biological glycosylation of curcuminoids 
Despite the fact that curcumin glycosides are yet to be discovered in nature, biological syntheses 
of curcuminoid glycosides have been successfully explored. The main aim of investigating 
biological systems was to achieve greater regioselective glycosylation and avoid the protection 
and de-protection steps necessary for chemical syntheses. Two types of enzyme have been shown 
to perform curcumin glucosylation, glucosidases and glycosyltransferases.  
The two instances of glucosidase catalysed curcuminoid glycosylation both utilised commercially 
available enzyme preparations. The first evidence of glucosidase catalysed curcumin 
glycosylation was presented by Vijayakumar et al. 136 in which they used an α-glucosidase from 
Rhizopus. Usually used for the hydrolysis of α-D-glucosides, by optimising the pH and 
stoichiometry of reagents, the highest yield of curcumin-bis-α-D-glucoside was achieved at 48 %. 
Similarly, Shimoda et al. 137 used an almond β-D-glucosidase, to produce curcumin 
monoglucoside, however, the yield was much lower at 19 %. 
The first observation of a glycosyltransferase catalysed glycosylation of curcuminoids was in 
2003: Kaminaga et al. 138 reported that Catharanthus roseus cell suspension cultures converted 
exogenously applied curcumin to five different glucosides (curcumin 4’-O-β-D-glucoside; 
curcumin 4’-O-β-D-gentiobioside; curcumin 4’,4”-O-β-D-diglucoside; curcumin 4’-O-β-D-
gentiobiosyl 4”-O-β-D-glucoside and 4’,4”-O-β-D-digentiobioside (Figure 13)). They showed 
that curcumin was not only glycosylated once, but up to four times forming curcumin 4’,4”-O-β-
D-digentiobioside. This high level of glycosylation had not been seen before, with most plant cell 
cultures converting exogenous compounds with multiple hydroxyls to only the monoglucoside 
139,140. The water solubility of curcumin 4’,4”-O-β-D-digentiobioside was shown to be an 
impressive 20 million fold greater than curcumin (6.6 x 10 2 µmol ml-1 compared to 3.0 x 10 -5 
µmol ml-1) 138: the other glucosides also showed greatly improved hydrophilicity. Addition of a 
stress elicitor, methyl jasmonate, to the C. roseus cells, saw the yield of glucoside production 
increase to 2.5 µmol g-1 fresh cells (32 %) 138. 
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Figure 13. Curcumin glucosides produced by C. roseus cell culture.  
Five curcumin glycosides were produced by C. roseus cell culture: curcumin 4’-O-β-D-glucoside; curcumin 4’-O-β-
D-gentiobioside; curcumin 4’,4”-O-β-D-diglucoside; curcumin 4’-O-β-D-gentiobiosyl 4”-O-β-D-glucoside and 4’,4”-
O-β-D-digentiobioside. 
 
The UGT responsible for mono- and di- glucosylation was characterised the following year as 
CaUGT2 (GenBank accession number AB159213, Appendix 1.3) 1. Expression of CaUGT2 in E. 
coli showed that it preferentially converted curcumin to curcumin monoglucoside, followed by 
catalysis of curcumin monoglucoside to curcumin diglucoside (Figure 14). CaUGT2 showed 
optimal activity between pH 7.5-8. Phylogenetic analysis of CaUGT2, placed it within group D 
of the Family 1 UGTs, along with Arabidopsis UGT73C6 and other diverse UGTs 1. When 
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incubated with curcumin and UDP-glucose in vitro for three hours, CaUGT2 was able to produce 
curcumin diglucoside in a 74 % yield. When the analogous whole cell assay was performed in E. 
coli, only 4 % curcumin monoglucoside could be detected 1. CaUGT2 has also been shown to 
glycosylate a range of phenolics including carvacrol, thymol, eugenol and vanillin but at a lower 
efficiency than curcumin glycosylation 141. A specific amino acid, Cys377, has been shown to 
have an important role in the catalytic activity of CaUGT2, although this residue has little 
influence in other UGTs tested, so is thought to be unique to CaUGT2 127. 
Being the first characterised glycosyltransferase to allow the production of curcumin glucosides, 
CaUGT2 was subsequently used by Masada et al. 142, to create an in vitro curcuminoid glucoside 
production platform. There are problems with using UGTs as in vitro catalysts as UDP-glucose 
is an expensive starting material and the reaction by-product, UDP, inhibits the glycosylation 
reaction, therefore as the reaction proceeds, it slows down. Masada et al. 142 combatted these 
problems by co-expressing a recombinant sucrose synthase from Arabidopsis (AtSUS1) alongside 
CaUGT2, which could regenerate UDP-glucose. By creating this one-pot recycling system, the 
yield of curcumin glucosides increased nine-fold. 
In 2009, the identity of the sugar-sugar glycosyltransferase that formed the curcumin 
gentiobiosides and digentiobiosides in C. roseus plant culture was published as CaUGT3 
(accession number AB443870) 143. CaUGT3, purified from C. roseus plant cell culture, catalysed 
the conversion of curcumin 4’-O-β-D-glucoside and curcumin 4’,4”-O-β-D-diglucoside to 
curcumin 4’-O-β-D-gentiobioside and 4’,4”-O-β-D-digentiobioside, respectively (see Figure 14) 
144. As well as being able to glycosylate curcumin glycosides, it also showed activity towards 
other flavonoid glycosides such as quercetin 3-O-glucoside and apigenin 7-O-glucoside 143. To 
date, CaUGT3 has not been explored for the bioproduction of curcuminoid gentiobiosides. 
Despite no previous reports of Parthenocissus tricuspidata cell culture glycosylating exogenous 
substrates, Shimoda et al. 145 showed that it was able to glycosylate exogenous curcuminoids 145. 
Although unrelated to C. roseus, P. tricuspidata cell culture was also able to produce a range of 
glycosylated curucuminoids as shown in Figure 13. Currently, the enzymes responsible for these 
conversions have not been identified.  
As has been shown, utilising the glycosyltransferase enzymes present in plants to modify 
exogenous substrates is an effective way to produce glycosyl-conjugates of curcuminoids. The 
enzymatic reactions have greater specificity and utilise milder conditions compared to chemical 
glucosylation. However, the scope for scaling the enzymatic production of curcuminoid 
glycosides has not been explored.  
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Figure 14. Schematic of curcumin glucosylation as catalysed by CaUGT2 and CaUGT3. 
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 Project Aims 
This study aimed to explore the heterologous expression of plant secondary metabolic enzymes 
to produce and improve the bioavailability curcuminoid chemicals. Both a microorganism and 
plant host, S. cerevisiae and Nicotiana benthamiana, were to be investigated as chassis organisms. 
As curcuminoids are poorly bioavailable, glycosyltransferases were to be explored as a way of 
synthesizing more bioavailable conjugates. Whilst previous curcuminoid biosyntheses have 
utilised enzymes from plant sources which themselves do not produce curcuminoids, this study 
aimed to discover and utilise enzymes from C. longa which synthesizes curcuminoids. 
To identify new enzymes, rapid amplification of cDNA ends (RACE) PCR, metabolite profiling 
and protein activity assays were used. Chapter 2 details the attempts to obtain a full-length coding 
sequence of a 4CL from C. longa. It also describes the expression and activity of At4CL5, DCS 
and CURS1 in S. cerevisiae and N. benthamiana in the attempt to produce curcuminoids from 
phenylpropanoic acids.  
In Chapter 3, the search for a curcuminoid UGT in C. longa is described. Additionally, the 
development of CaUGT2 as a biocatalyst to produce bioavailable curcuminoid glycosides and the 
scale up of the bioconversion is investigated.  
Chapter 4 outlines the methods which were used and then Chapter 5 summarises the conclusions 
of the studies, possible future work and discusses this works contribution to the wider literature. 
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Chapter 2. Biosynthesis of curcuminoid chemicals 
2.1 Introduction  
Curcuminoids are highly bioactive diarylheptanoids produced in the rhizomes of the turmeric 
plant (Curcuma longa). The three main curcuminoids; curcumin, demethoxycurcumin and 
bisdemethoxycurcumin (see Figure 1) are made via the polyketide synthase pathway and are 
structurally similar yet have different biological and physicochemical properties 79,93. The ratio of 
the three curcuminoids is determined by the abundance of starting materials and isoforms of 
enzymes present 95,96. The main aim of this project was to individually biosynthesise the three 
curcuminoid chemicals in a heterologous host.  
Although curcuminoids have been heterologously produced in E. coli (yield ~ 100 mg L-1), 
unwanted derailment products were also produced due to the use of curcuminoid synthase (CUS) 
from O. sativa 146. In this study different enzymes were to be used to reduce derailment products 
and Saccharomyces cerevisiae (Bakers’ yeast) was chosen as a primary host. S. cerevisiae was 
chosen because of its enhanced ability to express eukaryotic proteins over E. coli, similar 
intracellular compartments to those of plant cells and wide use in biotechnological processes 
38,147,148. Tobacco (Nicotiana benthamiana) was also to be investigated and compared as a chassis 
platform for curcuminoid production.  
 
 
Figure 15. The main phenylpropanoic acids present in plant biomass. 
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To produce curcuminoids, phenylpropanoids (or phenylpropanoic acids) were chosen as starting 
materials due to their abundance in bio-refinery waste, allowing for the sustainable production of 
curcuminoids from a low value feedstock (Figure 15). They have been successfully used in the 
bio-production of other aromatic, high value chemicals such as vanillin 149,150. Using ferulic acid 
as a substrate would theoretically allow curcumin production; p-coumaric acid would yield 
BDMC and DMC could be produced from a mix of both. Caffeic and cinnamic acid could be used 
as starting materials to produce less abundant natural curcuminoids such as dicinnamoylmethane. 
Sinapic acid is not a natural starting material for curcuminoid biosynthesis. Unpublished work 
carried out by Prof Rob Edwards’ group determined that phenylpropanoic acids do not negatively 
affect the growth of S. cerevisiae at the concentrations to be used. In yeast, phenylpropanoic acids 
have also been shown to be metabolised by PAD1 (phenylacrylic acid decarboxylase 1) and FDC1 
(ferulic acid decarboxylase 1). Some bioengineering studies of S. cerevisiae utilising 
phenylpropanoids, knocked out these competing pathways 151, however, the literature showed 
their rate of catabolism to be minimal 152 so is not always necessary if the introduced heterologous 
pathway can outcompete the endogenous metabolism. In tobacco, exogenous phenylpropanoids 
are anticipated to have no detrimental effects at low concentrations due to being present for 
endogenous lignin biosynthesis 153. The effect of exogenous curcuminoids upon tobacco leaf 
tissue was unknown. 
To catalyse the biotransformation of phenylpropanoids to curcuminoids a 4-coumarate coenzyme 
A ligase (4CL), to activate the substrate, and polyketide synthase(s), to condense the activated 
substrates, were required (Figure 16). To date, the polyketide synthases required for the 
condensation reactions have been identified in C. longa as isoforms of DCS and CURS 93, but the 
4CL has not. Nonetheless, curcuminoid biosynthesis is believed to proceed via a 4CL as shown 
in Figure 7. Therefore, to heterologously produce curcuminoids, a 4CL would need to be 
identified from C. longa or an available coding sequence chosen from another organism. 
 
 
 
Figure 16. The enzymatic steps needed to produce curcuminoids from phenylpropanoids. 
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4-coumarate CoA ligases 
4CLs play a key role in plant metabolism by helping to shuttle the carbon flux from primary 
metabolism along the phenylpropanoid pathway into secondary metabolism. They are found in 
all plants examined to date 154. The phenylpropanoid pathway begins with the deamination of the 
amino acids phenylalanine or tyrosine (derived from the shikimate pathway) by 
phenylalanine/tyrosine ammonium lyase (PAL/ TAL) (see Figure 7). If phenylalanine is the 
starting material, C4-hydoxylase hydroxylates the para position of benzene ring producing p-
coumaric acid. p-Coumaric acid can then be hydroxylated again by C3H or methylated by O-
methyltransferase or CCoAOMT giving the four main phenylpropanoids cinnamic acid, p--
coumaric acid, ferulic acid and caffeic acid. The phenylpropanoids are then activated by 4CL 
forming CoA esters. Different 4CL isoforms within, and between, plant species exhibit different 
phenylpropanoid substrate preferences; however, p-coumaric, ferulic and caffeic acid are 
generally preferred with little activity shown towards cinnamic acid 153. There are also a few 
examples of 4CLs accepting sinapic acid as a substrate 155. The activated phenylpropanoyl-CoA 
esters can then be used as precursors to form numerous compounds including lignin, flavonoids 
and coumarins which play important roles in growth and responding to biotic and abiotic stresses 
153,156.  
4CLs use coenzyme A (CoA) to convert phenylpropanoic acids, into their respective CoA thiol 
esters. 4CL catalysis is a two-step process which utilises ATP and Mg2+ and proceeds via a 4-
hydroxycinnamoyl-adenylate intermediate 155,157. This places 4CLs into a large superfamily of 
enzymes known as adenylate forming enzymes which have divergent functions and include firefly 
luciferases, acyl-CoA synthetases and peptide synthetases. 4CL peptide sequences contain two 
highly conserved regions box I (SSGTTGLPKGV) and box II (GEICIRG) which flank the region 
involved in substrate recognition 158. 
In tobacco, parsley and hybrid poplar, all the 4CL isoforms show similar activity towards p-
coumaric, ferulic, caffeic and cinnamic acid 154,159–161, whereas Arabidopsis, poplar, rice and 
switchgrass 4CLs have differential substrate utilisation profiles 162–165. This has been taken as 
evidence that the 4CLs that exhibit different substrate specificities, function in different metabolic 
pathways 166. In the dicotyledons studied, Arabidopsis and aspen, the 4CLs can be split into two 
groups: type I and type II depending on their involvement in phenolic metabolism or lignin 
biosynthesis 162,163. The monocotyledons, rice and switchgrass, have a different phenolic and 
monolignol composition, with their 4CLs grouping into type III and type IV, respectively 164,167,168. 
The most extensively studied 4CLs are from the model plant, Arabidopsis. There are four 
characterised 4CLs: At4CL1, 2, 3 and 4 (although named At4CL4 in original studies, it is now 
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referred to as At4CL5 166). At4CL1, 2 and 5 belong to type I whereas At4CL3 belongs to type II; 
not only differing in their substrate specificity but, also their expression patterns 162. At4CL1 
prefers p-coumaric and caffeic acid; At4CL2 accepts just p-coumaric acid and At4CL3 has the 
best activity with p-coumaric and ferulic acid 162. At4CL5 was the second 4CL identified to CoA 
esterify sinapic acid 166, a rarely catalysed 4CL reaction, the first was from soyabean 169. At4CL5 
shows the lowest Km for sinapic acid followed by ferulic acid and p-coumaric acid 166. It is 
understood to be the size and hydrophobicity of the substrate binding pocket that determines the 
substrate binding specificity 170–172. 
The best described monocotyledonous 4CLs are from O.sativa (rice), of which there are five 
known in the genome: Os4CL1-5, all exhibiting different catalytic properties. Os4CL1 has a low 
turnover rate, Os4CL2 prefers ferulic acid, Os4CL3 has the highest turnover and together with 
Os4CL4 shows high affinity for ferulic acid and p-coumaric acid and Os4CL5 has a broad activity 
as well as being able to accept sinapic acid 173. Of the five rice 4CLS, Os4CL3 was shown to be 
the most highly expressed in all tissues. Os4CL2 is the only rice 4CL which belongs to the type 
IV clade involved in flavonoid biosynthesis, whereas the other four are associated with type III 
lignin formation 164. Other monocotyledonous 4CLs, such as those from switchgrass (Panicum 
virgatum) are currently being studied, as silencing 4CLs leads to a decrease in the lignin content 
of the plant improving it as feedstock for biofuel 165.  
To date, no full length 4CL from C. longa has been identified. This project aimed to address this 
using the available transcriptome data and rapid amplification of cDNA ends  polymerase chain 
reaction (RACE PCR) 174. The newly identified 4CL coding sequence (CDS) was to be used in 
the heterologous curcuminoid biosynthetic pathway.  
 
Curcuminoid type III polyketide synthases 
To perform the condensation of the activated CoA ester with malonyl-CoA to produce 
curcuminoids, there were two options for choosing polyketide synthases. There was the single 
enzyme curcuminoid synthase (CUS) from O. sativa or diketide CoA synthase (DCS) and a 
curcumin synthase (CURS), from C. longa (see Figure 5 and Figure 6). CUS has substrate 
preference for p-coumaroyl-CoA resulting in BDMC being the main product 90. There are multiple 
isoforms of DCS and CURS which have differing substrate preferences 95. 
DCS and CURS were chosen over CUS as the latter has no in vivo function in rice, shows low 
substrate promiscuity and produces unwanted products when expressed heterologously 93. There 
are two isoforms of DCS, 1 and 2, however DCS2 is not described in the literature (unpublished 
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data, Kita, et al. 94), therefore DCS1 was chosen; it is most commonly referred to as DCS. From 
the three isoforms of CURS (1, 2 and 3), CURS1 was chosen as it has the broadest substrate 
specificity and is the most well characterised 95.  
For expression in yeast, the chosen coding sequences, 4CL, DCS and CURS1, were to be cloned 
into yeast expression vectors. The vectors, pYES2 and pESC were chosen due to previous use 
within Prof Rob Edward’s and Prof Ian Graham’s research groups 175,176. Yeast strains, BJ2168, 
G175 and BY4722 were used for these proof of concept studies, although other production strains, 
such as CEN.PK2, are more commonly used by industry and biotechnology 148. A variety of 
strains were used throughout the project due to differing auxotrophies, phenotype and availability 
(see Materials and Methods). The enzymes were to be cloned and transformed into yeast in two 
ways: individually into compatible yeast expression vectors and altogether in a single open 
reading frame construct separated by the 2A polypeptide CDS. The curcuminoid biosynthetic 
pathway was to be reproduced in tobacco using Agrobacteria tumefaciens mediated transient 
expression 177. This required cloning the CDSs of 4CL, DCS and CURS1 into the pFGC5941 
binary vector. This would allow a comparison of the yeast and tobacco production platforms.  
2.2 Results 
2.2.1 Investigating the heterologous expression of curcuminoid biosynthetic enzymes in 
S. cerevisiae 
2.2.1.1 The heterologous expression of a 4CL 
Choosing a 4CL 
As there is no known coding sequence for a 4CL from C. longa, it was decided to search the C. 
longa NCBI transcript database. Using the NCBI tBLASTn expressed sequence tags (EST) 
search, five distinct ESTs with the highest homology (63-76 % sequence identity) to rice Os4CL3 
were identified: DY382977.1, DY391029.1, DY382750.1, DY390122.1 and DY391030.1 (see 
Appendix 2.1) 173. A 4CL from rice was chosen as the query sequence because rice is a 
monocotyledon, like C. longa, and it has the best described 4CLs. Os4CL3 was specifically 
chosen as it has the highest turnover rate of the five 4CLs in rice, is the most highly expressed 
4CL in all rice tissues, and shows good activity towards ferulic and p-coumaric acid 173.  
When analysed phylogenetically, rice and Panicum virgatum (switchgrass) monocotyledon 4CLs 
(Os4CL1-5 and Pv4CL1-2, respectively) were aligned as previously shown by Sun et al. 164: 
Os4CL2 and Pv4CL2 belong to type IV whereas the rest belong to type III (Figure 17). Type IV 
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Os4CL2 and Pv4CL2 have both been described to be involved in flavonoid biosynthesis 165,173, 
whereas the type III 4CLs are involved in lignin biosynthesis 164. The similarity of the five putative 
C. longa 4CLs to the members of type III suggests that they are likely to be type III 4CLs.  
The five C. longa ESTs did not cover the full-length Os4CL3 CDS with both the N and C terminal 
sequences missing (Figure 18). Of the five ESTs, the longest, DY382977.1 (839 nucleotides in 
length, compared to full-length 4CLs of ~1650 nucleotides) gave 47 % coverage and 70 % amino 
acid homology to Os4CL3. However, when analysing the key substrate binding region bordered 
by the conserved peptide motifs, Box I and Box II, the latter part of the substrate binding region 
was missing (Figure 19).  
 
 
Figure 17. Phylogenetic analysis of five potential 4CL ESTs from C. longa. 
The five potential 4CL ESTs from C. longa are compared with other monocotyledon 4CLs: Os4CL1-5 from rice and 
Pv4CL1 and Pv4CL2 from switchgrass. They arrange into two groups based on their sequence identity as shown by 
Sun et al. 164. Os4CL2 and Pv4CL2 belong to type IV, whereas Os4CL1, 3-5 and Pv4CL1 belong to type III. Similarity 
of the C. longa 4CL ESTs to the type III 4CLs suggests they are likely to belong to the type III class of 4CLs.  
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Figure 18. Amino acid sequence alignment of five potential C. longa 4CL ESTs and Os4CL3. 
The homology of DY382977.1, DY391029.1, DY382750.1, DY390122.1 and DY391030.1 and Os4CL3 is compared: 
the darker the shade of blue, the higher the homology between the amino acid sequences. 
 
 
Figure 19. 4CL substrate binding domain comparison between Os4CL3 and DY382977.1.  
The sequence is reduced to the region flanked by the conserved peptide motifs box I (underlined red) and box II 
(underlined green). The darker the shade of blue, the greater the homology between the two sequences. The sequences 
show 70 % homology, although the C-terminal end of the substrate binding region of DY382977.1 is missing. The 
denoted numbering is according to each single polypeptide, as found in the database. 
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The ability to detect the five chosen ESTs in C. longa RNA was first checked. RNA was extracted 
from C. longa rhizomes using a method specific for tissue high in polyphenolics and lignin (see 
Materials and Methods) 178. cDNA synthesis was then carried out, upon which polymerase chain 
reaction (PCR) and nested PCR was carried out using primers designed to amplify the five ESTs 
(see Primer Table in Materials and Methods): only DY382977.1 and DY391029.1 could be 
amplified giving the products of the expected sizes, 0.8 kB and 0.4 kB, respectively (Figure 20A). 
The PCR products were sequenced and compared to the expected EST sequence from the NCBI 
transcript database (Figure 20B and C). DY382977.1 cDNA amplified from RNA isolated from 
rhizomes showed more variation to the NCBI transcript database than DY391029.1, with multiple 
single nucleotide polymorphisms and insertions. Despite this, as DY382977.1 was the longest 
detectable mRNA, it was chosen as the sequence to work with. As both the C and N terminal were 
missing (see Figure 18) 3’, 5’ RACE PCR was required to obtain a full-length, functional 
sequence. In spite of multiple attempts (using larger quantities of rhizome tissue, freshly extracted 
RNA, newly synthesized cDNA and a range of different PCR primers and PCR conditions) the 
full-length DY382977.1 CDS was not amplified.  
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Figure 20. Verifying expression of DY382977.1 and DY391029.1. 
(A) Agarose gel showing PCR products, using DY382977.1 (0.8 kB) and DY391029.1 (0.4 kB) specific primers to 
amplify cDNA, giving bands at expected sizes. The nucleotide sequence of DY382977.1 and DY391029.1 from cDNA 
synthesized from RNA extracted from C. longa rhizomes is compared to the expected NCBI EST sequences: (B) 
sequence alignment of DY382977.1 PCR product (cDNAseq1) with expected DY382977.1 database sequence; (C) 
sequence alignment of DY391029.1 PCR product (cDNAseq2) with expected DY391029.1 database sequence. 
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Expression and activity of 4CL5 in S. cerevisiae 
To allow progression with the heterologous production of curcuminoids, it was decided to use a 
4CL from a different source. Os4CL3 had exhibited poor enzymatic activity in S. cerevisiae (Dr 
F. Sabbadin, Prof Rob Edward’s Lab, unpublished data) so a 4CL from Arabidopsis was chosen, 
as these are the most well described group of 4CLs. At4CL5 (AT3G21230.1, see Appendix 2.2, 
henceforth denoted as 4CL5), was chosen as, of the Arabidopsis 4CLs tested in proof of concept 
studies, it had shown the best enzymatic activity in yeast (Dr H. Housden, Edward’s Lab, 
unpublished data).  4CL5 also  has the widest substrate specificity of the Arabidopsis 4CLs 179. 
4CL5 CDS was PCR amplified from Arabidopsis thaliana RNA and cloned into the pYES2 vector 
translationally fused to a Strep-tag using restriction and ligation (kindly donated by Dr H. 
Housden, Prof Rob Edward’s Lab) (Figure 21A). S. cerevisiae cells were transformed with 
pYES2-4CL5 as verified by PCR, giving the expected product at 1.7 kB (Figure 21B). 
Transcription of 4CL5 from the pYES2-4CL5 vector was verified by reverse transcription-PCR 
(RT-PCR), giving the expected product at 0.9 kB (Figure 21C). Western blot analysis confirmed 
protein expression of Strep-tagged 4CL5, with the protein detected at 63 kD, as expected (Figure 
21D). By carrying out whole cell (in vivo) and protein extract (in vitro) assays, it was anticipated 
that heterologous protein activity and endogenous yeast activity could be distinguished.  
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Figure 21. Cloning, transformation and expression of pYES2-4CL5.  
(A) pYES2-4CL5 plasmid, for the expression of 4CL5 in S. cerevisiae under the control of a galactose inducible 
promoter. CYC1- transcriptional terminator for efficient termination; URA3- selection for transformants in yeast host 
strains with a ura3 genotype. Primers are denoted by arrows for DNA and cDNA amplification: B1- F_Asc1_4Cl5; 
B2- R_Xba1_4CL5; C1- Haz_4CL5_int_L; C2- Haz_4CL5_int_R, see Materials and Methods for primer sequences. 
(B) Agarose gel electrophoresis showing diagnostic PCR products from PCR performed upon DNA extracted from 
transformed yeast, using primers B1 and B2 to determine positive transformation of yeast cells. The expected product, 
at 1.7 kB was amplified; pYES-4CL5 plasmid was used as a positive control template. (C) Agarose gel electrophoresis 
showing diagnostic PCR products from PCR performed upon cDNA synthesized from RNA extracted from transformed 
yeast cells, using primers C1 and C2 to determine transcription of 4CL5 from the pYES2-4CL5 vector. The expected 
product, at 0.9 kB was amplified; pYES-4CL5 plasmid was used as a positive control template. (D) Western blot 
analysis using Strep-Tactin to detect Strep-tagged 4CL5 protein (63 kD) in protein extracted from yeast cells 
transformed with the pYES2-4CL5 plasmid. Ponceau stained membrane is shown as a loading control. pYES2-EV is 
an empty vector control.  
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Whole yeast cells, expressing 4CL5, were fed p-coumaric acid and LC-MS analysis was used to 
observe the expected appearance of the product, p-coumaroyl-CoA. After 24 hours, p-coumaroyl-
CoA could not be detected in the yeast cells or in the media, however, p-coumaric acid in the 
medium was consumed (Figure 22). As the consumption of p-coumaric acid is notably higher in 
yeast transformed with pYES2-4CL5 than it is in the empty vector control (pYES2-EV) (90 % 
reduction compared to 27 %, after 24 hours) it was concluded that 4CL5 was enzymatically active, 
despite the product not being detected.  
 
Figure 22. In vivo p-coumaric acid consumption by pYES2-4CL5 transformed yeast cells.  
The HPLC (260 nm) peak area was used for quantification of p-coumaric acid, see Appendix 2.3 for p-coumaric acid 
chromatogram. The pYES2-4CL5  yeast culture consumed p-coumaric acid significantly faster than that transformed 
with pYES2-EV. The data are means ± standard deviations (n = 3).  
 
 
Figure 23. In vivo ferulic acid consumption by pYES2-4CL5 transformed yeast cells.  
The HPLC (260 nm) peak area was used for quantification of ferulic acid, see Appendix 2.4 for ferulic acid 
chromatogram. The pYES2-4CL5  yeast culture consumed ferulic acid significantly faster than that transformed with 
pYES2-EV empty vector control. 
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The in vivo feeding study was then carried out with ferulic acid for comparison. Additionally, a 
new quadripartite analytical LC method, adapted for improved detection of aromatic CoA esters, 
based on Larson et al. 180, was used (see Materials and Methods). Like p-coumaric acid (see Figure 
22), ferulic acid was consumed at a quicker rate by the pYES2-4CL5 expressing yeast cells 
compared to that of pYES2-EV (Figure 23). However, it took 96 hours for ferulic acid to be 
completely consumed, not ~24 hours as seen with p-coumaric acid. The production of feruloyl-
CoA was searched for using the new LC-MS method: however, while feruloyl-CoA standard 
could be detected (see Appendix 2.5 for spectral data), production of feruloyl-CoA by pYES2-
4CL5 yeast culture could not (Figure 24). 
Despite a decrease in substrate, the CoA ester products from in vivo 4CL5 catalysis could not be 
detected by LC-MS, so in vitro assays were carried out. This was to ascertain whether 4CL5 was 
carrying out the expected catalysis in yeast or producing unexpected products. Protein was 
extracted from yeast cells expressing pYES2-4CL5 and pYES2-EV and assayed for activity 
towards cinnamic, p-coumaric, caffeic and ferulic acid. No phenylpropanoyl-CoA esters were 
produced at 0 or 20 hours by yeast transformed with pYES2-EV, as expected (Figure 25A to D). 
However, phenylpropanoyl-CoA esters were produced by pYES2-4CL5 yeast protein extract 
after 20 hours (Figure 25A to D), with parental mass ions of the CoA esters of cinnamic, p-
coumaric, caffeic and ferulic acid detected at m/z 897.5, 913.5, 929.5 and 897.5, respectively (see 
Appendices 2.6-2.8 for spectral data).  
 
 
Figure 24. In vivo feruloyl-CoA production by yeast cells transformed with pYES2-4CL5. 
The cultures were fed with ferulic acid and feruloyl-CoA production was quantified by MS. No feruloyl-CoA, could 
be detected using LC-MS, whether in the cells or media. Detection of the feruloyl-CoA standard shows the analytical 
method was functioning. The data are means ± standard deviations (n = 3). 
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Figure 25. In vitro phenylpropanoyl-CoA ester production by pYES2-4CL5 yeast protein extract. 
Activity of pYES2-4CL5 and pYES2-EV crude protein extract, at 0 and 20 hours, to produce phenylpropanoyl-CoA 
esters from cinnamic, p-coumaric, caffeic and ferulic acid as quantified by MS peak areas: (A) ([M+H]+ 897.5), (B) p-
coumaroyl-CoA ([M+H]+ 913.5), (C) caffeoyl-CoA ([M+H]+ 929.5) and (D)feruloyl-CoA ([M+H]+ 943.5) 
respectively. See Appendices 2.6- 2.8 for spectral data. The data are means ± standard deviations (n = 3). 
 
As in vitro 4CL5 activity was detected towards cinnamic, p-coumaric, caffeic and ferulic acid, its 
activity towards novel substrates, which may offer the first step in the biosynthesis of non-natural 
curcuminoids, was also tested (Figure 26). 4-Methoxycinnamic acid, 3,4-dimethoxycinnamic acid 
and 4-dimethylaminocinnamic acid were chosen because of their para electron donating groups, 
which are important for curcuminoid bioactivity 80. 4-Fluorocinnamic acid was chosen because 
of the improved pharmacokinetic properties of fluorinated curcuminoids compared to curcumin 
181,182. 
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Figure 26. Non-natural phenylpropanoids. 
They were assayed with yeast crude protein extract containing 4CL5, to ascertain whether 4CL5 can accept these 
molecules as substrates. 
 
 
Figure 27. In vitro production of non-natural phenylpropanoyl-CoA esters by pYES2-4CL5 yeast protein extract. 
Activity of pYES2-4CL5 and pYES2-EV crude protein extract to produce non-natural phenylpropanoyl-CoA esters 
from ferulic, 4- methoxycinnamic, 3,4-dimethoxycinnamic and 4-dimethylaminocinnamic acid was quantified at 0, 3 
and 24 hours, using MS peak area: (A) feruloyl-CoA ([M+H]+ 943.5), (B) 4- methoxycinnamoyl-CoA ([M+H]+ 927.5), 
(C) 3,4-dimethoxycinnamoyl-CoA ([M+H]+ 958.5) and (D) 4-dimethylaminocinnamoyl-CoA ([M+H]+ 940.5). See 
Appendices 2.9- 2.11 for spectral data. The data are means ± standard deviations (n = 3).  
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The activity of 4CL5 towards the novel substrates was assayed in vitro (3 and 24 hours) in an 
analogous manner to the natural phenylpropanoids. Ferulic acid was used as a positive control for 
the assay: feruloyl-CoA was only produced in the presence of 4CL5 crude protein as expected 
(Figure 27A). pYES2-4CL5 crude protein catalysed the conversion of novel substrate 4-
methoxycinnamic acid to 4-methoxycinnamoyl-CoA, with 4-methoxycinnamoyl-CoA increasing 
over time (Figure 27B). 3,4-Dimethoxycinnamic acid and 4-dimethylaminocinnamic acid were 
also accepted as substrates by 4CL5. However, instead of the CoA esters accumulating, as shown 
with feruloyl-CoA and 4-methoxycinnamoyl-CoA, the amount of CoA esters peaked at 3 hours, 
then decreased to virtually zero by 24 hours (Figure 27C and Figure 27D). 4-Fluorocinnamoyl-
CoA could not be detected in the mass spectra when 4-fluorocinnamic acid was incubated with 
4CL5 crude protein, indicating that this was the only novel substrate that 4CL5 did not accept as 
a substrate. 
2.2.1.2 Investigating the heterologous expression of DCS  
To investigate the activity of the second biosynthetic enzyme, the DCS coding sequence 
(AB495006.1, from C. longa rhizome, Appendix 1.1) was ordered from GenScript USA in the 
pUC57 plasmid. It was subsequently cloned into the pESC yeast expression vector to allow the 
translational fusion with a myc tag (Figure 28A) as verified by Sanger sequencing. S. cerevisiae 
cells were transformed with this construct and transformation was verified by PCR (Figure 28B). 
Transcription and expression of DCS was validated by RT-PCR and western blotting using an 
anti-myc primary antibody (Figure 28C and Figure 28D). 
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Figure 28. Cloning, transformation and expression of pESC-DCS.  
(A) pESC-DCS plasmid, for the expression of DCS in yeast under the control of a galactose inducible promoter GAL1. 
CYC1 transcriptional terminator for efficient termination of mRNA; TRP1 gene offered selection for transformants in 
yeast host strains with a trp1 genotype. Primers are denoted by arrows for DNA and cDNA amplification: B1- 
F_Asc1_DCS; B2- R_Xba1_DCS; C1- F_DCS_160; C2- DCS_1044_R, see Materials and Methods for primers 
sequences. (B) Agarose gel electrophoresis showing diagnostic PCR products from PCR performed upon DNA 
extracted from transformed yeast cells, using primers B1 and B2 to determine positive transformation of yeast cells. 
The expected product, at 1.2 kB was amplified; pESC-DCS plasmid positive control template. (C) Agarose gel 
electrophoresis showing diagnostic PCR products from performed upon cDNA synthesized from RNA extracted from 
transformed yeast cells, using primers C1 and C2 to determine transcription of DCS from the pESC-DCS vector. The 
expected product, at 0.9 kB was amplified; pESC-DCS positive control template. (D) Western blot analysis using an 
anti-myc primary antibody to detect myc-tagged DCS protein (42 kD) in protein extracted from yeast cells transformed 
with the pESC-DCS plasmid. Ponceau stained membrane is shown as a loading control. pESC-EV is an empty vector 
control.  
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DCS preferentially utilises feruloyl-CoA as a substrate with which it condenses malonyl-CoA to 
produce diketide CoA esters 93, therefore feruloyl-CoA was chosen as the model substrate to test 
the activity of DCS in yeast. The activity of DCS was first tested in in vivo cell culture assays. 
4CL5 activity was to provide feruloyl-CoA for larger in vivo assays as feruloyl-CoA cannot 
permeate the yeast cell membrane, therefore needed to be made within the cell 183. Although the 
phenylpropanoyl-CoA products of 4CL5 catalysis could not be detected in in vivo assays, it had 
been shown that the enzyme was active (see Figure 25), so it was anticipated that DCS would be 
able to out-compete the endogenous metabolism of the CoA esters and produce feruloyl diketide-
CoA. Yeast cell cultures expressing pYES2-4CL5 alone, pESC-DCS alone and co-expressing 
both pYES2-4CL5 and pESC-DCS were fed ferulic acid (S. cerevisiae naturally produces 
malonyl-CoA so it was not supplemented) 184. Samples of the cells and medium were taken after 
24 and 96 hours and analysed by LC-MS to determine whether feruloyl diketide-CoA had been 
formed by the culture co-expressing pYES2-4CL5 and pESC-DCS. The positive molecular ion, 
[M+H]+ 986.7 (feruloyl diketide-CoA Mr = 985.7 g mol-1), was searched for, however, there was 
no presence of this ion. A decrease in ferulic acid over time, compared to pESC-EV, suggested 
that 4CL5, whether expressed alone or in combination with DCS, was consuming substrate and 
therefore likely to be producing feruloyl-CoA as a substrate for DCS (Figure 29). The depletion 
of ferulic acid was not significantly different between the culture expressing pYES2-4CL5 alone 
or pESC-DCS and pYES2-4CL5 in combination. As the phenylpropanoyl-CoA ester produced 
by 4CL5 is believed to be further metabolised by the yeast cells, it may be that the recombinant 
DCS protein cannot compete with the endogenous pathway. Equally, as ferulyol-CoA production 
by 4CL5 could not be detected in in vivo assays (see Figure 24), it is possible that the product of 
DCS, feruloyl diketide-CoA, may also be undetectable.  
 
 
Figure 29. Ferulic acid consumption by pYES-4CL5 and pESC-DCS transformed yeast cells. 
Ferulic acid in the culture medium was quantified by HPLC UV (260 nm) peak area. pESC-EV yeast culture showed 
no consumption of ferulic acid, whereas those transformed with pYES2-4CL5 and both pYES2-4CL5 and pESC-
DCS did, at similar rates.  
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To investigate DCS activity further, and establish if a lack of substrate availability was indeed an 
issue, an in vitro assay was carried out. CoA esters are costly to purchase so efforts were made to 
synthesize feruloyl-CoA using 1,1’-carbinoyldiimidazole and CoA trilithium salt 185. Although 
synthesis of feruloyl-CoA was successful, purification was problematic so feruloyl-CoA was 
finally purchased for use in vitro assays in which lower quantities of substrate are required. Crude 
protein was extracted from pESC-DCS transformed yeast cells and assayed for DCS activity by 
incubation with feruloyl-CoA and malonyl-CoA as described by Katsuyama et al.93 (see Materials 
and Methods). LC-MS was used to determine whether DCS had condensed feruloyl-CoA and 
malonyl-CoA by searching for the molecular ion [M+H]+ 986.7 (feruloyl diketide- CoA Mr = 
985.7 g mol-1): alike to in vivo assays, there was no presence of this ion. Although, with no 
available molecular standard, it cannot be concluded with 100 % certainty.  Katsuyama et al. 93 
reported that DCS was also able to produce derailment products benzalacetone and 
dehydrozingerone. Evidence for these compounds was looked for in the mass spectra data, 
without success. To confirm that DCS, or endogenous yeast enzymes, were not converting 
feruloyl-CoA into something else, the amount of this starting material was quantified by mass 
spectrometry (Figure 30). There was no discernible difference in the amount of feruloyl-CoA 
detected after 1 hour incubation with crude protein extract from yeast cells transformed with 
pESC-EV or  pESC-DCS, inferring that feruloyl-CoA was not being consumed by DCS.  
 
 
Figure 30. In vitro feruloyl-CoA consumption by pESC-DCS yeast protein extract. 
After 1 hour incubation with crude protein extract from yeast cells transformed with pESC-EV (empty vector control) 
or pESC-DCS there is no significant difference between the amount of feruloyl-CoA remaining in the empty vector 
control compared with the pESC-DCS protein extract. Feruloyl-CoA consumption was quantified by MS peak area. 
The data are means ± standard deviations (n = 3). 
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Addressing the codon bias between S. cerevisiae and DCS 
In an attempt to troubleshoot the lack of diketide-CoA products produced by DCS protein in S. 
cerevisiae, a focussed collaboration with the research teams led by Prof Nia Bryant and Prof Bob 
White in the Biology Department at the University of York was initiated. Prof Nia Bryant and 
Prof Bob Whites’ research focuses upon heterologous protein expression in yeast and tRNAs, 
respectively. To heterologously produce a recombinant protein, the nucleotide coding sequence 
must be able to be ‘read’ by the host’s translational machinery and matched with complementary 
tRNAs carrying the correct synonymous amino acids. However, the codon usage varies greatly 
between organisms and even between differentially expressed proteins in the same organism 186. 
As an organism’s codon bias correlates with the abundance of cognate tRNAs 187, differential 
codon bias between a heterologous gene and a host can have a profound effect upon heterologous 
protein production 188. When synthesized by GenScript, the nucleotide sequence of DCS was not 
codon optimised; this was so it could be heterologously expressed in both S. cerevisiae and 
tobacco. Additionally, it has been shown that although codon optimisation can increase 
translation, it can alter mRNA secondary structure, therefore stability, and overall decrease gene 
expression and protein production 189. 
A possible rationale for the lack of detectable DCS activity was hypothesized to be that the codon 
usage of S. cerevisiae is not optimal for correct DCS expression. Not only does a mismatch in 
codon bias reduce protein quantity, but also quality, as the incidence of frame shifting and 
misincorporation of amino acids increases during translation 188. DCS has previously been 
heterologously expressed by Katsuyama’s group; this was in E. coli (BL21) and the gene was not 
codon-optimised 93, therefore, the main difference to the work described in this project is the 
heterologous host.  
Although DCS protein was produced in yeast expressing pESC-DCS (see Figure 28D), this could 
be due to codon wobble allowing non-synonymous tRNAs to translate heterologous codons for 
which there were no, or little, endogenous tRNAs 190. It was hypothesized that creating a yeast 
strain expressing tRNAs to resolve the issue of codon bias with DCS, would allow the quality and 
quantity of heterologous DCS protein to increase 188. To test this hypothesis, the number of copies 
of each tRNA in S. cerevisiae was compared to the codon bias of DCS, as well as the functionally 
active 4CL5 (Figure 31). Arabidopsis 4CL5 was expressed and functionally active in yeast (see 
Figure 21C and Figure 25) without codon optimisation. Which may be due to Arabidopsis and S. 
cerevisiae sharing a similar codon usage space 186. Therefore, the codon usage of 4CL5 was used 
to further inform which codons may be impeding DCS expression and activity. Codons which 
were of a higher abundance in DCS than 4CL5 and had little or no yeast tRNAs were searched 
for. Codons which met these criteria were considered as potential targets for increasing DCS 
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expression. Of the 9 codons identified (CGC, CTC, GCC, GCG, CTG, GTC, TAT, CCC and 
CGG) 3 codons were chosen which were anticipated to be beneficial for DCS expression: CTG, 
CTC and GCG (see Figure 31). Of the 390 DCS codons, 60 codons were one of the three chosen 
codons which either had no (CTC, GCG) or only had one (CTG) corresponding S. cerevisiae 
tRNA. The chosen codons were shown to be spread throughout the DCS coding sequence (Figure 
32). Although none of the codons correspond to the four crucial active site residues (highlighted 
in green), they are in close proximity to these sites so may cause frame slipping and incorrect base 
incorporations at these crucial positions. 
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Figure 31. Comparison of S. cerevisiae tRNA bias and the codon usage of C. longa DCS and Arabidopsis 4CL5.  
Highlighted in red boxes are three codons that were chosen for optimisation. They have no (CTC, GCG) or one (CTG) S. cerevisiae tRNA(s), and DCS contains more of that particular codon than 
4CL5.    
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Figure 32. DCS coding sequence showing codons that have no/low number of tRNAs in S. cerevisiae.  
GCG- highlighted in red, CTC- highlighted in orange, CTG- highlighted yellow, highlighted in green are the codons 
that correspond to the residues in the DCS active site: TGC- Cys 163, TTT- Phe 214, CAC- His 302 and AAC- Asn 
335 191.  
 
To rebalance the codon bias between S. cerevisiae and DCS, tRNAs for the three chosen codons, 
from either Schizsaccharomyces pombe or S. cerevisiae, were identified (Table 1). The three 
chosen tRNA nucleotide sequences were identified in their respective chromosomes with 
approximately 250 bp of flanking sequence to help sub-cloning (Appendix 2.12). The three tRNA 
coding sequences were synthesized by Invitrogen in the pMA vector, then subsequently cloned 
into yeast expression vectors pRS416 and pRS426. The vectors pRS416 and pRS426 were chosen 
due to being low copy centromeric and high copy episomal plasmid copies of one another. A high 
and a low copy plasmid were used for two reasons. One, tRNA expression in eukaryotes is 
determined by copy number 186, so a high copy plasmid was theorised to give greater tRNA 
expression. Two, a low copy plasmid was used in case high copy expression of the tRNAs over-
loaded the yeast cell’s tRNA capacity. The tRNA nucleotide sequences were cloned individually 
and all three together into the pRS416 and the pRS426 vectors using restriction and ligation 
(Figure 33). Cloning with the low copy pRS416 plasmid was carried out as part of this PhD 
project; cloning with the high copy pRS426 plasmid was carried out by Dr Aga Urbanek (Prof 
Nia Bryant’s research group, University of York). Once correct cloning into both plasmid types 
was verified by Sanger sequencing, all eight vectors were co-transformed into S. cerevisiae cells 
with pESC-DCS as well as the corresponding empty vector controls. 
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Table 1. tRNAs chosen to be expressed in S. cerevisiae. 
Codon 
Abundance 
in DCS 
Number tRNAs in 
S. cerevisiae 
Amino acid Substitute tRNA 
CTG 17 1 Leucine Schizsaccharomyces pombe (Leu1) 
CTC 20 0 Leucine Saccharomyces cerevisiae (Leu2) 
GCG 23 0 Alanine Schizsaccharomyces pombe (Ala) 
 
 
 
Figure 33. Yeast pRS416 and pRS426 tNRA expression vectors. 
The three chosen tRNAs were cloned individually and together into pRS416 and pRS426 vectors. pRS416 is a low 
copy centromeric plasmid, pRS426 is a high copy episomal plasmid. Ala- Schizsaccharomyces pombe, alanine; Leu1- 
Schizsaccharomyces pombe, leucine; Leu2- Saccharomyces cerevisiae, leucine.  
 
Yeast cells, transformed with pESC-DCS and each of the tRNA vectors, were induced by the 
addition of 2 % galactose. The heterologous tRNAs did not require induction as eukaryotic tRNA 
expression is controlled by two intragenic regions 192,193. Protein extraction was performed and 
the quantity of DCS was analysed by western blotting (Figure 34). The western blot analysis of 
yeast cells transformed with the pRS416 set of plasmids was inconclusive as there was a 
contaminating band at the size DCS protein is expected, 42 kD, so only results from the pRS426 
plasmids is shown. DCS was expressed at low levels from pESC-DCS. Expression of all three 
tRNAs increased the amount of DCS expressed (see Figure 34). The addition of S. pombe leucine 
tRNA (Leu1) alone showed no effect upon the quantity of DCS protein expressed, whereas S. 
cerevisiae leucine tRNA (Leu2) increased the amount of DCS expressed. This was evident when 
expressed alone or in combination with the other tRNAs (see Figure 34). Individually, the effect 
of S. pombe alanine (Ala) could not be tested due to problems transforming yeast cells with the 
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pRS426-Ala vector. It was assumed S. pombe alanine tRNA did not have an effect upon DCS 
expression, as DCS expression was equivalent when expressed alongside both pRS426-Leu2 and 
pRS426-3tRNA. This suggests that only Leu2 allows an increase in DCS expression.  
As the quantity of DCS protein could be increased with the co-expression of S. cerevisiae leucine 
tRNA (pRS426-Leu2), the effect of S. cerevisiae leucine tRNA upon DCS protein quality was 
tested by carrying out an enzymatic assay. It was hypothesized that, in addition to allowing an 
increase in the quantity of protein expression, Leu2 may also allow a crucial improvement in 
protein quality allowing DCS enzyme activity to be detected. Crude protein was extracted from 
yeast transformed with pESC-DCS alone, or co-transformed with pRS426-Leu2, or pRS426-
3tRNA. The protein was then incubated with feruloyl-CoA and malonyl-CoA and assayed for the 
production of feruloyl diketide-CoA. As was the case with previous DCS performance in in vitro 
assays, no desired product could be detected by LC-MS. To ascertain the availability of feruloyl-
CoA and investigate the possibility that DCS may be converting the substrate into unexpected 
products, feruloyl-CoA was quantified by MS peak area (Figure 35). The addition of pRS426-
Leu2 had no observable effect upon DCS activity, inferred from no consumption of feruloyl-CoA, 
whether expressed alone (pRS426-Leu2) or in combination with Leu1 and Ala (pRS426-3tRNA). 
This observation lead to the conclusion that the lack of detectable DCS activity is not likely to be 
due to a codon mismatch between DCS and the S. cerevisiae heterologous host.  
 
 
Figure 34. Western blot analysis of DCS protein expression. 
Western blot analysis using anti-myc primary antibody (α-myc) to detect myc-tagged DCS protein expected at 42 kD. 
DCS was cloned into the pESC vector such that it was myc-tagged. DCS is expressed in low levels from pESC-DCS. 
DCS protein increases when expressed in yeast cells co-transformed with pRS426-3tRNA. This appears to be due to 
Leu2 and not Leu1. Anti-3-phosphoglycerte kinase 1 (α-Pgk1) detection was used as a loading control. Western blot 
analysis courtesy of Dr Aga Urbanek, Bryant research group, University of York.  
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Figure 35. Feruloyl-CoA consumption by protein extracted from yeast cells transformed with pESC-DCS and 
supplemental tRNAs. 
MS peak area quantification of feruloyl-CoA after 60 minutes incubation with malonyl-CoA and crude protein extract 
from yeast cells transformed with pESC-EV, pESC-DCS, pESC-DCS and pRS426-EV, pESC-DCS and pRS426- Leu2, 
pESC-DCS and pRS426-3tRNA. There is no significant difference between the amount of feruloyl-CoA remaining in 
the pESC-EV empty vector control assay compared to that of pESC-DCS. The addition of pRS426-Leu2 has no effect 
upon DCS activity, measured by consumption of feruloyl-CoA, whether expressed alone (pRS426-Leu2) or in 
combination with Leu1 and Ala (pRS426-3tRNA). The data are means ± standard deviations (n = 3). 
 
2.2.1.3 Investigating the heterologous expression of CURS1  
CURS1 (AB495007.1, Appendix 1.2, from C. longa rhizome tissue) catalyses the condensation 
of a phenylpropanoyl-CoA ester with a diketide-CoA ester to produce curcuminoids (see Figure 
6). Due to the diketide-CoA ester substrate of CURS1 being unavailable commercially and very 
difficult to synthesize chemically, assaying the activity of CURS1 relied upon the successful 
expression and activity of 4CL5 and DCS to produce the substrate.  
To investigate the activity of the third curcuminoid biosynthetic enzyme, CURS1 was synthesized 
by GenScript USA in the pUC57 plasmid. It was subsequently cloned into the pESC-DCS dual 
expression vector where it was translationally fused to a FLAG tag (Figure 36A). Yeast cells were 
transformed with this construct as verified by PCR, showing the expected product size of 1.2 kB 
(Figure 36B). Transcription of CURS1 was determined by RT-PCR on RNA extracted from yeast 
cells induced to express CURS1 from pESC-DCS-CURS1. PCR upon the cDNA derived from 
reverse transcription of the RNA gave a product at the expected size of 1.0 kB (Figure 36C). 
However, CURS1 protein could not be detected by western blotting of protein extracts from the 
same yeast cells (Figure 36D). Furthermore, when in vitro assays were performed using protein 
from yeast transformed with pYES2-4CL5 and pESC-DCS-CURS1, the expected curcumin 
product could not be detected (Figure 37). 
72 
 
 
Figure 36. Cloning, transformation and expression of pESC-DCS-CURS1.  
(A) pESC-DCS -CURS1 plasmid, for the expression of CURS1 in yeast under the control of the GAL10 galactose 
inducible promoter. CYC1-transcriptional terminator for efficient termination; TRP1- selection for transformants in 
yeast host strains with a trp1 genotype. Primers are denoted by arrows for DNA and cDNA amplification: B1- 
F_Asc1_CURS1; B2- GAL10R; C1- CURS1_F; C2- CURS1048_R, see Materials and Methods for primer sequences; 
(B) Agarose gel electrophoresis showing diagnostic PCR products from PCR performed upon DNA extracted from 
transformed yeast, using primers B1 and B2, to determine positive transformation of yeast cells. The PCR product was 
at the expected size of 1.2 kB; pESC-DCS-CURS1 plasmid was used as a positive control template (see Materials and 
Methods for primers); (C) Agarose gel electrophoresis showing diagnostic PCR products from PCR performed upon 
cDNA synthesized from RNA extracted from transformed yeast cells, using priemrs C1 and C2 to determine 
transcription of CURS1 from the pESC-DCS-CURS1 vector. The PCR product was at the expected size of 1.0 kB; 
pESC-DCS-CURS1 plasmid was used as a positive control template (see Materials and Methods for primers); (D) 
Western blot analysis using an anti-FLAG primary antibody to detect FLAG-tagged CURS1 protein (42 kD) in protein 
extracted from yeast cells transformed with the pESC-DCS -CURS1 plasmid. Ponceau stained membrane is shown as 
a loading control. pESC-EV is an empty vector control. The FLAG-tagged control protein (AbCam Positive Control 
Lysate) is evident (41 kD) when western blot analysis using anti-FLAG is used, whereas CURS1 is not, indicating no 
CURS1 protein expression.  
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Figure 37. Curcumin production by yeast protein extracted from pYES2-4CL5 and pESC-DCS-CURS1 transformed 
cells. 
Quantification by MS of curcumin produced in vitro by pYES2-EV and pYES2-4CL5 + pESC-DCS-CURS1 protein 
extract fed ferulic acid. See Appendix 2.13 for curcumin mass spectrum. No curcumin production could be detected 
using LC-MS although detection of the curcumin standard shows the analytical method was functioning. The data are 
means ± standard deviations (n = 3). 
 
2.2.1.4 Expression of curcuminoid biosynthetic enzymes mediated by the 2A 
polypeptide  
The 2A polyprotein is found in the cardio- and aphtho- (or foot and mouth disease virus; FMDV) 
genera of the picornavirus family. It is a 19 amino acid long sequence that causes ‘ribosome 
skipping’ giving multiple translational products from one open reading frame 194. Since its 
discovery, it has proven to be active in all eukaryotic systems tested 195,196 and has been used to a 
multitude of ends, from the stoichiometric production of therapeutic proteins to reconstituting 
biosynthetic pathways 197–199. The most commonly used 2A sequence is from FMDV (F2A) and 
it has been successfully used in Bakers’ yeast 175,200.  The ability of the F2A polypeptide to produce 
stoichiometric amounts of protein was to be utilised in this study to create a tuneable expression 
system. In tandem with investigating the activity of 4CL5, DCS and CURS1 when expressed 
individually, work was carried out into the expression and activity of these enzymes when linked 
by the F2A polypeptide in one ORF (pYES2-4CL5-F2A-DCS-F2A-CURS1) (Figure 38). If one 
of the enzymes proved rate limiting, additional copies of that gene could be added to the F2A 
mediated construct to increase the amount of enzyme translated and in turn increase metabolic 
flux. To allow the pathway to be broken down, DCS and CURS1 were also linked by the F2A 
polypeptide (pYES2-DCS-F2A-CURS1) (Figure 38). 
Transformation of yeast cells with pYES2-4CL5-F2A-DCS-F2A-CURS1 (pYES2-4DC) was 
verified by PCR upon DNA extracted from yeast colonies (Figure 38B). Primers were used for 
amplification of each of the genes giving products of the expected sizes: 4CL5 at 1.7 kD; DCS at 
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1.2 kD and CURS1 at 1.2 kD. Western blot analysis of yeast transformed with pYES2-4DC was 
unsuccessful due to contaminating bands at the expected sizes of the heterologously expressed 
proteins. However, western blot analysis of yeast cells transformed with pYES2-DCS-F2A-
CURS1 was successful (Figure 38C). When expressed from pYES2-DCS, DCS appears at the 
expected molecular weight, 42 kD. When expressed from pYES2-DCS-F2A-CURS1, DCS 
appears at ~ 47 kD, this is thought to be due to the addition of F2A (2.3 kD). The majority of the 
DCS protein appears to be cleaved from CURS1 as there is negligible protein detectable at 85 kD 
(the molecular weight of DCS-F2A-CURS1 protein). Therefore, it was concluded that the F2A 
polypeptide, linking DCS and CURS1, performed as expected, with the majority of the protein 
present in the cleaved form. 
Although western blot analysis was inconclusive, yeast cell culture transformed with pYES2-4DC 
was assayed for its ability to convert ferulic acid to curcumin (Figure 39). pYES2-DCS-CURS1 
was not investigated as pYES2-4DC allowed the assay to be conducted with readily available 
ferulic acid which could be CoA esterified by the 4CL5. As seen with the individually expressed 
enzymes, it was only possible to detect activity from the 4CL5 enzyme: yeast transformed with 
pYES2-4DC consumed ferulic acid faster than the pYES2-EV (see Figure 39). Although pYES2-
4DC appeared to consume ferulic acid faster than 4CL5 alone, no curcumin or feruloyl-CoA or 
feruloyl-diketide-CoA intermediates could be detected by LC-MS. 
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Figure 38. Cloning, transformation and expression of pYES2-DCS-F2A-CURS1 and pYES2-4CL5-F2A-DCS-F2A-
CURS1.  
(A) pYES2-DCS-F2A-CURS1 and pYES2-4CL5-F2A-DCS-F2A-CURS1 plasmids for the 2A polyprotein mediated 
expression of DCS, CURS1 and 4CL5 in yeast under the control of the GAL1 galactose inducible promoter. CYC1- 
transcriptional terminator for efficient termination; TRP1- selection for transformants in yeast host strains with a trp1 
genotype. Primers are denoted by arrows for DNA and cDNA amplification: B1- F_Asc1_4CL5; B2- R_XbaI_4CL5; 
B3- F_Asc1_DCS; B4- R_XbaI_DCS; B5- CURS1_F; B6- pYESrseq, see Materials and Methods for primer sequences. 
(B) 0.8 % Agarose gel showing diagnostic PCR products verifying yeast transformation with pYES2-4CL5-F2A-DCS-
F2A-CURS1 (pYES2-4DC) using primers B1 and B2 for 4CL5 detection, B3 and B4 for DCS detection and B5 and 
B6 for CURS1 amplification. PCR carried out upon pYES2-4CL5-F2A-DCS-F2A-CURS1 plasmid control was used 
as a control. (C) Western blot using anti-HIS primary antibody to visualise F2A polypeptide cleavage of protein 
expressed from pYES2-DCS-F2A-CURS1. Excellent cleavage is shown with the majority of DCS detected as single 
DCS protein (42 kD) and not linked to CURS1 (85 kD). DCS protein from yeast expressing pYES2-DCS-F2A-CURS1, 
appears at a slightly higher molecular weight than expected due to the presence of the F2A linker. The band at 
approximately 50 kD, in both lanes, was not identified. Ponceau stain loading control is shown below.  
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Figure 39. Ferulic acid consumption by pYES2-4CL5-F2A-DCS-F2A-CURS1 yeast cells. 
Ferulic acid was quantified by HPLC UV (260 nm) in the culture medium. pYES2-EV yeast cells showed no 
consumption of ferulic acid, whereas, over 96 hours, those transformed with pYES2-4CL5 and pYES2-4DC (pYES2-
4CL5-F2A-DCS-F2A-CURS1) did.  
 
2.2.2 Investigating curcuminoid biosynthesis in Nicotiana benthamiana 
With their ability to produce organic compounds from sunlight and water via photosynthesis, 
plants are able to function as sustainable chassis organisms for the recombinant production of 
secondary metabolites. Plant metabolic pathways occur in multiple subcellular locations, 
exemplified by the monoterpene indole alkaloid biosynthesis pathway which takes place in five 
different subcellular compartments 201. The idea of compartmentalising biosynthetic reactions was 
successfully used to produce the cyanogenic glycoside dhurrin in N. benthamiana chloroplasts 
202. Therefore, it was hypothesized that the curcuminoid biosynthetic enzymes may function as 
expected in a more ‘natural’ plant host such as tobacco, compared to S. cerevisiae. To test this, 
A. tumefaciens mediated transient expression of the three curcuminoid biosynthetic enzymes was 
planned. 
The fate of curcuminoid related compounds in tobacco 
Before carrying out assays with the heterologous enzymes, the fate of the model phenylpropanoid 
starting material, p-coumaric acid, and curcuminoid product, curcumin, was investigated. For 
curcumin biosynthesis in tobacco to be optimal the curcuminoid biosynthetic pathway would need 
to be orthologous, with both p-coumaric acid and curcumin not being metabolised by tobacco 
tissue allowing accumulation of the curcumin product. 
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First, the fate of the model phenylpropanoid starting material, p-coumaric acid was assayed. Leaf 
discs were cut from tobacco leaves and incubated in 1.0 mM and 2.5 mM p-coumaric acid 
solutions. A leaf disc assay was carried out so that the leaf tissue could be easily supplied 
substrates (see Materials and Methods). After 24 hours, the leaf discs incubated in the 2.5 mM p-
coumaric acid solution began to turn yellow and senesced, whereas those in the 1.0 mM p-
coumaric acid solution remained green and healthy until 48 hours, as monitored by visual 
inspection. Hence, all subsequent assays using p-coumaric acid were carried out in 1.0 mM 
solutions for 48 hours. As monitored by reverse phase HPLC over 48 hours, the tobacco tissue 
caused a decrease in p-coumaric acid shown by a decrease in the UV (250 nm) peak area (Figure 
40). The appearance of new peaks in the HPLC chromatogram at 13.9 and 15.3 minutes, after 24 
and 48 hours incubation with 1.0 mM p-coumaric acid, but not in the control lead to the conclusion 
that p-coumaric acid was being metabolised or causing the synthesis of new metabolites (Figure 
41). Looking at the MS negative ion analysis, the m/z of these peaks was 325.2 and 976.2 
respectively. Without further analysis it is postulated that the peak with m/z 325.2 is the glucoside 
of p-coumaric acid and the peak with m/z 976.2 is composed of three p-coumaric glucosides. As 
neither of these chemicals showed a fragmentation ion corresponding to p-coumaric acid, m/z 
163.0, this suggests the peaks are new chemicals synthesized due to the presence of p-coumaric 
acid, not chemical conjugations or modifications of p-coumaric acid itself.  
 
 
Figure 40. p-Coumaric acid decreased when incubated with tobacco leaf tissue. 
 p-coumaric acid was quantified by HPLC UV (250 nm) peak area at 0, 24 and 48 hours; the most significant decrease 
was shown over the first 24 hours. Data is from the combined analysis of 10 leaf discs, from 3 individual plants.  
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Figure 41. Reverse phase HPLC UV (250 nm) chromatograms showing decrease in p-coumaric acid. 
p-Coumaric acid in the tobacco leaf incubation solution was monitored by HPLC UV (260 nm) at (A) 0 hours, (B) 24 
hours and (C) 48 hours; (D) methanol negative control. The most significant decrease was shown over the first 24 
hours. New peaks were apparent after 24 and 48 hours at RT 13.9 and 15.3 minutes. Data is from combined analysis 
of 10 leaf discs, from 3 individual plants. 
 
 
Figure 42. Curcumin decreased when incubated with tobacco leaf tissue. 
Curcumin was quantified by HPLC UV (425 nm) peak area at 0, 24 and 48 hours. After 24 hours, the majority of 
curcumin was no longer detectable. Data is from combined analysis of 10 leaf discs, from 3 individual plants. 
 
Secondly, the fate of curcumin incubated with tobacco leaf tissue was investigated. Tobacco leaf 
discs were incubated in 0.2 mM curcumin solution for 48 hours. Curcumin was monitored and 
quantified by HPLC (Figure 42): after 24 hours, no curcumin was detectable. As there were no 
new peaks in the HPLC trace which could elude to the metabolism of curcumin, the MS total ion 
current (TIC) trace was examined further: the auto-oxidation degradation product of curcumin, 
bicyclopentadione m/z 399.1 was apparent 203. This suggested that as well as tobacco metabolising 
curcumin it was also degrading independently. 
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Unless the metabolism of p-coumaric acid and curcumin in tobacco could be prevented, tobacco 
would be unlikely to prove a successful chassis for curcuminoid biosynthesis. Turmeric rhizomes 
are highly specialised for the production of secondary metabolites such as curcuminoids: in an 
investigation by Koo et al. 174, they showed that the branchpoint enzyme to curcuminoid 
biosynthesis, PAL, is only expressed in the rhizomes and is not detected at all in the leaves. Due 
to curcuminoids only being produced in the underground rhizomes of the turmeric plant, it was 
hypothesized that light may affect their accumulation. This hypothesis was supported in the 
current study by the detection of bicyclopentadione, an auto-oxidative degradation product of 
curcumin 110,204, which is produced in the presence of free radicals. Therefore, the leaf disc 
incubations with p-coumaric acid and curcumin were repeated in the dark.  
After 48 hours in solution without tobacco tissue, p-coumaric acid remains at initial levels in both 
light and dark conditions (Figure 43). However, when incubated with leaf tissue, p-coumaric acid 
is degraded. Initially p-coumaric acid degradation occurs faster in the light than in the dark, but 
after 48 hours the extent of degradation is comparable.  
After 48 hours in light conditions, curcumin in solution is degraded by ~ 70 %; when leaf discs 
are present, this increases drastically with virtually no curcumin remaining (0.34 %) (Figure 44). 
In the dark, curcumin degradation is barely evident after 48 hours in solution; with 96 % 
remaining. When leaf discs are added to the dark incubation, curcumin levels drop to 42 % 
indicating metabolism by the leaf tissue. Therefore, while light alone causes curcumin breakdown, 
endogenous activity of leaf tissue results in significant light-independent degradation.  
 
Figure 43. Percentage change in quantified  p-coumaric acid when incubated with leaf tissue in the light and 
dark. 
p-Coumaric acid in incubation solution was quantified by HPLC UV peak area (250 nm) after 0, 24 and 48 hours 
with and without tobacco leaf discs in the light and dark. Data is from combined analysis of 10 leaf discs, from 
3 individual plants. 
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Figure 44. Percentage change in quantified curcumin when incubated with leaf tissue in the light and dark. 
Percentage of curcumin, measured by HPLC UV peak area (425 nm) after 0, 24 and 48 hours after incubation 
with and without tobacco leaf discs in the light and dark. Data is from combined analysis of 10 leaf discs, from 
3 individual plants. 
 
 
Exploring the ability of curcuminoid biosynthetic heterologous enzymes to outcompete the 
endogenous metabolism of p-coumaric acid 
To replicate the curcuminoid biosynthesic pathway in tobacco, the same three CDSs as used for 
expression in yeast, 4CL5, DCS and CURS1, were cloned into the pFGC5941 binary vector 
(Figure 45). When the binary vector is transformed into Agrobacterium tumefaciens, the bacterial 
suspension can be infiltrated into leaf tissue allowing transient expression of the cloned gene 
(agro-infiltration). The extent to which the heterologous enzymes could compete with the 
endogenous and degradative pathways of p-coumaric acid and curcumin was to be assessed using 
LC-MS analysis.  
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Figure 45. pFGC5941 binary vectors for expression of curcuminoid biosynthetic enzymes in tobacco. 
pFGC5941 binary vectors for transformation of Agrobacterium tumefaciens for the transient expression of the 
curcuminoid biosynthetic enzymes 4CL5, DCS and CURS1 in tobacco leaf tissue. The region of the vector which 
transforms the plant tissue is known as transfer, or T-DNA and is flanked by the left border (LB) and the right border 
(RB).  The octopine synthase terminator (OCS T) was used. Basta resistance gene (BAR) is used for stable expression 
in plants.  
 
With the expectation that heterologous 4CL5 may be able to out-compete the metabolism of p-
coumaric acid, leaf disc tissue was harvested from plants agro-infiltrated with a series of 
differently transformed A. tumefaciens culture combinations: pFGC5941-4CL5; both pFGC5941-
4CL5 and pFGC5941-DCS; and pFGC5941-4CL5, pFGC5941-DCS and pFGC5941-CURS1. 
This was to allow each step of curcuminoid biosynthesis to be monitored. When heterologous 
expression of the curcuminoid biosynthetic enzymes was quantified by quantitative PCR (qPCR), 
4CL5 was the only transcript that could be detected in elevated levels: 1500 times greater than 
the control (Figure 46). There were no detectable transcripts of DCS or CURS1 from agro-
infiltration with pFGC5941-DCS or pFGC5941-CURS1 respectively.  
Heterologous enzyme activity was monitored by LC-MS analysis. The only enzyme that appeared 
to be active was 4CL5, and activity could only be detected when assayed in the light (Figure 47): 
there is a faster decrease in p-coumaric acid when incubated with leaf tissue transformed with 
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4CL5, than untransformed tissue. However, this is only significant at 24 hours (61 % utilised after 
24 hours compared to 26 %) and furthermore, no p-coumaroyl-CoA ester product could be 
detected. When p-coumaric acid was incubated in the dark with pFGC5941-4CL5 agro-infiltrated 
leaf tissue, after 48 hours there was no change in its abundance. This suggests that the activity of 
4CL5 is dependent upon light, whether this is a direct or indirect effect remains to be addressed. 
4CLs are known to be induced by stress 156, but light has not been described as a regulator of 
4CL5 activity or expression. The lack of detection of DCS and CURS1 metabolites is most likely 
due to an absence of enzyme production since an increase in the corresponding transcripts was 
not detected. 
 
Figure 46. qPCR quantifying 4CL5, DCS and CURS1 expression in tobacco. 
qPCR was performed upon RNA extracted from un-infiltrated tobacco leaf tissue and leaf tissue agro-infiltrated with 
pFGC5941-4CL5, pFGC5941-DCS or pFGC5941-CURS1. The only transcript apparent is that of 4CL5 from 
expression of pFGC5941-4CL5. There is no difference in DCS or CURS transcript abundance whether the leaf tissue 
is agro-infiltrated with pFGC5941-DCS, pFGC5941-CURS1 or not.  
 
 
Figure 47. Quantification of p-coumaric acid when incubated with leaf tissue transformed with pFGC5941-
4CL5. 
p-Coumaric acid was quantified by HPLC peak area, UV (250 nm) after 0, 24 and 48 hours after incubation with 
control tobacco leaf discs or with pFGC5941-4CL5. Data is from combined analysis of 10 leaf discs, from 3 
individual plants.  
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2.3 Discussion and Future Work 
Due to the bioactivity of the three curcuminoids, curcumin, DMC and BDMC, the initial objective 
of this work was to evaluate platforms for their heterologous biosynthesis. S. cerevisiae and N. 
benthamiana were selected for evaluation. To produce curcuminoids in these systems the coding 
sequences for the three biosynthetic enzymes necessary to convert phenylpropanoids to 
curcuminoids, 4CL5, DCS and CURS1, were amplified and cloned into appropriate expression 
vectors and transformed into yeast cells or agro-infiltrated into N. benthamiana leaf tissue. In 
yeast, the genes were transformed either individually or as a single unit linked by the 2A 
polypeptide. In both systems, the only enzyme for which evidence of activity was demonstrated 
was 4CL5. Consequently, it has not been possible to biosynthesise curcuminoids in either host. 
Investigating S. cerevisiae as a heterologous host for curcuminoid biosynthesis 
A CDS of a 4CL from C. longa was to be used as the first enzyme in the biosynthetic pathway. 
The best described monocotyledonous 4CLs are from rice, and they belong to one of two classes, 
III or IV 164 (class I and II are in dicots 162). Using the CDS of monocotyledonous Os4CL3, five 
partial coding sequences of 4CLs were identified from C. longa transcriptome data. Phylogenetic 
analysis of these partial sequences showed them all to align with the type III 4CLs from rice and 
switchgrass and are therefore likely to be involved in lignin biosynthesis. Due to the abundance 
of curcuminoids in the rhizome tissue, this was unexpected, as it would have been anticipated that 
some of the 4CL ESTs from rhizome tissues would be involved in secondary metabolism. Despite 
multiple attempts it was not possible to amplify full length C. longa 4CL from C. longa rhizome 
RNA. As an alternative, a known and characterised 4CL was evaluated. 
4CL5 was chosen due to it exhibiting the widest substrate specificity of the four Arabidopsis 4CLs 
172,179,205. In addition to being able to produce natural phenylpropanoyl-CoA ester products of all 
natural phenylpropanoyl substrates tested in vitro (see Figure 25), 4CL5 was also able to produce 
CoA esters of non-natural substrates 4- methoxycinnamic acid, 3,4-dimethoxycinnamic acid and 
4-dimethylaminocinnamic acid (see Figure 27). The accumulation of the novel CoA esters varied: 
4- methoxycinnamoyl-CoA abundance increased over time, like feruloyl-CoA, however 3,4-
dimethoxycinnamoyl-CoA 4-dimethylaminocinnamoyl-CoA peaked at 3 hours. This may be due 
to a lower stability of 3,4-dimethoxycinnamoyl-CoA and 4-dimethylaminocinnamoyl-CoA. The 
versatility of 4CL5 to accept a variety of substrates has since been demonstrated by Eudes et al. 
151; its ability to do so was successfully utilised to produce over 160 different anthranilates in S. 
cerevisiae. The flexible substrate specificity of 4CL5 is thought to be due to its larger substrate 
binding pocket compared to other Arabidopsis 4CLs: amino acid 418 in the substrate binding 
pocket is a smaller valine, compared to isoleucine 171,205. Therefore, although 4CL5 was unable to 
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be used towards producing curcuminoids in this study, it has shown the potential to be a valuable 
enzyme for the synthesis of a variety of natural and non-natural polyphenolics.  
The lack of detectable phenylpropanoyl-CoA esters in 4CL5 in vivo cell culture assays was a 
problem as their availability was required for the subsequent steps of curcuminoid biosynthesis 
(see Figure 16). One possible explanation for the lack of accumulation of phenylpropanoyl-CoA 
esters in vivo is that they are broken down in a process involving peroxisomal catabolism similar 
to that of fatty acid CoA esters. In S. cerevisiae, fatty acids destined for metabolism via β-
oxidation first require transport into the peroxisome 206. Fatty acids cross the peroxisomal 
membrane in two ways, either passively as free fatty acids or actively transported by the 
PXA1/PXA2 heterodimeric ABC transporter as CoA esters 207–209. Therefore, blocking transport 
of CoA esters into the peroxisome, could avert the metabolism of the phenylpropanoyl-CoA 
esters. 
Individual disruption of PXA1 or PXA2 in yeast exhibits impaired growth on oleic acid by ~50 
% 207,208. Based on the assumption that, as with oleoyl-CoA esters, phenylpropanoyl-CoA ester 
transport into peroxisomes (and therefore subsequent catabolism) is dependent on PXA1 and 
PXA2, the corresponding gene-disruption mutants (pxa1 and pxa2) were obtained from GE 
Healthcare. The plan was to transform these with pYES2-4CL5 and test for accumulation of 
phenylpropanoyl-CoA esters produced by 4CL5. The phenotypes of pxa1 and pxa2 were first 
tested by growing on agar plates in which oleic acid was the sole carbon source. Wild type S. 
cerevisiae (BY4742) can utilise oleic acid as the sole carbon source and grown normally whereas 
growth should be impaired in pxa1 and pxa2 210. However, the mutants that were obtained did not 
exhibit this phenotype, that is they utilised oleic acid as effectively as wild type (Appendix 2.14), 
and thus they were considered not suitable to test for accumulation of phenylpropanoyl-CoA 
esters. 
It may not be necessary to knockout phenylpropanoyl-CoA ester utilisation in yeast, as long as 
the heterologous enzyme using the CoA ester, in this case DCS, can out-compete the endogenous 
yeast system. 4CL5 successfully competes with the endogenous yeast enzyme PAD1 for 
phenylpropanoic acids and previous work creating heterologous biosynthetic pathways in S. 
cerevisiae comprising 4CLs had previously proven successful 211,212. Therefore, despite no 
detectable production of CoA esters in cell culture by 4CL5, it was considered possible that DCS 
could out-compete endogenous yeast metabolism for CoA ester substrate availability. Despite 
DCS protein being detected by western blot analysis (see Figure 28) enzymatic activity in vivo 
and in vitro, as analysed by LC-MS, was not.  In collaboration with Professors Bryant and White, 
it was hypothesized that due to a codon mismatch between DCS and S. cerevisiae translational 
machinery, the DCS protein may not be translated correctly yielding a non-functional enzyme. 
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This was addressed by co-expressing three tRNAs from S. cerevisiae or S. pombe that were 
absent, or present in very low levels in S. cerevisiae, but whose codons were abundant in DCS. 
The S. cerevisiae leucine tRNA that corresponded to the CTC codon allowed an increase in 
protein production (see Figure 34), but the increase in protein quantity did not result in detectable 
enzyme activity (see Figure 35). The other two tRNAs (for codons CTG and CGC) had no effect 
upon protein abundance. This may be because these tRNAs were from S. pombe, rather than S. 
cerevisiae: for transcription, many S. pombe tRNAs contain an essential upstream promoter 
element unlike the tRNAs studied from S. cerevisiae 213,214.  To investigate expression of the 
tRNAs further, a Northern blot should be carried out to ascertain the levels of tRNA. It should 
also be considered that over expressing a tRNA may not necessarily allow greater protein 
expression as tRNAs require modifications and many other cellular components to be functional. 
In fact, under-acetylated tRNAs can actually cause a decrease in translational fidelity as missense 
substitutions increase 186. 
Although expressing tRNAs to balance the codon usage of Bakers’ yeast with DCS did not result 
in enzyme activity being detected, creating a yeast strain that is engineered to produce tRNAs to 
address codon bias for heterologous gene expression of non-optimised sequences may prove 
useful. Such a strain would enable yeast to produce high quantity and high quality non-codon 
optimised recombinant proteins, an idea which has already shown to be beneficial and marketable 
as evidenced by Novagen’s Rosetta E. coli strains. It has the potential to allow increased 
expression of cDNA libraries in S. cerevisiae and reduce the costs associated with codon 
optimisation and gene synthesis.   
There are at least two possible reasons why DCS enzyme activity was not detected: either the 
protein was not correctly assembled or the internal environment of the yeast cell was not 
conducive for catalysis. Katusuyama’s enzymatic studies of DCS determined the enzyme’s 
optimum conditions to be 25- 35 ̊ C and pH 6.5- 7.5 95. Yeast in vivo assays were carried out at 
30 ̊ C and pH was maintained at 6.0 215, consequently DCS would be expected to be active. Using 
the Technical University of Denmark’s Centre for Biological Sequence Prediction Server the 
amino acid sequence of DCS was analysed to predict potential subcellular localisation by 
ascertaining whether it contained any N-terminal presequences such as a chloroplast transit 
peptide, mitochondrial targeting peptide or secretory pathway signal peptide. The algorithm did 
not predict DCS to contain any N-terminal signal peptides, so it is unlikely that DCS was non-
functional because of incorrect subcellular localisation. However, polyketide synthases are known 
to associate with the membrane of the endoplasmic reticulum and that the presence of multi-
enzyme complexes localised here, facilitate metabolic reactions 216.  This indeed could be a key 
factor towards the lack of detectable DCS activity. Other avenues such as incorrect protein folding 
should be investigated.  
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The final enzyme in the heterologous pathway, CURS1, was not fully investigated in this study 
due to the lack of substrate availability. Future work would require the synthesis of the substrate 
by DCS or using chemical synthesis. In publications by Katsuyama 93,95, where the activity of 
CURS1 was assayed, cinnamoyldiketide-N-acetylcysteamine, a substrate analogous to the natural 
substrate was used instead 218.  
Stoichiometric co-expression of the three different genes was also attempted using the F2A 
polypeptide as a linker. Exceptional F2A cleavage was ascertained between DCS and CURS1 
(see Figure 38D) when expressed from pYES2-DCS-F2A-CURS1, with little uncleaved protein 
being detected by western blot analysis. Although enzymatic activity was not apparent, the highly 
efficient cleavage illustrated the potential of F2A for yeast biosynthetic pathway production. 
Investigating N. benthamiana as a heterologous host for curcuminoid biosynthesis 
The three necessary biosynthetic curcuminoid enzymes, 4CL5, DCS and CURS1 were 
successfully cloned into the pFGC5941 vector and transformed into Agrobacterium tumefaciens 
to allow their transient expression in N. benthamiana via agro-infiltration. Before investigating 
the biosynthetic pathway, the fate of p-coumaric acid and curcumin in N. benthamiana was 
evaluated since the metabolism of curcumin would be highly undesirable by a chassis system for 
curcuminoid production. Unfortunately, over 48 hours, both p-coumaric acid and curcumin were 
metabolised by tobacco (see Figure 43 and Figure 44). Exogenous p-coumaric acid caused the 
appearance of two new detectable compounds, whose identities were not ascertained. There are 
known endogenous 4CLs in tobacco 219, so it is plausible that p-coumaric acid was CoA-esterified 
and taken up into phenylpropanoid metabolism or lignin biosynthesis 220. In animals, exogenous 
curcumin is reduced to tetra- or hexa-hydrocurcumin and conjugated with glucuronic acid or 
sulfate or cleaved to ferulic acid and vanillin before being excreted 114,221. However, there are no 
known pathways for the metabolism of exogenous curcumin in plants. Plant metabolism of 
xenobiotics usually proceeds via three phases: biotransformation, bioconjugation and deposition 
in the vacuole or incorporation into the cell wall 222. In solution, curcumin’s minor degradation 
products are vanillin, ferulic acid, and feruloylmethane and the major degradation product is a 
bicyclopentadione, the result of auto-oxidative incorporation of O2 and rearrangement 110,204.  Only 
the latter was detected in the mass spectrum after tobacco tissue had been incubated with curcumin 
solution. This may be due to the sequestration of curcumin conjugates for which the extraction 
method was insufficient.  
Despite tobacco metabolising p-coumaric acid, it was hypothesized that, as in yeast, heterologous 
4CL5 would be able to compete with the endogenous enzymes and shuttle the substrate into 
curcuminoid biosynthesis. This was indeed observed, as leaf tissue agro-infiltrated with 
pFGC5941-4CL5 caused a decrease in p-coumaric acid quicker than the control (see Figure 47). 
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However, no p-coumaroyl-CoA production by 4CL5 could be detected. Further leaf disc 
incubation assays should be carried out with p-coumaroyl-CoA to attempt to ascertain its fate in 
tobacco.  
As curcuminoid biosynthesis occurs in underground rhizomatous tissue, the effect of dark 
conditions upon the degradation of p-coumaric acid and curcumin was investigated. Assays 
carried out in the dark showed a reduction in the degradation and metabolism of both p-coumaric 
acid and curcumin. However, curcumin degradation was mainly caused by light alone (see Figure 
44). Although light deprivation slowed the metabolism of p-coumaric acid, 4CL5 did not exhibit 
any activity as it did in the light suggesting a dependency upon light (see Figure 47). This could 
be explained by a reduction of ATP produced in the dark (ATP is involved in the first step of the 
two step CoA-esterification reaction) due to a reduction in photosynthesis. Another avenue which 
could be investigated to reduce p-coumaric acid consumption by tobacco leaf tissue is utilising 
RNAi to silence genes whose enzyme products are involved in utilising p-coumaric acid for lignin 
biosynthesis. However, repression of certain lignin biosynthetic enzymes, such as O-
methyltransferases, strongly affected plant development so much consideration of target genes is 
needed 223.  
Enzymatic activity of the second two enzymes of the curcuminoid biosynthetic pathway, DCS 
and CURS1, could not be detected in tobacco. This is likely due to a lack of expression of the 
enzymes as ascertained by qPCR (see Figure 46). The problems with expressing and detecting 
activity of the two type III polyketide synthases in both hosts needs to be addressed further. It 
would be valuable to compare the expression and activity of the non-codon optimised DCS and 
CURS1 used in this project, with the codon optimised versions successfully utilised by Rodrigues 
et al. 107 in E. coli. 
In both systems the only enzyme to exhibit activity was 4CL5. A lack of chemical standards for 
the product of DCS catalysis (and substrate of CURS1) made assays and further analysis difficult. 
Both p-coumaric acid and curcumin were metabolised in the tobacco leaf system making it a poor 
host for production of curcuminoids. The fact that C. longa rhizomes can accumulate 
curcuminoids, suggests that curcuminoid biosynthesis may be compartmentalised. Ginger, a 
fellow member of the Zingiberaceae family, accumulates secondary metabolites within large lipid 
bodies 101. This environment may be conducive to DCS and CURS1 activity whereas heterologous 
yeast and tobacco are not. Furthermore, curcumin showed a high rate of degradation in the 
solution applied to the tobacco leaf tissue. In conclusion, one can identify multiple reasons why 
curcuminoid biosynthesis was not achieved in either heterologous host system. 
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Chapter 3. The production of glucosylated curcuminoids  
3.1 Introduction 
Curcuminoids exhibit a plethora of medicinal benefits, however, their poor bioavailability is a 
drawback to their efficacy as drug molecules 115. Consequently, there is a lot of interest in 
increasing the bioavailability of curcuminoids such as creating liposomal or nanoparticulate 
formulations, administration with adjuvants or creating structural analogues with improved 
biophysical properties 112,118,224,225. Glucosylation of hydrophobic molecules is a well-known 
strategy to enhance water solubility 226: curcumin monoglucoside is 230 times more soluble in 
water than curcumin and curcumin diglucoside is 10 million times more soluble in water than 
curcumin 138. Compared to chemical glucosylation, enzymatic glucosylation offers greater regio- 
and stereo specificity and allows milder reaction conditions 119. One aim of this project was to use 
biocatalysis to produce more bioavailable, glucosylated curcuminoids. 
UDP-glycosyltransferases (UGTs) catalyse the glucosylation of small molecules, with the 
majority using uridine diphosphate-glucose (UDP-glucose) as a sugar donor. In plants, they 
function to mediate the stability, solubility and activity of endogenous secondary metabolites as 
well as detoxifying xenobiotics such as herbicides 226. By doing so they maintain intracellular 
homeostasis whilst responding to abiotic and biotic stresses. 
The diverse range of substrates, along with the enantio- and regioselectivity of UGTs, offers a 
huge potential for biocatalysis. Biotechnology has explored plant cell cultures for their ability to 
glucosylate a wide variety of industrially relevant aromatic compounds such as vanillin 227, 
hydroquinone 228 and capsaicin 229. All these processes utilised Catharanthus roseus plant cell 
culture and this is to date, the only plant from which UGTs that glucosylate curcuminoids have 
been characterised 138. Although, there is evidence that P. tricuspidata cell culture can also 
glucosylate curcumin, there is no sequence data for the enzymes involved 145. In both systems, 
when exogenous curcumin was applied to plant cells extracts, a series of glucoside, di-glucoside, 
gentiobioside, and digentiobiosides were produced, all of which were β-anomers (see Figure 13). 
The only instance of curcumin-α-glucoside production by enzyme catalysis was using an 
amyloglucosidase from the fungus Rhizopus 136.  
The cDNA sequence for the two UGTs responsible for curcumin glucosylation by C. roseus cell 
culture were isolated and the corresponding enzymes characterised 1,143. The two enzymes were 
designated CaUGT2 and CaUGT3. CaUGT2 converts both curcumin and curcumin 
monoglucoside to curcumin monoglucoside and curcumin diglucoside, respectively; the KMs of 
89 
 
which are 19 and 63 µM, respectively. However, its ability to glucosylate curcuminoids other 
than curcumin was not studied. CaUGT3, a sugar-sugar glycosyltransferase which was able to 
add an additional sugar group onto the existing sugar moiety of curcumin glucosides, produced 
curcumin gentiobiosides (see Figure 14). 
This project aimed to express a curcuminoid UGT in S. cerevisiae to produce curcuminoids 
glucosides, with enhanced bioavailability. It was expected to be an improvement upon current 
proof-of-concept biosyntheses by being easily scalable, therefore allowing the creation of an 
industrially relevant, greener alternative to the chemical synthesis of curcuminoid glucosides. To 
date, no UGTs have been identified in C. longa or its Zingiberaceae family member ginger (Z. 
officinale) which produces secondary metabolites similar to curcuminoids such as 6-gingerol. 
This study aimed to investigate C. longa as a source of a novel curcuminoid UGTs that could be 
used in a heterologous yeast system.  
3.2 Results 
3.2.1 Searching for curcuminoid glucosides in C. longa metabolite extracts 
To produce glucosylated curcuminoids in yeast, a UGT enzyme which could glucosylate 
curcuminoids was needed. Although CaUGT2 from C. roseus could be used, the discovery of a 
novel UGT from C. longa was first explored. As C. longa rhizome tissue is the primary tissue in 
which curcuminoid biosynthesis occurs 174, evidence of curcuminoid UGT activity was looked 
for in these organs. Using LC-MS analysis, it was first investigated whether curcumin glucosides 
could be identified in C. longa metabolite extracts. 
LC-MS metabolite analysis of extracts from 13 samples (n = 30) of C. longa rhizome tissues 
collected from 9 different locations across Vietnam (Table 2) had previously been performed in 
the CNAP metabolite profiling unit by Dr Tony Larson in collaboration with Kieu Oahn Nguyen, 
University of Science and Technology, Hanoi, Vietnam. The extraction and LCMS detection 
conditions were suitable for detection of curcuminoids and other molecules (see Materials and 
Methods). 
The five most abundant metabolites extracted from the C. longa rhizome tissues were quantified 
by their mass spectrum peak areas (Figure 48). Due to the size of their parent ions, these were 
identified as the three main curcuminoids (curcumin, DMC and BDMC (see Figure 1)) and two 
sesquiterpenes, ar-turmerone and turmerone (Figure 49). The most abundant secondary 
metabolites were the turmerone sesquiterpenes. In all the samples curcumin was the most 
prevalent curcuminoid, with lower amounts of DMC and BDMC present at similar levels. There 
was a clear variability in the amount of secondary metabolites within and between the samples. 
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The two samples from the Lạng Sơn province (HLLS and BSLS) overall contained the greatest 
amount of secondary metabolites. BVNH, LNBG, TLHB and YTHB contained approximately 
tenfold less metabolites than the rest of the samples. 
  
Table 2. C. longa  rhizome samples gathered from across Vietnam. 
Abbreviation Location (Province) 
BVNH Ba Vì (Hà Nội) 
HLLS Hữu Lũng (Lạng Sơn) 
BSLS Bắc Sơn (Lạng Sơn) 
LDI Garden 48 (Lâm Đồng) 
LDII Garden 56 (Lâm Đồng) 
LGBG Lạng Giang (Bắc Giang) 
LNBG Lục Nam (Bắc Giang) 
KTNA Kẻ La Thượng (Nghệ An) 
DHQT Đông Hà (Quảng Trị) 
ATTQ An Tường (Tuyên Quang) 
XMHB Xuân Mai (Hòa Bình) 
YTHB Yên Thủy (Hòa Bình) 
TLHB Tân Lạc (Hòa Bình) 
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Figure 48. Quantification of the five most abundant secondary metabolites in Vietnames C. longa samples. 
MS peak area was used to quantify the five most abundant secondary metabolites present in C. longa rhizomes from 13 samples from across Vietnam. MS peak area: turmerone m/z 219.17, Ar-
turmerone m/z 217.16, curcumin m/z 369.13, DMC m/z 339.12 and BDMC m/z 309.11. The data are means ± standard deviations (n = 30). With thanks to Kieu Oahn Nguyen for collecting and 
performing extractions upon the samples and Dr Tony Larson for providing access to the structured mass spectra dataset.
92 
 
 
Figure 49. Chemical structures of sesquiterpenes ar-turmerone and turmerone. 
 
The abundance of curcumin in each of the samples was plotted on the basis of collection site 
location (Figure 50A). The north of Vietnam, in the Lạng Sơn province, provided rhizomes with 
the greatest curcumin abundance (BSLS and HLLS), with the second most abundant, LTTQ, 
nearby in Tuyên Quang (Figure 50B). This may be due to their location in the fertile Red Delta, 
and the fact that the north of Vietnam has a more humid tropical climate, favouring C. longa 
growth compared to that of southern Vietnam. However, the accessions with the lowest 
abundance, LNBG and BVHN, were also located in the Red Delta area. Due to the small number 
of accessions and lack of detailed information on the harvest sites (such as age of plant, nitrogen 
abundance, soil pH, presence of heavy metals and pest populations) no firm conclusion could be 
made about the geographical influence upon secondary metabolite abundance.  
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Figure 50. Map of Vietnam showing the sampling locations of the C. longa rhizome samples.  
The size of each red point mirrors the abundance of curcumin, quantified by MS peak area, in the turmeric 
rhizome sample gathered from that area. (A) All of Vietnam. (B) The dotted region in (A) is shown in more detail 
in to highlight the lowest abundance samples. 
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The LC-MS data was further analysed for the presence of glucosylated curcuminoids. No 
detectable mass ions corresponding to the expected sizes of glucosylated curcumin, DMC or 
BDMC were present in the dataset. Glutathionylated and sulfonated bioconjugates of 
curcuminoids were also searched for, but could not be found. The lack of curcuminoid conjugates, 
not only glucosides, was surprising as curcuminoids are extremely abundant in the rhizome tissue. 
This lead to the suggestion that the plant most likely utilises another strategy to modulate 
curcuminoid activity and storage. A comparison of the abundance of the secondary metabolites 
extracted from the rhizome tissues showed that the amounts of curcuminoids correlated as 
expected, with curcumin and DMC showing an almost perfect Pearson correlation (r (28) = 0.98, 
p < 0.01 (Table 3)). Interestingly, the abundance of the turmerones and curcuminoids also showed 
a high Pearson correlation co-efficient e.g. the correlation between curcumin and turmerone 
abundance was r (28) = 0.78, p < 0.01. This correlation wasn’t expected as the sesquiterpene and 
polyketide pathways are distinct. Ginger, a fellow member of the Zingiberaceae family, utilises 
hydrophobic secondary metabolites such as sesquiterpenes to form liposomal droplets around its 
polyphenolic bioactives 101. Due to the correlation of sesquiterpene and curcuminoid abundance, 
it is possible that C. longa utilises a similar strategy to ginger; using turmerones to dissolve and 
encapsulate curcuminoids without the need for glucosylation or bioconjugation. 
 
Table 3. Pearson correlation co-efficients between the abundance of the top five most prevalent metabolites in C. longa 
rhizome tissue as quantified by parent ion MS peak area. 
The darker the colour, the greater the correlation. Degrees of freedom = 28, p < 0.01. 
 Turmerone Ar-turmerone Curcumin DMC BDMC 
Turmerone 1.00 0.91 0.78 0.78 0.78 
Ar-turmerone 0.91 1.00 0.66 0.62 0.60 
Curcumin 0.78 0.66 1.00 0.98 0.98 
DMC 0.78 0.62 0.98 1.00 0.97 
BDMC 0.78 0.60 0.98 0.97 1.00 
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As there were no curcuminoid glucosides detected in the LC-MS dataset of the 13 C. longa 
rhizome samples from Vietnam, it was decided to perform a different, more intensive metabolite 
extraction. A methanolic Soxhlet extraction was performed upon fresh C. longa rhizomes and a 
liquid-liquid extraction was carried out with the expectation of separating any curcumin 
glucosides from other metabolites. LC-MS analysis was carried out upon all extracts, yet again 
no curcumin glucosides could be detected in the LC chromatogram or mass spectrum. To further 
investigate the question of curcuminoid glucosylation, a glycosidase assay was performed upon 
the extract using a Trichoderma reesei cellulase and products were detected by HPLC analysis 
(Figure 51). The rationale of this experiment was that the cellulase would cleave any glycosidic 
bonds causing a disappearance or shift of HPLC chromatogram peaks. This was observed for the 
monoglucosylated curcumin positive control (Figure 51A): the curcumin monoglucoside peak, m 
(RT 8.9 minutes), disappears with glycosidase treatment. The peak for the aglycone curcumin, c 
(RT 12.4 minutes), remained unaffected, as expected. Analysis of the methanolic rhizome extract 
showed there was no change in the chromatogram before and after glycosidase treatment, leading 
to the conclusion that there were no glucosylated curcuminoids in the rhizome methanolic extract 
(Figure 51B). 
 
 
Figure 51. Glycosidase assay of C.longa metabolite extract as monitored by HPLC. 
HPLC chromatograms (425 nm) of C. longa rhizome methanol extract treated with and without cellulase. The 
positive control (A) shows a disappearance in the curcumin monoglucoside peak (m, RT 8.9 minutes) in the 
presence of glycosidase. (B) There was no difference in the HPLC traces of the methanol extract treated with, 
and without glycosidase. Curcumin (c, RT 12. 4 minutes), the major peak in all the samples, remained unaffected 
by glycosidase treatment. 
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3.2.2 Searching for evidence of curcuminoid UGTs in C. longa   
To investigate whether the lack of detectable glucosides in C. longa was due to a lack of UGTs, 
protein was extracted from C. longa rhizomes and assayed for UGT activity. Protein extract from 
Arabidopsis (A. thaliana) and rice (O. sativa) was also investigated for UGT activity towards 
curcuminoids. Radiolabelled 14C-UDP-glucose was incubated with the protein extracts and 
potential acceptor substrates curcumin, DMC, BDMC (see Figure 1) and the positive control 
substrates 2,4,5- trichlorophenol (TCP) and quercetin (Figure 52). TCP is a degradation product 
of many xenobiotics and persists in the environment, therefore is a typical UGT substrate 230. 
Quercetin is a flavonoid which has been shown to be glycosylated by many different UGTs 130.  
Transfer of the 14C-glucose radiolabel to the potential acceptors was quantified by scintillation 
counting of the ethyl acetate layer after liquid-liquid extraction (Figure 53) (see Materials and 
Methods). There was no UGT activity evident towards methanol as expected. Activity towards 
the model substrates TCP and quercetin showed that the radiolabelling assay was functioning and 
UGTs in the plant protein extracts were functioning and could be detected. C. longa rhizome 
protein extract exhibited the greatest activity towards TCP (Figure 53A) whereas Arabidopsis 
protein extract showed the greatest UGT activity towards quercetin (Figure 53B). O. sativa 
protein extract showed the greatest glucosylation activity of the three plant protein extracts tested 
and exhibited comparable activity towards both TCP and quercetin (Figure 53C). There was 
however no evidence of UGT activity towards curcumin, DMC or BDMC by any of the plant 
protein extracts.  
 
 
Figure 52. Chemical structures of quercetin and 2,4,5-trichlorophenol. 
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Figure 53. UGT activity of C. longa, A. thaliana and O. sativa protein extracts. 
The UGT activity of the extracted protein from (A) C. longa, (B) A. thaliana and (C) O. sativa protein towards 
curcumin, DMC and BDMC was determined by transfer of 14C-glucose and measured by scintillation counting. TCP 
and quercetin were used as positive controls; methanol was the negative control. The data are means ± standard 
deviations (n = 3). 
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To date, the only characterised UGT to glucosylate curcumin is CaUGT2 from Catharanthus 
roseus 1. Therefore, to search for novel curcuminoid UGTs in C. longa, the amino acid sequence 
of CaUGT2 was used as a query for a tBLASTn search of the NCBI C. longa rhizome 
transcriptome database. Two potential full length CDS were found (JW777458.1 and 
JW773795.1, Appendix 3.1) which although both showed 83 % query coverage, shared only 39 
% (Figure 54A) and 37 % (Figure 54B) sequence identity with CaUGT2. Due to the lack of 
evidence of curcuminoid glucosylation in C. longa together with the low homology between 
JW777458.1, JW773795.1 and CaUGT2, it was decided not to further characterise these cDNAs.   
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Figure 54. Amino acid sequence alignment between CaUGT2, JW777458.1 and JW773795.1. 
(A) Subject JW777458.1, Query CaUGT2, 83 % coverage, 39 % identity. (B) Subject JW773795.1, Query CaUGT2, 
83 % coverage, 37 % identity. 
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3.2.3 Investigating the activity of recombinant CaUGT2  
The apparent lack of C. longa curcuminoid UGTs led to the decision to use CaUGT2 from C. 
roseus for development of a biocatalytic platform for curcuminoid glucosylation in S. cerevisiae. 
CaUGT2 had been shown to produce curcumin mono- and diglucosides in in vitro experiments, 
but only curcumin monoglucoside when in vivo experiments were carried out in E. coli 1,231.  
The nucleotide sequence of CaUGT2 (AB159213.1, Appendix 1.3) was synthesized by GenScript 
and cloned into the pUC57 vector. To validate CaUGT2’s ability to glucosylate curcumin, and to 
test its activity towards DMC and BDMC, which had not been done previously, its activity was 
initially checked by expression in E. coli. The CaUGT2 nucleotide sequence was cloned into the 
pET vector where it was translationally fused to a Strep-tag (Figure 55A). pET-CaUGT2 was 
transformed into E. coli and protein was extracted for in vitro analysis. Protein expression was 
assessed by western blot analysis using Strep-tactin (Figure 55B). No protein was detected from 
the empty vector control (pET-EV) as expected, whereas CaUGT2, translationally fused to the 
Strep-tag, was detected at the expected size, 55 kD. In fact, CaUGT2 expression was so high, it 
was visible by Ponceau staining. The crude protein extract was used in an in vitro assay testing 
for CaUGT2’s ability to glucosylate curcuminoids and phenylpropanoids using 14C-UDP-glucose 
(Figure 56). Scintillation counting showed protein extracted from E. coli transformed with pET-
CaUGT2 produced glucosides of the positive controls TCP and quercetin, as well as the three 
curcuminoids, curcumin, DMC and BDMC. This is the first time CaUGT2 has been shown to 
glucosylate DMC and BDMC. The four main phenylpropanoids, the building blocks of 
curcuminoids, were also tested in the in vitro assay. Contrary to work by Huang et al. 141, CaUGT2 
was able to glucosylate caffeic acid, but only to approximately one tenth of the level of the 
curcuminoids. The other three phenylpropanoids, cinnamic, ferulic and p-coumaric acid, were not 
glucosylated (see Figure 56). 
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Figure 55. Cloning and expression of CaUGT2 in E. coli.  
(A) CaUGT2 was cloned into the pET vector and translationally fused to the Strep-tag nucleotide sequence allowing 
CaUGT2 protein production in E. coli to be analysed by western blot using Strep-tactin (B). CaUGT2 was observed at 
the expected size of 55 kD. No Strep-tagged protein was evident in the pET-EV, empty vector control. The Strep-tactin 
western blot is shown above the ponceau stain loading control.  
 
 
Figure 56. In vitro CaUGT2 activity towards curcuminoids and phenylpropanoids. 
UGT activity was determined by transfer of 14C-glucose to the substrate which was measured by scintillation counting. 
2,4,5-Trichlorophenol (TCP) and quercetin were used as positive controls, methanol was the negative control. The data 
are means ± standard deviations (n = 3). 
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Having confirmed CaUGT2 expression in E. coli the CaUGT2 CDS was cloned into the pBEVY 
yeast expression vector using Gibson Assembly (Figure 57A) and transformed into S. cerevisiae. 
Transformation  was verified by PCR analysis of DNA extracted from yeast cells (Figure 57B): 
there is no PCR product for the empty vector control (pBEVY-EV) when using a CaUGT2 
specific primer in combination with a vector primer, but there is the correct sized product when 
DNA extracted from pBEVY-CaUGT2 yeast was used as a template (1.5 kB). Strep-tagged 
CaUGT2 protein could be detected by western blot analysis using Strep-tactin, whereas, no 
protein was detected in empty-vector control extracts (Figure 57C). 
  
Figure 57. Cloning and expression of pBEVY-CaUGT2.  
(A) CaUGT2 was translationally fused to the Strep-tag nucleotide sequence in the pBEVY vector. (B) Agarose gel 
showing PCR products, when CaUGT2 specific primers (see Primer Table in Material and Methods) were used to 
amplify DNA extracted from yeast cells transformed with pBEVY-CaGUT2, pBEVY-EV (empty vector control) or 
the pBEVY-CaUGT2 plasmid. (C) Western blot analysis, using Strep-tactin upon protein extracted from yeast cells 
expressing pBEVY-CaUGT2 or pBEVY-EV. Strep-tagged CaUGT2 protein is seen at the expected size of 55 kD. 
Ponceau stain of the nitrocellulose membrane is used as a loading control.  
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In an analogous experiment to that carried out in E. coli, the in vitro activity of CaUGT2 in crude 
protein extract from S. cerevisiae carrying pBEVY-CaUGT2 was carried out. Instead of using 
radiolabelled 14C-UDP glucose, cold UDP-glucose was used and LC-MS analysis was carried out 
to ascertain activity towards curcumin, DMC and BDMC. All three curcuminoids were 
glucosylated by S. cerevisiae protein extract containing CaUGT2, as can be seen by the 
accumulation of the respective monoglucosides, measured by the area of their parental mass peaks 
in the mass spectrum (Figure 58A, B and C). The identity of the glucosides was verified by their 
fragmentation loss of 162 mass units which is characteristic of glucosides due to the loss of 
glucose, as exemplified in Figure 59 with curcumin glucoside. Curcumin monoglucoside has a 
parental mass ion of 528.8, whereas DMC and BDMC have parental mass ions 498.9 and 468.9, 
respectively (see Appendices 3.2 and 3.3 for spectral data). Over the 60 minutes assayed, the 
monoglucosides of all three curcuminoids steadily increased in abundance. There was no evidence 
for production of diglucosides in these in vitro assays of protein extracts. Despite CaUGT2 being 
described by Kaminaga et al. 1 as being able to mono- and diglucosylate curcumin in E.coli in 
vitro assays, in these yeast in vitro experiments CaUGT2 was only observed to produce 
monoglucosides. 
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Figure 58. Curcuminoid monoglucoside production by S. cerevisiae pBEVY-CaUGT2 protein extract. 
LC-MS analysis of protein extracted from yeast expressing pBEVY-CaUGT2 or pBEVY-EV. Production of 
monoglucosides was quantified by MS peak area: (A) curcumin monoglucoside [M-H]- 528.8, (B) DMC 
monoglucoside [M-H]- 498.8 and (C) BDMC monoglucoside [M-H]- 468. 
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Figure 59. Mass spectrum of curcumin monoglucoside, m/z 528.9 [M-H]-. 
There is a characteristic mass loss of a glucose unit at m/z 366.9. [M-162]-. 
 
As monoglucosides of all three curcuminoids were produced in in vitro assays, in vivo yeast whole 
cell assays were performed. As only monoglucosides were produced in vitro and only 
monoglucosides were produced when Kaminiga et al.1, performed whole cell E. coli assays, it 
was uncertain whether curcumin diglucosides would be produced in yeast whole cell assays. Due 
to the financial cost of DMC and BDMC, they were not used as substrates for these larger cell 
culture assays; only curcumin was used.  
When 25 ml S. cerevisiae cell cultures, transformed with the empty vector control (pBEVY-EV) 
were fed with curcumin, no curcumin glucosides were produced, as detected and quantified by 
LC-MS analysis (Figure 60). When yeast cell culture expressing pBEVY-CaUGT2 was fed with 
curcumin both mono- and diglucosylated curcumin was produced (see Appendices 3.4 and 3.5 
for spectral data). The HPLC retention times of the glucosylated products were comparable with 
literature values: curcumin monoglucoside eluted at 11.7 minutes and curcumin diglucoside 
eluted at 7.9, comparable with literature values of 11.8 and 7.4 minutes 1, respectively using the 
same HPLC column and solvent system (Figure 61). It was apparent from the HPLC 
chromatograms that the majority of the curcumin substrate was associated with the yeast cells, 
whereas the mono- and diglucoside products were associated with both the media and the cells 
(Figure 62). The LC-MS peak area indicated that the majority of the monoglucoside was 
associated with the cells, whereas the majority of the diglucoside appeared to be in the media (see 
Figure 60). Curcumin monoglucoside production was rapid, with curcumin monoglucoside being 
detected at the earliest time point, 0 hours, within the yeast cells. At 24 hours, curcumin 
106 
 
monoglucoside appeared in the media, but at a lower level to what was observed in the cells. In 
contrast to curcumin monoglucoside, curcumin diglucoside appeared later, at 24 hours, and the 
levels detected were always higher in the media than in the yeast cells (Figure 60).  
 
 
Figure 60. Curcumin mono- and diglucoside production by yeast cells expressing pBEVY-CaUGT2. 
Curcumin glucosides were quantified by MS parent ion peak area. Cells transformed with pBEVY-EV did not allow 
the production of curcumin mono- or diglucosides. Curcumin monoglucosides were produced by cells expressing 
pBEVY-CaUGT2, the majority of which accumulated within, or was associated with, the cell. Curcumin diglucosides 
were produced by cells expressing pBEVY-CaUGT2, the majority of which accumulated in the media.  
 
 
Figure 61. HPLC chromatogram (UV 425 nm) showing curcumin, curcumin monoglucoside and curcumin diglucoside. 
Curcumin (RT 15.4 minutes), curcumin monoglucoside (RT 11.7 minutes) and curcumin diglucoside (RT 7.9 minutes); 
the RTs are comparable with literature values using the same HPLC solvent system, at 15.8, 11.8 and 7.4 minutes 
respectively1.  
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Figure 62.  HPLC chromatogram (UV 425 nm) of pBEVY-CaUGT2 cell and media extracts. 
24 hours after addition of curcumin to cell culture curcumin (c) is most prevalent in the cells, whereas the curcumin 
monoglucoside (m) and curcumin diglucoside (d) are in the both the cells and media.  
 
3.2.4 A simple spectroscopic analysis of curcumin glucoside production 
Curcumin’s characteristic yellow colour quickly depleted after it had been added to the yeast cell 
culture as curcumin is taken up by the cells 232. As curcumin was glucosylated and became more 
water soluble, some of it passed back into the media causing the culture to become significantly 
more yellow. The difference in intensity of yellow colour between a curcumin fed yeast culture 
transformed with the empty vector control (pBEVY-EV) and that expressing CaUGT2 (pBEVY-
CaUGT2) is apparent in Figure 63. 
 
Figure 63. Expression of pBEVY-CaUGT2 in yeast causes the cell culture to become curcumin’s characteristic 
yellow colour. 
A visual difference in the intensity of yellow colour between yeast cultures transformed with either pBEVY-CaUGT2 
or pBEVY-EV after 48 hours incubation with curcumin is apparent: the pBEVY-CaUGT2 displays a much brighter 
yellow colour.  
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As the presence of curcumin glucosides in the media, caused the culture to become yellow, it was 
investigated whether this colour change could be measured spectrophotometrically to allow 
simple tracking of the CaUGT2 glucosylation reaction. The absorbance maxima of the curcumin 
glucosides are the same as curcumin, 425 nm (see Appendix 2.13). pBEVY-CaUGT2 or pBEVY-
EV yeast cultures were fed either curcumin, or methanol as control, and the culture media was 
monitored by its absorption at 425 nm (Figure 64). The methanol fed pBEVY-CaUGT2 showed 
no absorbance at 425 nm throughout the time course due to the lack of curcumin present. At 0 
hours, both of the curcumin-fed cultures exhibited a high initial absorbance around 0.3, due to the 
presence of curcumin in the media. This decreased over the first 3 hours as curcumin was 
presumably taken up by the yeast cells, giving an absorbance lower than 0.1. For the rest of the 
experiment, the pBEVY-EV culture exhibited this low absorbance around 0.1. For the pBEVY-
CaUGT2 culture, this low absorbance remained constant until 20 hours but then increased up to 
0.4 at 50 hours and remained at this level up to 72 hours. This was presumed to be due to the 
production of curcumin glucosides and their increased solubility in the media.  
To validate that the change in absorbance was due to the presence of curcumin glucosides in the 
media, the correlation between absorbance and quantifiable curcumin glucosides was determined. 
Extracts from the media were analysed by LC-MS and the abundance of glucosides, as quantified 
by HPLC peak area, was compared to the absorbance of the media (Figure 65). Both curcumin 
monoglucoside (Figure 65A) and diglucoside abundance (Figure 65B) strongly correlated with 
the absorption of the media measured using a spectrophotometer; r (16) = 1.00, p < 0.01  and  r 
(16) = 0.97, p < 0.01, respectively. Due to these near perfect Pearson correlation values between 
the absorbance of the media and the abundance of glucosides in the media, it was concluded that 
the production of curcumin glucosides could be monitored simply using absorbance 
measurements of the media instead of carrying out HPLC analysis. 
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Figure 64. Absorbance (425 nm) of media from yeast cultures expressing pBEVY-CaUGT2 or pBEVY-EV. 
When pBEVY-CaUGT2 yeast culture was fed methanol, the A425 nm reading was 0.0. When pBEVY-EV yeast culture 
was fed curcumin, the initial A425 nm reading is 0.3 but decreased over time as curcumin was absorbed by the cells. 
When pBEVY-CaUGT2 was fed curcumin, the initial A425 nm decreased from 0.3, for the first 20 hours, but then 
increased due to the presence of curcumin glucosides in the media. 
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Figure 65. Change in colour of media correlates with presence of curcumin glucosides. 
Correlation between abundance of (A) curcumin monoglucoside and (B) curcumin diglucoside as quantified by HPLC 
(UV 425 nm) and absorbance (425 nm) of the culture media. Continuous lines show absorbance of the media, measured 
spectrophotometrically, dashed lines show peak areas of glucoside as quantified by HPLC. Both curcumin 
monoglucoside (A) and curcumin diglucoside (B) show a very strong correlation between the abundance of the 
glucosides present in the media and the colour change of the media.  
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3.2.5 Large-scale production of curcumin glucosides  
As yeast cell culture expressing pBEVY-CaUGT2 successfully produced curcumin mono- and 
diglucosides and this could be simply monitored spectrophotometrically, the reaction was scaled 
up 200 times from a 25 ml shake flask to a 5 L bioreactor. This required the addition of antifoam 
but all other media components were kept at the same concentration (see Materials and Methods). 
The bioreaction was monitored over 72 hours using Applikon software as well as manual 
measurements of the cell culture growth (OD600) and glucoside production (Abs 425 nm) (Figure 
66). The fermentation temperature was kept at 30 ̊ C and the dissolved oxygen was kept above 40 
% using the sparger and baffles. For the first 4 hours, up until the addition of curcumin, the culture 
grew rapidly. Subsequently, for the next 20 hours after curcumin addition, the culture showed 
very little change with minimal cell growth. However, after 30 hours, growth increased up to 50 
hours, shown by the increase in optical density (OD) (600 nm) and decrease in dissolved oxygen 
caused by the increased demand for oxygen. Throughout the bioreaction, the pH decreased from 
the pH of the media, 4.5, to 2.5; the most rapid decrease occurred during the period of rapid cell 
growth. Curcumin glucoside production correlated with culture growth as monitored by 
absorbance at 425 nm. When the fermentation was ended, the OD and Abs (425 nm) were still 
increasing suggesting there is potential for further increases in yield.
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Figure 66. 72-hour pBEVY-CaUGT2 S. cerevisiae bioreaction profile. 
Recorded and generated by Applikon fermenter software. pH (black), temperature (burgundy), dissolved oxygen (green) and stirrer speed (blue) were automatically monitored, with readings every 
hour. Optical density 600 nm (OD) (teal) and glucoside production (magenta) were measured manually. 
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To obtain chemical standards of the glucosides and allow an approximate yield of the large scale 
bioreaction to be calculated, the aim was to purify the glucosides from the media. To reduce 
curcumin aglycone recovery and aid purification of glucoside product, n-butanol was chosen as a 
more polar solvent to perform liquid-liquid extraction of the glucosides over ethyl acetate. The 
butanol extract was concentrated by rotary evaporation and the resultant crude product was 
analysed by LC-MS: all glucosides had been extracted from the media (Figure 67A). However, 
curcumin aglycone and other media components were also extracted from the media along with 
the glucosides (Figure 67B). The majority of the curcumin glucoside isolated appeared to be in 
the monoglucosylated form. To purify the glucosides from one another and the curcumin 
aglycone, flash chromatography was considered. Elution conditions were first tested using a 100 
mg solid phase extraction (SPE) column. Using different percentages of methanol, curcumin 
mono- and diglucoside could be separated from each other as well as from contaminants: 
therefore, a simple methanol gradient was used for flash chromatography. The resultant fractions 
were collected and those containing curcumin mono- or diglucoside were combined (Figure 68A 
and Figure 68B). Although the glucosides were successfully separated, there were still 
contaminants in the samples. For further purification prep-HPLC was carried out. As less 
curcumin diglucoside was recovered from flash chromatography compared to curcumin 
monoglucoside (64 mg compared to 168 mg), prep-HPLC was only carried out upon curcumin 
monoglucoside. Unfortunately, the majority of the curcumin monoglucoside appeared to elute at 
an earlier RT than expected (6.5 minutes, instead of ~11 minutes) and appeared as various 
conjugates, such as complexing with sodium formate ([M–H+68]-). Only one fraction contained 
pure curcumin monoglucoside which eluted at the expected RT and with the correct parental mass 
ion (Figure 69). As a result, the amount of curcumin monoglucoside purified was low, 9.3 mg. 
Using the purified curcumin monoglucoside, a standard curve was plotted relating the amount of 
curcumin monoglucoside with the spectrophotometric absorbance at 425 nm (Figure 70). From 
this, the amount of curcumin monoglucoside produced during the fermentation was estimated to 
be 160 mg (32 mg L-1 culture), an approximate yield of 60 %.  
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Figure 67. Curcumin glucoside extraction from media. 
HPLC chromatograms (425 nm) showing: (A) fermentate after butanol extract; (B) butanol extract containing 
curcumin (c, RT 15.8 minutes), curcumin monoglucoside (m, RT 11.6 minutes) and curcumin diglucoside (d, RT 
6.9 minutes). 
 
 
 
Figure 68. Curcumin glucoside flash chromatography purification. 
HPLC chromatograms (425 nm) showing: (A) pooled curcumin monoglucoside (m, RT 10.8 minutes) fractions from 
flash chromatography; (B) pooled curcumin diglucoside (d, RT 7.0 minutes) fractions from flash chromatography. 
Contaminants are apparent in both pools. 
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Figure 69. HPLC UV (425nm) chromatogram of pure curcumin monoglucoside.  
Curcumin monoglucoside elutes at RT 11.21 minutes. The peak at 11.06 minutes is also curcumin monoglucoside. 
 
 
Figure 70. Linear relationship between the concentration of curcumin monoglcyoside in solution and the absorbance 
(425 nm) measured spectrophotometrically.  
The data are technical means ± standard deviations (n = 3). 
 
3.2.6 Optimising media conditions for curcumin glucoside production 
During pBEVY-CaUGT2 yeast whole cell assays, cell growth was retarded for approximately 24 
hours after curcumin was added to the bioreaction, as well as a concomitant lag in detectable 
glycoside production (see Figure 66). As it appeared that the production of curcumin glucosides 
increased with cell growth, different conditions were investigated to ascertain their affect upon 
yeast cell growth and curcumin glucoside production.  
The effect of different carbon sources was initially investigated. The standard carbon source used 
to grow the pBEVY-CaUGT yeast culture was raffinose. Because the expression of CaUGT2 
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from the pBEVY vector is induced by galactose and repressed  by glucose 233, these two sugars 
were investigated first. To assist in optimisation of the growth media a series of questions were 
considered: Was induction tightly controlled? Was addition of galactose necessary? What 
happens when glucose, an inhibitor of induction, was added to the media? Answering such 
questions would allow an optimal and cost-effective sugar to be chosen as a carbon source for the 
fermentation. 
Initially, shake flask cultures expressing pBEVY-CaUGT2 or pBEVY-EV were fed curcumin or 
methanol, plus or minus 2 % (w/v) galactose. It was expected that induced and non-induced 
cultures may grow similarly, but the production of curcumin glucosides should be much higher 
in the induced culture as this should contain much more expressed enzyme. As expected, the 
induced and non-induced cultures grew at a similar rate and to a similar extent (Figure 71A). 
Despite the prediction that curcumin glucoside production would increase due to increased 
CaUGT2 expression, glucosides were detected to a similar level irrespective of whether galactose 
induction was carried out (Figure 71B). A possible explanation for this observation is that 
CaUGT2 expression is occurring in the absence of galactose, possible due to a leaky GAL1 
promoter. To test for this, RNA was extracted from induced and non-induced cells, from which 
cDNA was synthesized. PCR, using CaUGT2 specific primers was carried out upon the cDNA 
and the products were separated using agarose gel electrophoresis (Figure 72). There were no 
PCR products evident for the empty vector controls, whether induced or not, as expected. The 
positive plasmid control, gave a product at the expected size, 0.7 kB. Induced pBEVY-CaUGT2 
transformed cells also gave a PCR product as anticipated. If expression of CaUGT2 from the 
pBEVY vector was tightly controlled by galactose induction, CaUGT2 RNA should not be 
detectable from the non-induced culture. However, a PCR product was detected thus indicating 
that expression of CaUGT2 occurs in the absence of galactose. When the results are corrected for 
template abundance using the constitutive actin control, CaUGT2 mRNA is more abundant in the 
culture that had been induced with galactose. Nonetheless, even though levels of CaUGT2 mRNA 
are greater in the induced cultures, CaUGT2 expression in the non-induced cultures allows a 
similar levels of curcumin glucosylation.  
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Figure 71. Investigating the induction of CaUGT2 expression upon cell growth and glucoside production. 
Comparison of the cell culture growth (A) and curcumin glucoside production (B) of induced (with galactose) and non-
induced (without galactose) yeast cultures expressing pBEVY-CaUGT2 or pBEVY-EV. Methanol was used as a 
control substrate. The data are means ± standard deviations (n = 3). 
 
 
Figure 72. Expression of CaUGT2 when induced and non-induced. 
Agarose gel showing 0.7 kB PCR products when using CaUGT2 specific primers upon cDNA derived from pBEVY-
CaUGT2 or pBEVY-EV transformed cells that were, or were not, induced. PCR products are evident for pBEVY-
CaUGT2 derived cDNA, whether expression was induced by addition of galactose or not. Actin was used as a control, 
the PCR product of which is shown at 0.9 kB. 
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As curcumin glucosides were produced without galactose induction (see Figure 71B) the effect 
of glucose repression upon pBEVY-CaUGT2 expression was investigated. Glucose represses 
expression from the GAL1 promoter 233, therefore it was suggested that addition of glucose to the 
media may reduce the amount of CaUGT2 expressed and the amount of curcumin glycoside 
produced. However, adding 2 % (w/v) glucose to the culture medium was also expected to 
increase cell growth, as glucose is the preferred carbon source in S. cerevisiae 234. When glucose 
replaced raffinose in the media there was no difference in pBEVY-CaUGT2 cell culture growth 
(Figure 73A). There was also no difference in curcumin glucoside production compared to the 
raffinose control, again eluding to a possible lack of control of CaUGT2 expression by the GAL1 
(Figure 73B). 
 
 
Figure 73. Investigating the repression of CaUGT2 expression upon cell growth and glucoside production. 
Comparison of the cell culture growth (A) and curcumin glucoside production (B) of yeast cultures expressing pBEVY-
CaUGT2 or pBEVY-EV growing in 2 % (w/v) raffinose yeast media (pBEVY-CaUGT2 + curcumin, 2 % raffinose), 
or  2 % (w/v) glucose yeast media (pBEVY-CaUGT2 + curcumin, 2 % glucose). Methanol was used as a control 
substrate. The data are means ± standard deviations (n = 3). 
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The effect of adding supplemental raffinose to the pBEVY-CaUGT2 culture medium was also 
investigated. It was reasoned that by increasing the carbon source, cell growth rates should be 
promoted and hence increase the production of curcumin glucosides. 1 ml of additional 40 % 
(w/v) raffinose was added to the 25 ml cell cultures twice, at 24 hours 48 hours, giving an overall 
total of 6.5 % (w/v) raffinose. Cell growth and curcumin glucoside production was again 
monitored spectrophotometrically (Figure 74). There was no increase in pBEVY-CaUGT2 cell 
growth (Figure 74A) however, an increase in curcumin glucoside production compared to cultures 
with the basal amount of raffinose was observed (Figure 74B). 
 
 
Figure 74. The effect of supplemental raffinose in the yeast media upon cell growth and glucoside production. 
Comparison of the cell culture growth (A) and curcumin glucoside production (B) of yeast cultures expressing pBEVY-
CaUGT2 or pBEVY-EV grown in standard yeast media (pBEVY-CaUGT2 + curcumin, 2 % raffinose), or media with 
additional raffinose (pBEVY-CaUGT2 + curcumin, 6.5 % raffinose). Methanol was used as a control substrate. The 
data are means ± standard deviations (n = 3).  
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As increasing, or changing, the carbon source did not affect cell growth (Figure 71 to Figure 74), 
it was hypothesized that other factors in the media were limiting growth and curcumin glucoside 
production. It had been reported that curcumin accumulates in the endoplasmic reticulum of S. 
cerevisiae where it chelates iron, depleting intracellular iron and reducing growth rate 232. It was 
theorised that since glucosylated curcumin is considered to have a greater ability to chelate iron 
leading to its use in iron overload therapy 111, this increased iron chelating effect could be retarding 
the growth of pBEVY-CaUGT2 S. cereviseae cells. To test this, cultures were set up with 
supplementary iron (50 µM FeSO4) and their growth and curcumin glucoside production were 
monitored. The iron treatment did allow the curcumin-fed pBEVY-CaUGT2 culture to grow at a 
similar rate and extent as the pBEVY-EV control cultures (Figure 75A), although additional iron 
did not allow an increase in glucoside production (Figure 75B).  
These results suggest that glucoside production is not limited by culture growth, but by some 
other factor. This may be something that limits the enzymatic reaction, such as the abundance of 
UDP-glucose, which once overcome, should allow curcumin glucoside production to increase 
with cell density. Such an explanation is also consistent with the fact that the induced and non-
induced cultures produce the same amount of curcumin glucosides even though the induced 
culture produces more UGT mRNA and probably more protein. 
 
Figure 75. The effect of supplemental iron (FeSO4) in the culture media upon cell growth and glucoside production. 
Comparison of the curcumin glucoside production (A) and cell culture growth (B) of yeast cultures expressing pBEVY-
CaUGT2 or pBEVY-EV growing in yeast media (pBEVY-CaUGT2 + curcumin), or iron supplemented yeast media 
(CaUGT2 + curcumin + FeSO4). Methanol was used as a control substrate. The data are means ± standard deviations 
(n = 3).  
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3.3 Discussion and future work 
Glucosylation offers a route to increase a molecule’s solubility in water therefore increasing its 
bioavailability and drug commercialisation potential. Due to the poor bioavailability of 
curcuminoids, glucosylation has been considered as a method to improve their water solubility 
and therefore their pharmacokinetic properties. Previous work utilising recombinantly expressed 
CaUGT2 from C. roseus had shown that curcumin diglucoside was only biosynthesized in cell-
free in vitro assays 1,235. This chapter aimed to develop a scalable platform for the production of 
both mono- and diglucosylated curcuminoids. 
Initially, C. longa was investigated as a source of a novel curcuminoid UGT. Despite two hits in 
the NCBI C. longa transcriptome database, based on sequence similarity to CaUGT2, there was 
no enzymatic or chemical evidence of C. longa being able to produce glucosylated curcuminoids. 
In-depth LC-MS analysis of metabolite extract from 13 accessions of C. longa from 9 provinces 
across Vietnam also showed no evidence of any other curcuminoid bio-conjugates. The data did 
however show a strong correlation in curcumin, DMC and BDMC abundance (see Table 3, r (28) 
= 0.97-1.00, p < 0.01). This was expected due to being metabolites from the same pathway, as 
has been shown in previous research by Ramirez-Ahumada et al., 2006 236 and Xie et al., 2009 
237.  Additionally, there was a strong correlation in the amount of turmerones and curcuminoids 
(see Table 3). This lead to the proposal that, like ginger, C. longa may  sequester its phenolic 
bioactive metabolites within liposomes of oily secondary metabolites, in C. longa’s case, 
turmerones. Metabolite data gathered by Xie et al. 237 from rhizomes subjected to 16 different 
growth conditions showed the presence of distinct metabolic modules, in which the curcuminoid 
production profiles also appeared to correlate with that of the turmerones, ar-turmerone and 
curlone. To further validate this hypothesis, microscopy could be carried out to determine the 
presence of such liposomal capsules. Additionally, the co-regulation of the C. longa curcuminoid 
biosynthetic pathway and sesquiterpene synthases involved in turmerone synthesis, as identified 
by Koo et al. 238, could be investigated using qPCR. 
Since it appears that C. longa does not naturally produce glucosylated curcuminoids, CaUGT2 
offered the possibility  to produce these in a heterologous system 1. CaUGT2 had been shown to 
mono- and diglucosylate curcuminoids in recombinant E. coli protein extracts but only produce 
monoglucosides in equivalent whole cell studies 1,138. In the current study, when CaUGT2 was 
heterologously expressed in E. coli, it glucosylated curcumin, as previously reported 1, and it was 
also found to glucosylate DMC and BDMC (see Figure 56). This was the first time it has been 
demonstrated that CaUGT2 has activity to curcuminoids other than curcumin. This made it an 
excellent candidate for the production of curcuminoid glucosides in a scalable microorganism 
such as S. cerevisiae.   
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In vitro assays using S. cerevisiae protein extract containing CaGUT2 only produced the curcumin 
monoglucoside (see Figure 58) whereas in vivo shake flask assays allowed the production of both 
curcumin mono- and diglucosides (see Figure 61). Curcumin monoglucosides were detected 
earlier than curcumin diglucosides which is theorised to be due to CaUGT2 having a lower Km 
for curcumin than curcumin monglucoside: 19.0 µM compared to 63.3 µM 1. The differential 
production of curcumin mono- and diglucosides depending on the heterologous host and in vivo 
or in vitro conditions is very interesting. When added to the fact that in yeast cell cultures assays, 
the glucoside products are present in the media (see Figure 60 and Figure 62) it seems to be that 
compartmentalisation may be important for diglucoside production. The fact that diglucosides of 
curcumin are more soluble in aqueous media than curcumin monoglucosides may be a factor 138.  
Membrane bound organelles, or an as yet unknown transport system, may be important for the 
production of curcumin diglucosides and this could explain the difference in the ability of E. coli 
and S. cereviseae to produce the diglucoside when expressing CaUGT2. Transport and organelle 
specific biosynthesis of glucosylated curcuminoids could be investigated further as a means of 
increasing glucoside yield or directing the production of one glucoside (mono- or di-) over the 
other. Interestingly, the highest yielding synthetic chemistry approach to synthesizing 
curcuminoid diglucosides utilised a biphasic solvent system which separated substrates and 
products 135. This rationale could be applied to a multiphase extractive fermentation to aid 
catalysis and extraction. Notably, this strategy proved successful for Paddon et al. 27, for the 
production of artemisinic acid. 
As both curcumin mono- and diglucosides could be produced by yeast cells expressing CaUGT2, 
the culture was successfully scaled up 200 times from a 25 ml shake flask to a 5 L bioreactor. It 
is usually scaling up from shake flasks to small bioreactors that is the most problematic stage of 
scaling bioreactions 239. The 5 L bioreaction gave a greater production of glucoside per ml of 
culture compared to 25 ml shake flasks as shown by a higher absorbance (425 nm) measurement: 
1.1 compared to an average of 0.7 (see Figure 64 and Figure 66). Furthermore, 25 ml shake flask 
cultures reached peak glucoside production after approximately 48 hours, whereas glucoside 
production was still increasing after 72 hours in the 5 L bioreactor. Therefore, to achieve the 
maximum potential yields, longer bioreactions should be investigated to determine a definite end 
of fermentation. 
Using purified curcumin monoglucoside, the yield of the 5 L bioreaction was estimated to be 60 
% or 32 mg L-1. This is an approximate yield as the amount of purified curcumin monoglucoside 
was low. Efforts need to be made to optimise the purification of the glucosides from the culture 
media. This could involve the previously mentioned biphasic extractive fermentation technique, 
investigating other liquid-liquid extractions, large scale SPE or silica column chromatography or 
different flash chromatography and prep-HPLC methods. Reduction of sodium formate curcumin 
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monoglucoside adducts could also be investigated by using a different prep-HPLC solvent 
additive instead of formic acid. The addition of formic acid may also have caused acid catalysed 
glycosidic bond hydrolysis reducing the amount of recoverable glucosides.  
The fact that curcumin glucoside products could be detected in the pBEVY-CaUGT2 yeast 
fermentate media, allowed a spectrophotometric assay to be developed to allow simple 
monitoring of the accumulation of product. This allowed the effect of different media 
compositions upon glucoside production to be monitored in order to optimise the process. 
Different carbon sources were explored in an attempt to increase cell growth since it is possible 
that this could also lead to an increase in glucoside production. The standard yeast media 
contained 2 % (w/v) raffinose, as this does not interfere with the expression of CaUGT2 from the 
pBEVY vector, which under the control of the GAL1 promoter is induced by galactose and 
repressed by glucose. First, galactose induction was investigated. There was no difference 
between induced and non-induced cultures (Figure 71) so galactose expression of CaUGT2 was 
hypothesized to be leaky; this was verified by RT-PCR (see Figure 72). However, to be certain 
that the expression of pBEVY-CaUGT2 results in CaUGT2 protein production, western blot 
analysis should be carried out.  
Secondly, to further examine the expression of CaUGT2, the outcome of growth and curcumin 
glucoside production was monitored when 2 % (w/v) glucose was added to the yeast media. 
Glucose is known to repress expression from the GAL1 promoter 233, so the expected balance 
between increased cell growth and CaUGT2 expression repression was unknown. Using glucose 
instead of raffinose as a carbon source had no effect on the growth of the culture or curcumin 
glucoside production (see Figure 73). This inferred something else was likely to be limiting cell 
growth and enzyme catalysis. 
Thirdly, the effect of supplemental raffinose was explored. Interestingly, supplemental raffinose 
did not increase cell growth, but did increase curcumin glucoside production (see Figure 74). This 
was not expected as in yeast raffinose is hydrolysed by invertase (β-fructosidase) to fructose and 
melibiose 240. Fructose can be utilised for respiration, but the disaccharide melibiose cannot be 
broken down by S. cerevisiae as it lacks α-galactosidase 241. Therefore, it was unknown how 
supplemental raffinose increased the production of curcumin glucosides. 
Curcumin is known to inhibit the growth of S. cerevisiae by increasing the G1 phase of the cell 
cycle due to intracellular iron chelation within the endoplasmic reticulum 232. Iron starvation was 
suspected to be heightened by curcumin glucosides as they exhibit greater effectiveness as an iron 
overload therapy compared to the curcumin aglycone 111.  Supplementing the pBEVY-CaUGT2 
culture media with FeSO4 allowed an increase in yeast cell culture growth (see Figure 75A). 
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However, an increase in culture growth did not translate to an increased production of curcumin 
glucosides (see Figure 75B). 
As the amount of curcumin glucosides produced was the same, regardless of induction media, it 
was concluded that the amount of enzyme was not limiting the production of glucoside. This was 
also evident when supplemental iron increased growth but not glucoside production (see Figure 
75) and supplemental raffinose increased glucoside production without an increase in cell growth 
(see Figure 74). Consequently, other factors which may affect the enzymatic reaction should be 
investigated such as varying the amount of UDP-glucose, especially as the by-product of the 
glucosylation, UDP, is an end-product inhibitor of UGT activity 242,243. Masada et al. 142, created 
a glucosylation system in E. coli which reduced UDP inhibition and increased UDP-glucose 
substrate by expressing Arabidopsis sucrose synthase 1 (catalyses breakdown of sucrose to UDP-
glucose and fructose) which increased the glucoside yield several fold. A similar recycling 
system, which relies upon the supplementation of sucrose could be used in yeast and would allow 
a cheaper carbon source, which does not affect expression of CaUGT2, to be used. Once the 
enzymatic reaction is no longer limiting, increasing cell growth, by addition of iron and using a 
favourable carbon source should then allow an even greater increase in glucoside production. 
There are of course, a range of other questions, the answers to which could improve curcumin 
glucoside production. What is the optimum amount of curcumin substrate for the growth of the 
culture? What transporters are involved in the influx of curcumin and efflux of curcumin 
glucosides to and from the yeast cell? What pH, temperature and oxygen concentrations are 
optimal? Furthermore, the system could be expanded, by adding other glycosyltransferases such 
as CaUGT3 that can form curcumin gentiobiosides with even greater water solubility 143.  The 
best chemical synthesis of curcumin diglucoside yields 71 % 135. With optimised bioreaction and 
extraction conditions, the yield of curcumin glucoside production by S. cerevisiae expressing 
CaUGT2 is expected to compete with the top performing curcumin glucosylation reactions 
documented to date. 
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Chapter 4. Materials and Methods 
4.1 Materials  
All chemicals were purchased from Sigma-Aldrich unless stated otherwise. Phenyl-propanoyl-
CoA esters were purchased at HPLC grade from PlantMetaChem (TransMIT Gesellschaft für 
Technologietransfer, Gießen, Germany). Molecular biology reagents, enzymes and kits were 
purchased from New England Biolabs, Promega, Thermo Scientific or Qiagen. Oligonucleotide 
primers were synthesized by and purchased from Eurofins MWG Operon. Gene synthesis was 
carried out by GenScript or Invitrogen. Reagents were used as solids or formulated in ultrapure 
water (18.2 MΩ cm-1) or HPLC grade methanol. All growth media was autoclaved or filter 
sterilised (0.42 µm) prior to use.  
4.2 Instrumentation  
Polymerase chain reactions were performed using a Bio-Rad DNA Engine PTC-200 Peltier 
Thermal Cycler. Nucleic acid quantification was carried out using a NanoDrop 1000 
spectrophotometer.  Spectrophometric measurements were taken using a Thermo Scientific 
Evolution 60S UV-Visible spectrophotometer. q-PCR was performed using a Bio-Rad My-IQ 
Single Color RT-PCR detection system. High-performance liquid chromatography was 
performed using a Thermo Finnigan Surveyor Plus HPLC System equipped with Xcalibur data 
analysis software. Mass spectrometry was performed using a Thermo Scientific LCQ Fleet ion 
trap mass spectrometer. Flash chromatography was carried out using a Biotage Isolera Prime 
system. Preparative HPLC was performed using an Agilent Varian Modular Analytical HPLC 
System. 5 L bioreaction was carried out using a 5 L Applikon bioreactor. Radioactivity 
scintillation counting was performed using a Packard Trib-Carb 2900TR Liquid Scintillation 
Analyzer.  
4.3 Methods 
 Investigating C. longa 4CLs 
Phylogenetic analysis of five putative 4CL ESTs from C. longa  
Phylogenetic analysis was carried out upon the following sequences: Os4CL1 (UniProt P17814), 
Os4CL2 (UniProt Q42982), |Os4CL3 (UniProt Q6ETN3), Os4CL4 (UniProt Q67W82), Os4CL5 
(UniProt Q6ZAC1), Pv4CL1 (ACD02135.1), Pv4CL2 (AHY94891.1), DY382977.1, 
DY391029.1, DY382750.1, DY390122.1 and DY391030.1. The phylogenetic tree was made in 
Jalview using an average distance tree from ClustalWS alignment. 
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Growing C. longa 
C. longa rhizomes were potted in a shallow tray and just covered with John Innes compost, silica 
sand and grit. They were watered well and covered with a propagator lid to give high humidity 
and left to grow at 37 ̊ C. Six weeks later, shoots from the rhizomes were visible and the 
propagator lid was removed. As the plants grew, they frequently needed to be split and re-potted.  
Extracting and purifying RNA from C. longa rhizome tissue 
For the extraction of RNA from C. longa rhizomes a method from Dong et al.,178 was adapted. 
Solutions were autoclaved or filter sterilised. Plastic ware was autoclaved. The pestle and mortars 
were bake at 200 ̊ C overnight. Per sample, 0.8 g of rhizome tissue was ground in a pre-cooled 
mortar with a pestle, in the presence of liquid nitrogen. The fine tissue powder was transferred 
with a precooled spatula into a 50 ml sterile falcon tube containing 4 ml extraction buffer (50 mM 
Tris-HC1 (pH 8.0), 300 mM sodium chloride, 5 mM EDTA, 2% (w/v) SDS, 0.5% (w/v) soluble 
polyvinylpyrrolidone (M.W. 360,000), 0.5 mM aurintricarboxylic acid and 14.3 mM β-
mercaptoethanol) and then vigorously mixed. The mixture was incubated in a water bath at 65 ̊ C 
for 10 minutes with occasional shaking. The mixture was then transferred into microcentrifuge 
tubes, and centrifuged for 15 minutes, 10 000 g, room temperature. The supernatant was moved 
into 2 fresh 2 ml microcentrifuge tubes and 93 μl of 3 M potassium acetate (pH 4.8) was added 
to each sample. After complete mixing, the tubes were placed on ice for 30 minutes, followed by 
centrifugation at 10 000g for 10 minutes at 4 ̊ C. The supernatant was transferred into fresh 2 ml 
microcentrifuge tubes, followed by addition of 667 μl 8 M lithium chloride. The mixture was left 
overnight at 4 ̊ C. The tube was then centrifuged at 12,000 g for 30 minutes at 4  ̊C, the supernatant 
was removed and the was washed twice with 1.33 ml 3 M sodium acetate (pH 5.2) by 
resuspending the pellet and further centrifugation at 10,000g for 10 minutes at room temperature. 
The final pellets were each dissolved in 667 μl RNase-free glass distilled water. Each crude RNA 
solution was mixed with an equal volume 667 μl of phenol (saturated with Tris-HCl, pH 8.0). The 
mixture was centrifuged at 10 000 g for 10 minutes at room temperature. The upper aqueous phase 
was transferred into a fresh 2 ml microcentrifuge tube. The aqueous phase was extracted once 
with an equal volume 667 μl of phenol/chloroform/isoamyl alcohol (24/23/1, v/v/v). The aqueous 
phase was further extracted once with an equal volume 667 μl of chloroform/isoamyl alcohol 
(23/1, v/v). The aqueous phase was then transferred into a fresh microcentrifuge tube, to which 
was added 66.7 μl 3 M sodium acetate (pH 5.2) and 1.73 ml absolute ethanol. The mixture was 
left overnight at -20 ̊ C. The mixture was then centrifuged at 10 000g for 10 minutes at 4 ̊ C after 
which the pellet was washed once with 70 % (v/v) ethanol (1.73 ml). After 5 minutes air drying, 
the RNA pellet was dissolved in 50 μl 60  ̊C RNase-free water and the concentration of RNA was 
measured using a NanoDrop spectrophotometer. 
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cDNA synthesis from C. longa RNA 
To obtain 4CL cDNA, 6 different primers were used, a generic polyA annealing primer and 5 
primers specific to each of the 4CL EST sequences: 10 mM Og2, Cl4CL1_R, Cl4CL2_R, 
Cl4CL3_R, Cl4CL4_R and Cl4CL5_R (see 4.3.10 Primer table). cDNA was synthesized using 
ThermoFisher Scientific SuperScript II Reverse Transcriptase. 0.5 ug of RNA was incubated with 
1 μl 10 µM dNTPs and the desired primer at 65 ̊ C for 5 minutes. 4 μl First strand buffer, 2 μl 0.1 
M DTT and 1 μl RNAse Out were then added to each reaction before incubation at 42 ̊ C for 2 
minutes. 1 μl SuperScript II Reverse Transcriptase was then added and cDNA synthesis was 
allowed to proceed for 2 hours at 42 ̊ C.  
 Polymerase chain reactions (PCR) 
For primers used see 4.3.10 Primer table 
NEB High Fidelity Phusion Polymerase PCR 
For cloning or RACE PCR where high fidelity of amplified sequence is required 
Component Volume 
Water  35.5 μl 
Buffer (HF/GC) 10 μl 
10 μM dNTPs 1 μl 
10 mM F-primer 1 μl 
10 mM R-primer 1 μl 
Template 1 μl  
Phusion polymerase 0.5 μl 
Total 50 μl 
   
Thermocycler conditions Temperature Time 
1. Denature 98 ̊ C 30 s 
2. Denature 98 ̊ C 10 s 
3. Anneal Primer melting temp. 30 s 
4. Extension 72 ̊ C 30 s /kb 
5. Cycle  (Steps 2-4) x 25-35 
6. Extension 72 ̊ C 5 minutes 
For hot start PCR, the reaction was held at the initial denaturing temperature and the polymerase 
was added. When DMSO was added to aid strand separation, it was carried out at 3 %. 
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NEB TAQ polymerase PCR 
For diagnostic PCR when fidelity isn’t as crucial. 
Component Volume 
Water 41.75 μl 
10 x Taq buffer 5 μl 
 10 μM dNTPs 1 μl 
10 mM F-primer 1 μl 
10 mM R-primer 1 μl 
Template 2 μl 
Taq polymerase 0.25 μl 
H2O 41.75 μl 
Total 50 μl 
 
Thermocycler conditions: Temperature Time 
1. Denature 95  ̊C 30 s 
2. Denature 95  ̊C 10 s 
3. Anneal Primer melting temp. 30 s 
4. Extension 68  ̊C 1 min /kb 
5. Cycle  (Steps 2-4) x 25-35 
6. Extension 68  ̊C 5 minutes 
 
Colony PCR 
 
Component Volume 
Water 11.925 μl 
10 x Taq buffer 1.5 μl 
 10 μM dNTPs 0.3 μl 
10 mM F-primer 0.3 μl 
10 mM R-primer 0.3 μl 
Taq polymerase 0.075 μl 
 Total 15 μl 
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Thermocycler conditions: Temperature Time 
1. Denature 95 30 s 
2. Denature 95 10 s 
3. Anneal Primer melting temp. 30 s 
4. Extension 68 1 min /kb 
5. Cycle  (Steps 2-4) x 25-35 
6. Extension 68 5 minutes 
 
Separation of nucleic acids using agarose gel electrophoresis  
To 1 x TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.0) 0.8 % (w/v) agarose was added 
and microwaved for ~1.5 minutes, until dissolved. Once cooled to ~60  ̊C 1 μl ethidium bromide 
was added, then the gel was cast. Once set, samples (mixed with an appropriate volume of 6 x 
loading buffer (10 mM Tris-HCl, 50 mM EDTA, 15 % (w/v) Ficoll 400, 0.03 % (w/v) 
bromophenol blue, 0.03 % (w/v) xylene cyanol) and ladder were loaded and electrophoresis 
was performed at 125 V for 25 minutes or to desired DNA resolution. The gel was imaged using 
a UVP GelDoc-It  Imaging System. 
 Cloning and transformation of E.coli and S. cerevisiae 
E. coli and S. cerevisiae strains 
E. coli strain Genotype Use 
XL-10 Gold TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F ṕroAB lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
Cloning  
Tunetta F- ompT hsdSB(rB
- mB
-) gal dcm (DE3) pRARE 
(CamR) 
Protein expression 
BL21 fhuA2 [lon] ompT gal [dcm] ΔhsdS Protein expression 
SoloPack TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F ṕroAB lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
StrataClone cloning  
 
Yeast strain Genotype 
BJ2168 MATa leu2 trp1 ura3-52 prb1-1122 pep4-3 prc1-407 gal2 
G175 MATα ADE2 MET his3 leu2 ura3 trp1 
BY4742 MATα his3 leu2 lys2 ura3 
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E.coli LB broth 
Luria-Bertani (LB) broth was prepared as follows: 1 % (w/v) peptone/ tryptone, 1 % (w/v) NaCl, 
0.5 % (w/v) yeast extract, pH 7 in distilled water. LB-agar was prepared as above with the addition 
of 1.5 % (w/v) agar. The media was autoclaved for sterility. 1 µM IPTG was added for protein 
induction. 
E.coli NZ amine- yeast extract (NZY) broth 
NZY broth was prepared as follows: 0.5 % (w/v) NaCl, 0.2 % (w/v) MgSO4, 0.5 % (w/v) yeast 
extract, 1 % (w/v) NZ amine pH 7.5 in distilled water. The media was autoclaved for sterility. 
Yeast extract- peptone- dextrose (YPD) medium 
YPD medium was prepared as follows: 2 % (w/v) peptone/ tryptone, 1 % (w/v) yeast extract, 2 
% (w/v) glucose. YPD-agar was prepared as above with the addition of 1.5 % (w/v) agar. The 
media was autoclaved for sterility. 
Yeast synthetic dropout medium (YSD) 
YSD medium was made according to the prototrophy of the transformed yeast strain as follows, 
for 1 L: 
Component Amount 
Yeast nitrogen w/o amino acids 0.67 % (w/v) 
Synthetic drop out medium: 
(Sigma Y1771 w/o Ura, Leu, Trp) 
w/o Ura 0.192 % (w/v)  
w/o Trp 0.192 % (w/v) 
  w/o Leu 0.162 % (w/v) 
Uracil 0.0076 % (w/v) 
Tryptophan 0.0076 % (w/v) 
Leucine 0.038 % (w/v) 
H2O To 950 ml 
  
The medium was autoclaved for sterility, then filter sterilised 40 % (w/v) raffinose was added to 
give a 2 % (w/v) raffinose solution (50 ml for 1 L of medium). For induction 40 % (w/v) galactose 
was added to give a 2 % (w/v) galactose solution. 
 To make 40 % (w/v) sugar solutions the desired amount of sugar was weighed to which, 
approximately half the desired volume of water was added. A microwave on medium heat was 
used to dissolve the sugar then the solution was topped up with water to the desired volume. The 
solution was then filter sterilised (0.42 µm) into a pre-autoclaved duran flask. 
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Plasmid DNA Cloning 
 
Cloning method Plasmids cloned  
pGEM T-easy ligation Putative C. longa 4CLs, pGEM vector 
Restriction and ligation by Dr H. 
Housden 
pYE2-4CL5 
Gibson Assembly pESC-DCS, pECS-DCS-CURS1, pYES2-4CL5-
F2A-DCS-F2A-CURS1, pBEVY-CaUGT2  
In-Fusion pYES2-DCS-F2A-CURS1, 
Restriction and ligation pRS416- Ala, pRS416- Leu1, pRS416- Leu2, 
pRS416- 3tRNA,  
pFGC5941-4CL5, pFGC5941-DCS, pFGC5941-
CURS1, pET-CaUGT2 
Cloning reactions were transformed into XL-10 Gold competent cells (see transformation 
protocol). Cells were plated onto LB-agar selective medium and incubated at 37 ̊ C overnight. 
Colony PCR was performed upon the colonies that grew to check for correct clones. If the PCR 
product was the expected size, selective LB medium was inoculated with the colony, grown 
overnight at 37 ̊ C with shaking, then DNA was extracted following the Qiagen mini-prep plasmid 
preparation protocol. The plasmid was then sent to GATC Biotech, with the correct sequencing 
primer for Sanger sequencing to verify correct cloning. Further details below. 
pGEM-T Easy cloning 
A 1:3 vector: insert cloning ratio was used and 50 ng of pGEM-T vector. Inserts were generated 
by PCR. The following reaction was set up and incubated at room temperature for hour: 
Component Volume 
2 x pGEM-T Buffer 5 μl 
pGEM-T easy vector (50 ng) 1 μl 
Insert 3 x no. of moles of vector (μl) 
T4 DNA Ligase 1 μl 
H2O 2 μl – volume of insert (μl) 
 Total 10 μl 
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Restriction and ligation  
NEB and Promega restriction enzymes were used. Restriction reactions were set up to generate 
the backbone and insert. Restriction enzymes were chosen based upon presence in the multiple 
cloning site of the vector backbone, absence in the cloning sequences and buffer compatibility. 
The restriction reaction was set up as below and incubated at the enzymes specific incubation 
temperature for 1-4 hours. 
Component Volume 
Water  16.3 μl 
10 x restriction enzyme buffer 2.0 μl 
DNA (~ 1 μg/μl) 1.0 μl 
Restriction enzyme 1 0.5 μl 
Restriction enzyme 2 0.5 μl 
Total 20.0 μl 
 
The reaction was then subjected to agarose gel electrophoresis to determine if restriction was 
successful and allow purification of the correct DNA fragment(s). Purification of DNA from 
agarose gels was carried out using Promega’s Wizard SV purification kit. Once purified, if 
necessary, and quantified, ligation was carried out, using ~ 100 ng of vector, and the chosen 
amount of insert depending on the ratio chosen (usually 1:3 vector: insert) as follows: 
DNA Ligation Volume 
T4 ligation buffer 1 μl 
Vector ~100 ng x μl 
Insert (correct molar ratio to vector) y μl 
H2O 8 – (+y) μl  
T4 DNA Ligase 1 μl 
Total 10 μl 
 
The ligation reaction was left to proceed for 3 hours at room temperature or 4  ̊C overnight. 2 μl 
of the reactions were then transformed into XL-10 Gold competent E. coli cells. 
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Gibson Assembly 
DNA inserts for Gibson Assembly were amplified by PCR using specially designed primers to 
create homologous regions between the ends of the inserts and the backbone. The insert was DpnI 
treated, then purified using Promega’s Wizard SV purification kit (see below). Vector backbones 
were linearised by restriction, as above for restriction and ligation cloning. The total amount of 
DNA insert and vector backbone fragments was kept between between 0.02- 0.5 pmols. 
Gibson Assembly reaction Volume 
50-100 ng vector   x μl 
100- 300 ng  
(2-3 x more, use 5 x more if < 200 bp) 
 y μl 
2 x Gibson Assembly master mix 10 μl 
Deionised water 10 – (x+y) μl 
 Total 20 μl 
 
2 μl of the reactions were then transformed into XL-10 Gold competent E. coli cells. 
In-Fusion cloning 
DNA inserts for In-Fusion cloning were amplified by PCR using specially designed primers to 
create homologous regions between the ends of the inserts and the backbone. The insert was DpnI 
treated, then purified using Promega’s Wizard SV purification kit (see below). Vector backbones 
were linearized by restriction, as above for restriction and ligation cloning, or created by PCR. 
In-Fusion cloning reaction Volume 
5 x In-Fusion HD enzyme premix   2 μl 
Vector  x μl 
Insert y μl 
Deionised water 8 – (x+y) μl 
Total 10 μl 
 
2 μl of the reactions were then transformed into competent XL-10 Gold E. coli cells.  
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DpnI DNA treatment 
To remove template DNA from PCR reactions to remove background colonies after cloning and 
transformation, DpnI digest was carried out: 
DpnI restriction digest Volume 
DpnI 1 µl 
DNA (~ 1 µg) 10 µl 
10 x CutSmart buffer 5 µl 
H2O 34 µl 
Total 50 µl 
 
Promega Wizard SV Gel and PCR Clean-Up System 
To purify DNA from PCR reactions or excised agarose gel DNA bands the Promega Wizard SV 
Gel and PCR Clean-Up kit was used. Following electrophoresis, excised DNA band was placed 
in a1.5ml microcentrifuge tube. 10 μl membrane binding solution, per 10 mg of gel slice, was 
added and incubated at 50– 65 ̊ C until the gel is dissolved. To PCR amplification reactions, an 
equal volume of membrane binding solution was added to the PCR amplification. The dissolved 
gel mixture or prepared PCR product was transferred to the minicolumn and incubated at room 
temperature for 1 minute before being centrifuged at 16 000 g, 1 minute. The minicoloumn was 
then washed with 700 μl membrane wash solution and centrifuged at 16 000 g for 1 minute. This 
wash was repeated with 500 μl membrane wash solution, then centrifuged at 16 000 g, 5 minutes. 
The minicolumn was transferred to a clean 1.5 ml microcentrifuge tube and pure DNA was eluted 
with 50 μl of nuclease-free water. The concentration of DNA was measured using a NanoDrop 
1000 spectrophotometer. 
E.coli transformation 
All steps were carried out under sterile conditions and on ice unless stated. Resultant colonies 
were screened for correctly cloned plasmids using colony PCR. Different cells were used for 
different transformations, see E. coli and S. cerevisiae strains. 
XL-10 Gold ultracompetent cells 
To a thawed 50 μl aliquot of XL-10 Gold cells in a 1.5 ml microcentrifuge tube, 2 μl of β-
mercaptoethanol was added and incubated on ice for 10 minutes, with swirling every 2 minutes. 
2 μl of cloning reaction was added, then incubated for 5 minutes on ice. The cells were then heat 
shocked for 1 minute at 42 ̊ C followed by 5 minutes on ice. 500 μl NZY medium was added 
before incubation at 37  ̊ C with shaking at 225-250 rpm for 1 hour. The cell culture was 
centrifuged for 1 minute at 5000 rpm and the supernatant was removed leaving ~100 μl. The pellet 
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was resuspended by flicking then spread on selective LB-agar plates; colonies were allowed to 
grow overnight at 37 ̊ C. 
Agilent SoloPack Gold competent cells 
SoloPack Gold cells were thawed on ice, to which 0.1- 50 ng of cloning reaction DNA was added, 
swirled, then incubated on ice for 30 minutes. The tubes were then heat shocked in a 42  ̊C water 
bath for 60 seconds then incubated on ice for 2 minutes. 175 μl of preheated (42  ̊C) NZY broth 
was added then the tubes were incubated at 37 ̊ C for 1 hour with shaking at 225-250 rpm. 200 μl 
of the transformation mixture was plated out on LB agar plates containing the appropriate 
selective antibiotic. Colonies were allowed to grow overnight at 37  ̊C. 
BL 21 cells  
BL21 cells were thawed on ice before 5– 10 ng of cloning reaction DNA, in a volume of 1– 5 μl, 
was added to the cells and mixed by tapping gently. The microcentrifuge(s) were incubated on 
ice for 30 minutes. The cells were heat shocked by incubating for 30 seconds at 42  ̊C from which 
they were quickly placed on ice. 250 μL of pre-warmed NZY medium was added before being 
placed in a shaking incubator at 37 ̊ C for 1 hour at 225 rpm. The transformation mixture was 
plated onto LB agar plates containing the appropriate antibiotic and colonies were allowed to 
grow overnight at 37 ̊ C. 
Qiagen Mini-prep DNA extraction from E. coli 
1-5 ml bacterial overnight culture was pelleted by centrifugation at 6800 x g for 3 minutes at room 
temperature. The pellet was resuspended in 250 μl Buffer P1 and transferred to a microcentrifuge 
tube. 250 μl Buffer P2 was added and mixed by inversion until clear. 350 μl Buffer N3 was added 
and mixed immediately centrifuged for 10 minutes at maximum speed. The supernatant was 
applied to the QIAprep spin column and centrifuged for 30– 60 s, then washed by adding 0.75 ml 
buffer PE and centrifuging for 30– 60 s, then a further minute to remove residual wash buffer. To 
elute DNA, 50 μl water was applied to the centre of the QIAprep spin column, let stand for 1 
minute, then centrifuged for 1 minute. The concentration of DNA was measured using a 
NanoDrop 1000 spectrophotometer. 
DNA Sanger sequencing 
For DNA Sanger sequencing, 5 µl of the purified plasmid DNA (80- 100 ng/µl) to be sequenced, 
combined with 5 µl of 5 µM sequencing primer was sent to GATC Biotech. Resultant sequence 
data was analysed using Jalview.  
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  Yeast manipulation 
Yeast chemical transformation 
The yeast strain to be transformed was patched (2 cm2) onto the correct selective agar and 
incubated overnight at 30 ̊ C. The transformation reagents were autoclaved. An aliquot of carrier 
single-stranded DNA (deoxyribonucleic acid sodium salt from salmon testes) in TE buffer (10 
mM Tris-HCl pH 8.0, 1.0 mM EDTA)) was heated in a boiling water bath for 5 minutes then 
chilled. A small portion of yeast was scraped from the agar plate and suspended in 1.0 ml of sterile 
water in a 1.5 ml microcentrifuge tube. The cells were pelleted at top speed in a microcentrifuge 
for 30 seconds and the supernatant was discarded.  The following components were added to the 
pellet, then incubated in a water bath at 42  ̊C for 45 minutes. 
 Component   Volume (µl) 
 PEG 3500 50% (w/v)   240 µl 
 LiAc 1.0 M (pH 8.4 - 8.9)  36 µl 
 Boiled SS-Carrier DNA (2 mg/ml)  50 µl 
 Plasmid DNA (0.1 to 1 µg) in water  34 µl 
 Total   360 µl 
  
The transformation mix was centrifuged at top speed for 30 seconds and the supernatant removed. 
The cell pellet was washed with 1.0 ml of sterile water before being resuspended in 1.0 ml of 
sterile water. 10 and 100 µl samples were plated onto YSD-agar plates of correct selection and 
incubated at 30 ̊ C for 3-4 days until colonies grew. 
DNA extraction from S. cerevisiae 
DNA was extracted from yeast cells to check transformation using a modification of the Qiagen 
MiniPrep kit. 10 ml yeast overnight culture was pelleted by centrifugation at 3000 g for 5 minutes. 
The pellet was resuspended in 800 µl Qiagen Miniprep buffer P1 and transferred to a screw top 
microcentrifuge tube. The tube was filled with 100 µm acid washed glass beads and the yeast cell 
suspension was subjected to tissue lysis using the Qiagen TissueLyserII for 5 minutes. The 
disrupted yeast cell suspension was transferred to a 1.5 ml microcentrifuge tube and centrifuged 
at maximum speed for 3 minutes. The supernatant was applied to the QIAprep spin column and 
centrifuged for 30–60 s, then washed by adding 0.75 ml Buffer PE and centrifuged for 30–60 s, 
then a further minute to remove residual wash buffer. To elute DNA, 50 μl water was applied to 
the centre of the QIAprep spin column, let stand for 1 minute, and centrifuged for 1 minute. 
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RNA extraction from S. cerevisiae 
RNA was extracted from yeast using the Qiagen RNeasy Mini kit. Per sample, a 10 ml yeast 
overnight culture was pelleted by centrifugation at 1000 x g for 5 minutes at 4  ̊C. The pellet was 
resuspended in 600 µl Buffer RLT and transferred to a TissueLyser tube containing 600 µl acid 
washed glass beads. The sample was agitated at top speed in the Qiagen TissueLyserII 
homogeniser. The lysate, after the beads settled, was transferred to a new microcentrifuge tube 
and centrifuged for 2 minutes at full speed. The supernatant was transferred to a new 
microcentrifuge tube and 1 volume of 70 % ethanol was added to the homogenized lysate, and 
mixed well by pipetting. The sample was transferred to an RNeasy spin column placed in a 2 ml 
collection tube and centrifuged for 15 seconds at 8000 x g. The flow through was discarded and 
700 μl Buffer RW1 was added to the RNeasy spin column and centrifuged for 15 seconds at 8000 
x g. The flow through was discarded and 500 μl Buffer RPE was added to the RNeasy spin column 
and centrifuged for 15 seconds at 8000 x g. The flow through was discarded and the RNeasy spin 
column was placed in a new 1.5 ml collection tube and 30–50 μl RNase-free water was applied 
directly to the spin column membrane and centrifuged for 1 minute at 8000 x g to elute the RNA. 
RNA was quantified using a NanoDrop 1000 spectrophotometer ready for DNase treatment and 
cDNA synthesis.  
To remove any uunwanted DNA from the extracted RNA, Promega DNase was used. To 8 µl 
RNA in water, 1 μl RQ1 RNase-Free DNase 10 x Reaction Buffer and 1 μl RQ1 RNase-Free 
DNase was added and incubated at 37 ̊ C for 30 minutes. Then 1 μl of RQ1 DNase Stop Solution 
was added and incubated at 65 ̊ C for 10 minutes to inactivate the DNase. 
For cDNA synthesis, Invitrogen SuperScript II reverse transcriptase (RT) was used. To the DNase 
treated RNA, 1 µl  Oligo(dT)12-18 (500 μg/mL) and 1 µl dNTP mix (10 mM each) was added then 
incubated at 65  ̊C for 5 minutes then chilled on ice. Then 4 μl 5 x First-Strand Buffer, 2 μl 0.1 M 
DTT and 1 μl RNaseOUT incubated at 42 ̊ C for 2 minutes. Then 1 μl SuperScript™ II RT was 
added and incubated at 42  ̊C for 50 minutes, then inactivated by heating at 70  ̊C for 15 minutes. 
 Protein extraction and analysis 
Ammonium sulphate precipitation of crude protein from plant tissue 
All steps were performed on ice where possible. ~4 g of plant tissue was ground under liquid 
nitrogen using a pestle and mortar to a fine powder, then transferred to a beaker chilled on ice. 
Immediately, 3 x (w/v) extraction buffer (50 mM Tris-HCl, 2 mM EDTA, 1 mM DTT, pH 7.5) 
and 50 g L-1 polyvinyl polypyrrolidont (PVPP) were added and mixed thoroughly. The slurry was 
filtered through a double layer of miracloth into chilled beaker. The filtrate was transferred to a 
centrifuge tube and centrifuged at 10 000g for 15 minutes at 4  ̊C. The proteinaceous supernatant 
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was retained.  The volume of supernatant was measured and ammonium sulphate, to give 80 % 
saturation, was added and stirred at 4 ̊ C for 30 minutes. The mixture was then centrifuged at 4000 
x g for 20 minutes at 4  ̊ C. The supernatant was discarded and the pellet was resuspended in 
working buffer (20 mM Tris-HCl, pH 8.0, 2 mM DTT). A 2 ml Zeba spin desalting column was 
filled with a water slurry of Sephadex-G25, placed in an empty 15 ml falcon tube then centrifuged 
at 2000 RPM for 2 minutes at 4 ̊ C. The column was washed three times with working buffer 
before the protein was applied then centrifuged. The flow through was collected and the protein 
concentration was measured using the Thermo Scientific BCA Protein Assay Kit or the Bio-Rad 
Bradford Protein Assay according to the manufacturer’s instructions. 
Protein extraction from E. coli 
Selective LB medium was inoculated with E. coli. The culture was grown overnight at 37 ̊ C with 
shaking at 225- 250 RPM; protein expression was induced by addition of  IPTG when the culture 
reached an OD of 0.4, to a working condition of 1 µM. After overnight growth, 5 ml of the culture 
was centrifuged at 3000 RPM for 5 minutes at 4 ̊ C. The pellet was resuspended in 1 ml extraction 
buffer (20 mM Tris-HCl pH 8.0, 2 mM DTT) and sonicated (3 x 15 seconds with 5 second breaks). 
The suspension was centrifuged at maximum speed for 3 minutes and the protein in the 
supernatant was then quantified using the Thermo Scientific BCA Protein Assay Kit or the Bio-
Rad Bradford Protein Assay according to the manufacturer’s instructions. 
Protein extraction from S. cerevisiae 
YSD medium was inoculated with the desired yeast strain and grown overnight at 37 ̊ C with 
shaking at 200 RPM. Once the culture reached OD 0.4, 40 % galactose (w/v) was added to the 
medium to give 2 % (w/v). 4 hours after induction, the culture was pelleted by centrifugation at 
3000 x g for 5 minutes at 4  ̊C. The pellet was weighed, for every 100 mg, 250 µl Sigma Y-PER 
Reagent was added with Sigma protease inhibitor cocktail P8215 (1 ml per 20 g wet yeast cells 
plus 1 M DTT to give 7.5 mM). The suspension was agitated at 200 RPM for 30 minutes, then 
centrifuged at 14 000 × g for 10 minutes. The supernatant was reserved for analysis. Protein 
concentration was quantified using the BCA Protein Assay Kit (Thermo Scientific) or the 
Bradford Protein Assay (Bio-Rad) according to the manufacturer’s instructions. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), Coomassie 
staining and western blot analysis. 
SDS-PAGE analysis was performed using a discontinuous gel system, with Bio-Rad Mini-
Protean Tetra cell apparatus. Bio-Rad Mini-Protean TGX stain-free 15 µl well precast gels were 
used to run samples. The tank apparatus was assembled and filled with Laemmli running buffer 
(25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS, pH 8.3). Protein samples (~ 50 µg) for analysis 
were mixed (4:1) with 4 x SDS loading buffer (83.3 mM Tris-HCl, 16.7 % (v/v) glycerol, 2.67 % 
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(w/v) SDS, 6.67 % (v/v) β-mercaptoethanol, 0.003 % (w/v) bromophenol blue, pH 6.8) and boiled 
for 5 minutes, before being loaded into the wells. 10 μl Bio-Rad pre-stained broad-range protein 
marker was also loaded to allow the estimation of the molecular weight of proteins. 
Electrophoresis was carried out at 200 V for 30 minutes. To visualise protein on the SDS gel, it 
was stained with Coomassie Brilliant Blue stain (0.1% Coomassie Brilliant Blue 50% methanol, 
10% acetic acid). To de-stain the gel, an acetic acid solution was used: 50 % water, 40 % 
methanol, and 10 % acetic acid.  
To allow western blot analysis, the protein was transferred from the SDS gel to a nitrocellulose 
membrane. To do this, nitrocellulose membrane was incubated in pre-chilled Towbin transfer 
buffer (25 mM tris-HCl, 192 mM glycine, 20 % (v/v) methanol) for 25 minutes at 4 °C. The SDS 
gel was also equilibrated in pre-chilled Towbin transfer buffer, for 15 minutes at 4 °C. The gel, 
membrane and protecting filter paper were arranged according to the Trans-Blot SD Semi-Dry 
Transfer Cell protocol and placed in the transfer cell which was operated at 10 V for 1 hour. 
Protein transfer was confirmed by staining in Ponceau solution (0.2 % Ponceau (w/v), 3 % 
trichloroacetic acid (v/v). To remove the stain, the membrane was washed in TBS (25 mM tris-
HCl, 150 mM NaCl, pH 7.5).  
For western blot analysis, the membrane was first blocked for 1 hour with TBS buffer plus 3 % 
(w/v) skimmed milk, then incubated with the primary antibody for 1 hour, according to the table 
below. The membrane was then washed 3 times for 5 minutes in TBST buffer (TBS 25 mM tris-
HCl, 150 mM NaCl, 0.05 % Tween-20 (v/v), pH 7.5). The membrane was then incubated with 
the secondary antibody for at least 1 hour according to the table below. Again, the membrane was 
washed 3 times for 5 minutes in TBST buffer before detection according to the table below was 
carried out. If the secondary antibody was an alkaline phosphatase (AP) conjugate, nitro-blue 
tetrazolium (NBT) and 5-bromo-4-chloro-3'-indolyphosphate (BCIP) were used for chromogenic 
blot analysis: the membrane was incubated for 2 minutes in 100 mM Tris-HCl, pH 9.5, then NBT/ 
BCIP solution (33 ul each per 10 ml in 100 mM Tris-HCl, pH 9.5) until staining was observed. If 
the secondary antibody was a horse radish peroxidase (HRP) conjugate: a 4-Chloro-1-naphthol 
tablet (4CN) was dissolved in 10 ml methanol, 2 ml of this was added to 10 ml of triethanolamine 
buffer saline and 5 ul of 30% H2O2, then used to develop stain. 
Epitope Primary antibody Secondary antibody Detection 
Strep-tag 1:5000 Strep-Tactin HRP conjugate - 4CN 
Anti-GFP 1:5000 Anti-GFP mouse 1:1500 Anti-mouse-AP NBT+BCIP 
Anti-HIS tag 1:3000 Anti-HIS HRP conjugate - 4CN 
Anti-myc tag 1:10000 Anti-c-MYC mouse 1:1500 Anti-mouse-AP NBT+BCIP 
Anti-FLAG 1:1500 Anti-FLAG rabbit 1:1500 Anti-rabbit-HRP 4CN 
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 Activity assays 
Trichoderma reesei cellulase assay 
200 µl of C. longa rhizome methanolic extract was dried using a Genevac centrifugal evaporator. 
The residue was resuspended in 0.5 ml 0.15 M citric phosphate buffer (pH 5.0) to which 1 mg ml-
1 cellulase (Trichoderma reesei ATCC 26921) was added and incubated at 30 ̊ C overnight. The 
sample was extracted twice with 0.5 ml ethyl acetate which was dried using a Genevac centrifugal 
evaporator and resuspended in methanol for LC-MS analysis (see Curcumin glucoside LC-MS 
analysis method). 
14C-UDP-glucose radiolabelling assay  
Protein was extracted from the organism to be assayed for UGT activity in biological triplicate. 
An aliquot of 14C-UDP glucose was measured using scintillation counting to determine the 
volume needed to give a reading of 50 000 dpm. The assay was set up as follows, with 14C-UDP 
glucose being added last:  
 Component Volume  
14C-UDP Glucose (50, 000 dpm) x  
1 mM substrate in Methanol 5  
Crude protein (50-100 ug) y 
BSA (20 mg/ml) 2.5 
20 mM Tris-HCl (pH 8.0, 2 mM DTT) 75 - x - y 
 Total 75 ul 
  
The reaction was incubated at 30  ̊C then quenched with 125 μl 0.3 M HCl, extracted with 200 μl 
water saturated ethyl acetate and centrifuged at maximum speed for 1 minute. 100 μl supernatant 
was added to 4 ml Ecoscint solution in scintillator tubes and scintillation counting was carried out 
using a Packard Trib-Carb 2900TR Liquid Scintillation Analyzer.  
In vitro crude protein assays 
Protein extracted from yeast transformed with the desired vector(s) was quantified using the 
Thermo Scientific BCA Protein Assay Kit or the Bio-Rad Bradford Protein Assay according to 
the manufacturer’s instructions.  
 4-coumarate CoA ligase 5 (4CL5) activity 
Crude protein extract containing 4CL5 (100 µg), was made up to 50 μl in 100 mM Tris-HCl buffer 
(pH 8.0) containing 10 mM DTT. To this was added 547 μl of 100 mM Tris-HCl buffer pH 8.0 
containing 1.6 mM coenzyme A, 8.3 mM ATP and 8.3 mM MgCl2. 3 μl 100 mM phenylpropanoic 
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acid substrate (in methanol) was added to give a concentration of 0.5 mM. The reaction was then 
incubated at 30 ̊ C. The reaction was stopped by adding an equal volume of methanol and the 
samples were centrifuged (16 000 g, 5 minutes), to pellet precipitated protein. The supernatant 
was analysed by LC-MS (see Phenylpropanoyl-CoA ester LC-MS analysis method 1). 
 Diketide-CoA synthase (DCS) activity 
Crude protein extract containing DCS, were assayed as carried out by Katsuyama, et al.93. To 50 
µg crude protein (in 40 μl Y-PER lysis buffer), 59 μl reaction buffer (100 mM phosphate buffer 
(pH 7.5), 50 mM malonyl-CoA) was added. Then 1 μl 10 mM feruloyl CoA was added and the 
reaction was incubated at 37 °C for 1 hour before quenching with 20 μl of 6 M HCl. The samples 
were centrifuged (16 000 g, 5 minutes), to pellet precipitated protein. The supernatant was 
analysed by LC-MS (see Phenylpropanoyl-CoA ester LC-MS analysis method 1). 
Curcuminoid synthase 1 (CURS1) activity 
Crude protein extract containing CURS1 (50 µg), was made up to 50 μl in 100 mM Tris-HCl 
buffer (pH 8.0) containing 10 mM DTT. To this was added 547 μl of 100 mM Tris-HCl buffer 
pH 8.0 containing 1.6 mM coenzyme A, 8.3 mM ATP, 8.3 mM MgCl2 and 0.5 mM malonyl-
CoA. 3 μl 100 mM phenylpropanoic acid substrate (in methanol) was added to give a 
concentration of 0.5 mM. The reaction was then incubated at 30 ̊ C. The reaction was stopped by 
adding an equal volume of methanol and the samples were centrifuged (16 000 g, 5 minutes), to 
pellet precipitated protein. The supernatant was analysed by LC-MS (see Phenylpropanoyl-CoA 
ester LC-MS analysis method 2). 
 Catharanthus roseus UDP-glycosyltransferase 2 
Crude protein extract containing CaUGT2 (50 µg), was made up to 100 μl in 50 mMTris–HCl 
buffer (pH 7.5), 2 mM UDP-glucose and 250 µM curcuminoid substrate. The reaction was 
incubated at 30 ̊ C for 30 minutes. The reaction was terminated by adding 200 μl methanol. After 
centrifugation at 16 000 x g for 10 minutes, the reaction products were analysed by LC-MS using 
a Phenomenex reversed phase Luna 5 µm C18(2) 100 Å, LC Column 250 x 4.6 mm (see curcumin 
glycoside method). 
In vivo yeast cell culture assay 
The same assay was performed for investigating the in vivo activity of 4CL5, DCS and CaUGT2 
expressing yeast cells. 25 ml 2 % (w/v) raffinose YSD medium, made according to the 
prototrophy of the transformed yeast strain to be investigated in a shake flask, was inoculated, 
and the yeast was grown over night at 30 ̊ C with shaking at 200 RPM. The OD600 was measured 
and adjusted to 0.4 and 40 % galactose was added to give 2 % (w/v) and induce protein production. 
After 4 hours induction, 25 μl of 0.1 M substrate was added and the culture was grown at 30 ̊ C 
with shaking at 200 RPM. The cultures were samples for analysis over 72-96 hours. To analyse, 
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1 ml of the culture was removed and centrifuged at 16 000 g for 3 minutes. 0.5 ml of supernatent 
was combined with 0.5 ml ethanol for analysis of the culture medium. The remaining supernatant 
was discarded and the pellet was washed with 1 ml of water, then repelleted. To the pellet, 200 μl 
methanol and 50 μl acid washed beads was added and lysed by vortexing for 30 seconds then 
centrifuged for 16 000 g for 3 minutes. The cell contents and media were separately analysed 
using the appropriate LC-MS method. 
Spectroscopic determination of curcumin glycoside production 
25 ml 2 % (w/v) raffinose YSD medium, made according to the prototrophy of the yeast 
transformed with pBEVY-CaUGT2, was inoculated, and the yeast was grown over night at 30  ̊C 
with shaking, 200 RPM. The OD600 was measured and altered to 0.4 and the medium was adjusted 
to the conditions to be investigated (such as supplemental raffinose, or adding FeSO4). 125 µl 0.1 
mM curcumin (in methanol) was added. As the cultures grew, at 30 ̊ C with shaking, 200 RPM, 
they were sampled and spectrophotometrically analysed over 72 hours. To sample, 1 ml was 
removed from the shake flask and centrifuged at 16 000 g for 3 minutes. The absorbance of the 
supernatant was then measured at 425 nm and recorded.  
5 L Fermentation 
25 ml 2 % (w/v) raffinose YSD medium, made according to the prototrophy of the yeast 
transformed with pBEVY-CaUGT2, was inoculated, and the yeast was grown over night at 30  ̊C 
with shaking, 200 RPM. 475 ml 2 % (w/v) raffinose YSD medium was inoculated with the 25 ml 
culture and grown over night at 30 ̊ C with shaking, 200 RPM. 4.5 L 2 % (w/v) raffinose, 2 % 
(w/v) galactose YSD medium, with 1 ml Sigma antifoam C, was added to the 5 L Applikon 
bioreactor and autoclaved. The media was then calibrated and set up for fermentation: 30 ̊ C, 250 
RPM stirring, ≥40 % dissolved oxygen. These parameters were monitored by the Applikon 
ezcontrol unit. The bioreactor was inoculated with the 500 ml culture and left to proceed under 
the control of the Applikon ezcontrol unit. After 4 hours, 25 ml 20 mM curcumin (in methanol) 
was added. Culture density (OD600) and glycoside production (by spectrophotometric analysis at 
425 nm) were manually monitored.  
  Heterologous expression in tobacco 
Agrobacterium transformation  
Agrobacterium tumefaciens, strain GV3101, was used for the Agrobacterium mediated 
transformation of tobacco leaf tissue. To a defrosted 100 µl aliquot of cells on ice, 2-3 µl (~ 300 
ng) of plasmid was added, then immediately frozen in liquid nitrogen. The cells were then 
defrosted for 5 minutes at 37 ̊ C then incubated on ice for 30 minutes. 250 µl LB was added and 
the cells were recovered at 28 ̊ C, using shaking at 200 RPM, for 1-3 hours. The cells were then 
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spread on LB- agar plates containing gentamicin and kanamycin to select for the agrobacterium 
transformed with the pFGC5941 plasmid. The plates were incubated at 28 ̊ C until colonies 
formed. 
Agro-infiltration and tobacco leaf disc assay 
Transformed A. tumefaciens was grown for 2 days at 28 ̊ C with shaking at 180 RPM, after which 
the cells were resuspended in 10 mM MgCl2 to give an OD600 of 1.0. Solutions of A. tumefaciens 
carrying each plasmid (pFGC-4CL5/DCS/CURS1) were combined as required. Using a 1 ml 
syringe, 4 week old Nicotiana benthamiana leaves were infiltrated with the MgCl2 cell solutions. 
After 5 days, 10 leaf discs (~ 200 mg tissue), representing the different enzyme combinations, 
were harvested and incubated in 1 ml of each of the solutions to be tested and incubated at 18 ̊ C, 
16 hours of light per day, 40 % rH. Samples were collected after 0, 24, and 48 hours. The plant 
tissue and solutions were added to 10 x ice cold acetone (w/v) and ground in a mortar and pestle 
using glass beads. The slurry was filtered through two layers of filter paper. Any remaining solids 
were further ground in 10 x ice cold 1:1 acetone:methanol (w/v). Again the slurry was filtered 
through two layers of filter paper and the filtrates were combined and evaporated to dryness using 
a Genevac centrifugal evaporator. The residue was resuspended in 200 µl of methanol and 
analysed by LC-MS (see Tobacco analysis LC-MS method). 
qPCR 
RNA was extracted from 100 mg transformed tobacco tissue using the Qiagen RNeasy Mini kit, 
the protocol of which was followed exactly. To remove any DNA from the extracted RNA, 
Promega DNase was used: to 8 µl RNA in water, 1 μl RQ1 RNase-Free DNase 10 x Reaction 
Buffer and 1 μl RQ1 RNase-Free DNase were added and incubated at 37  ̊C for 30 minutes. Then 
1 μl of RQ1 DNase Stop Solution was added to terminate the reaction and incubated at 65 ̊ C for 
10 minutes to inactivate the DNase. 
For cDNA synthesis Invitrogen SuperScript II reverse transcriptase (RT) was used: to the DNase 
treated RNA, 1 µl Oligo(dT)12-18 (500 μg/mL) and 1 µl dNTP mix (10 mM of each dNTP) were 
added then incubated at 65 ̊ C for 5 minutes then chilled on ice. Then 4 μl 5 x First-Strand Buffer, 
2 μl 0.1 M DTT and 1 μl RNaseOUT were added and incubated at 42  ̊C for 2 minutes. Next, 1 μl 
SuperScript II RT was added and incubated at 42  ̊C for 50 minutes, then inactivated by heating 
at 70 ̊ C for 15 minutes.  
For qPCR, the cDNA was diluted ten-fold with RNase free water and the reaction was set up as 
follows: 
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Component Volume  
SYBR green 10 ul 
Primer 1 1.6 ul 
Primer 2 1.6 ul 
RNase free water 4.8 ul 
cDNA 2 ul 
 Total 20 ul 
 
qPCR for each sample was performed in triplicate in a 96 well plate according to the Bio-Rad 
MyIQ protocol. Data analysis was carried out using the Bio-Rad analysis module.  
 
 Extraction of metabolites from C. longa rhizome tissue 
Extraction of metabolites from Vietnamese C. longa rhizome samples 
As performed by Kieu Oahn Nguyen (University of Science and Technology, Hanoi, Vietnam). 
The gathered samples were cleaned in water then freeze dried using an Edwards Modulyo Freeze 
Dryer. The sample was ground to a fine powder using a pestle and mortar. Extraction and 
detection had been optimised after investigating different solvents (100 % methanol, 50 %, 
acetone, 50 %, hexane), sample weight (20, 50, 100, 150 and 200 mg) and dilution (10, 20, 50 
and 100 fold). 50 mg powdered sample was mixed with 1 ml methanol and sonicated at 70  ̊ C for 
1 hour before being cooled at 4 ̊ C for 30 minutes and centrifuged at 10 000 g, 15 minutes. The 
supernatant was analysed by UPLC-MS (UPLC-LTQ Orbitrap MS analysis) and the data was 
analysed by Dr Tony Larson. 
Soxhlet extraction of metabolites from fresh C. longa rhizome tissue 
Fresh C. longa rhizome tissue (3 g) was ground to a powder using liquid nitrogen and a pestle 
and mortar. The powder was transferred to an extraction thimble and placed within the Soxhlet 
apparatus. 125 ml of methanol was heated allowing it to pass through the apparatus for 10 cycles, 
extracting metabolites from the ground rhizome tissue. The methanol extract was dried using a 
rotary evaporator and the residue was dissolved in water by sonication for 15 minutes. The water 
solution was subjected to liquid-liquid extraction with ethyl acetate three times. The ethyl acetate 
layers were combined and dried using a rotary evaporator. All layers were analysed by LC-MS 
(see Curcumin glycoside LC-MS analysis method). 
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  Liquid Chromatography-Mass Spectrometry (LC-MS) Analysis 
Samples for LC-MS were prepared by centrifugation at 16 000 g for 10 minutes, before decanting 
100 µl into a vial for analysis. Data was analysed using Thermo Scientific Xcalibur software. 
Phenylpropanoyl-CoA ester LC-MS analysis method 1 
Using a quadripartite solvent system and positive electrospray ionisation (ESI), 10 µl of sample 
was injected for analysis using a Phenomenex reversed phase Kinetex 5µm C18 100 Å, 50 x 2.1 
mm column at 30 ̊ C. The method was adapted from Larson and Graham, 2001 244. The solvent 
gradient was as follows: 
Time 
(minutes) 
Flow 
(ml/min) 
0.05 % 
TEA 
90 % acetonitrile, 
0.05 % TEA 
90 % acetonitrile, 
1 % acetic acid 
1 % acetic 
acid 
0.0 0.75 0.0 0.0 10.0 90.0 
5.0 0.75 0.0 0.0 80.0 20.0 
5.1 0.75 80.0 0.0 0.0 0.0 
7.0 0.75 97.0 3.0 0.0 0.0 
10.0 0.50 95.0 5.0 0.0 0.0 
10.1 0.50 95.0 5.0 0.0 0.0 
30.0 0.50 60.0 40.0 0.0 0.0 
30.1 0.50 0.0 100.0 0.0 0.0 
32.0 0.50 0.0 100.0 0.0 0.0 
32.1 0.50 0.0 100.0 0.0 0.0 
35.0 0.50 0.0 100.0 0.0 0.0 
35.1 0.50 0.0 0.0 10.0 0.0 
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Phenylpropanoyl-CoA ester LC-MS analysis method 2 
Using a quadripartite solvent system and positive ESI, 10 µl of sample was injected for analysis 
using a Phenomenex reversed phase Kinetex 5µm C18 100 Å, 50 x 2.1 mm column at 30 ̊ C. The 
method was adapted from Larson and Graham, 2001 244. The solvent gradient was as follows: 
Time 
(minutes) 
Flow 
(ml/min) 
0.25 % 
TEA 
90 % acetonitrile, 
0.05 % TEA 
90 % acetonitrile, 
1 % acetic acid 
1 % acetic 
acid 
0.0 0.75 0.0 0.0 10.0 90.0 
5.0 0.75 0.0 0.0 80.0 20.0 
5.1 0.75 80.0 0.0 0.0 0.0 
7.0 0.75 97.0 3.0 0.0 0.0 
10.0 0.50 95.0 5.0 0.0 0.0 
10.1 0.50 95.0 5.0 0.0 0.0 
50.0 0.50 60.0 40.0 0.0 0.0 
50.1 0.50 0.0 100.0 0.0 0.0 
52.0 0.50 0.0 100.0 0.0 0.0 
52.1 0.50 0.0 100.0 0.0 0.0 
55.0 0.50 0.0 100.0 0.0 0.0 
55.1 0.50 0.0 0.0 10.0 0.0 
 
Tobacco analysis LC-MS method 
Using a two solvent system and negative ESI, 10 µl of sample was injected for analysis using a 
Phenomenex reversed phase Synergi Polar-RP 80 Å 250 x4.6 mm column at 30 ̊ C. The solvent 
gradient was as follows: 
Time (minutes) Flow (ml/min) 95 % water, 5 % acetonitrile 100 % acetonitrile 
0.0 1.00 5.0 95.0 
2.0 1.00 5.0 95.0 
15.0 1.00 50.0 50.0 
25.0 1.00 55.0 45.0 
32.0 1.00 100.0 0.00 
34.0 1.00 100.0 0.0 
34.1 1.00 5.0 95.0 
37.0 1.00 5.0 95.0 
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UPLC-LTQ Orbitrap LC-MS analysis method 
Using a two phase solvent system and positive APCI, 10 µl of sample was injected for analysis 
using a Waters Acquity UPLC BEH Phenyl 1.7 μm 2.1x100 mm column at 60 ̊ C. The solvent 
gradient was as follows: 
Time 
(minutes) 
Flow (ml/min) 95 % water, 5 % methanol 
0.1 % Formic acid 
100 % methanol 
0.1 % Formic acid 
0.0 0.50 45.0 55.0 
2.50 0.50 45.0 55.0 
4.00 0.50 0.0 100.0 
4.40 0.50 0.0 100.0 
4.41 0.50 45.0 55.0 
5.00 0.50 45.0 55.0 
15.0 0.50 45.0 55.0 
 
Curcumin glycoside LC-MS analysis method  
Using a two phase solvent system and negative ESI, 10 µl of sample was injected for analysis 
using a Phenomenex reversed phase Luna 5 µm C18(2) 100 Å, 250 x 4.6 mm column at 30 ̊ C. 
The solvent gradient was as follows: 
Time (minutes) Flow (ml/min) 95 % water, 5 % methanol 100 % methanol 
0.0 1.00 60.0 40.0 
14.0 1.00 21.0 79.0 
15.0 1.00 0.0 100.0 
20.0 1.00 0.0 100.0 
23.0 1.00 100.0 0.0 
25.0 1.00 100.0 0.0 
27.0 1.00 60.0 40.0 
30.0 1.00 60.0 40.0 
30.0 1.00 60.0 40.0 
 
Flash chromatography 
Flash chromatography was carried out using a Biotage Isolera Prime system and a Reveleris C18 
Reversed-Phase 40 g cartridge. The sample, for purification, was dissolved in a minimum volume 
of 10 % methanol. After priming the system according to the Biotage manual guidelines, the 
sample was manually loaded onto the cartridge. Using a stepped methanol gradient, as below, 25 
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ml fractions were collected. The fractions were analysed by LC-MS (Curcumin glycoside LC-MS 
analysis method) to verify their contents, then pooled accordingly and concentrated using a 
Genevac centrifugal evaporator.  
Column volumes  Flow (ml/min) 100 % water 100 % methanol 
2.0 50.0 90.0 10.0 
1.0 50.0 90.0 10.0 
1.0 50.0 90.0- 80.0 10.0- 20.0 
1.0 50.0 80.0 20.0 
2.0 50.0 80.0- 60.0 20.0- 40.0 
1.0 50.0 60.0 40.0 
3.0 50.0 60.0- 0.0 40.0- 100.0 
4.0 50.0 0.0 100.0 
 
 
Preparative HPLC 
Preparative HPLC was carried out using an Agilent Varian Modular Analytical HPLC System 
and a Waters SunFire C18 OBD Prep Column, 100Å, 5 µm, 19 mm X 150 mm. The sample was 
dissolved in the lowest volume and lowest percentage methanol possible. After priming the 
system according to the Agilent manual guidelines, the sample was manually loaded onto the 
cartridge. Using a methanol gradient, as below, 12 ml fractions were collected. The fractions were 
analysed by LC-MS (Curcumin glycoside LC-MS analysis method) to verify their contents, then 
pooled accordingly and concentrated using a Genevac centrifugal evaporator. 
Time 
(minutes) 
Flow (ml/min) 100 % water, 0.1 % 
formic acid 
100 % acetonitrile, 0.1 
% formic acid 
0.0 10.00 70.0 30.0 
1.0 10.00 70.0 30.0 
19.0 10.00 0.0 100.0 
20.0 10.00 0.0 100.0 
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 Primer table 
  
Name Purpose Sequence  
Cl4CL1_R 
 
Cl4CL1_F 
Amplification of C. longa 
4CL cDNA DY382977.1 
Amplification of C. longa 
4CL cDNA DY382977.1 
CCAGGCACATCGACAGCAC  
 
GCACCCTTTGACTCTGCTCC 
Cl4CL2_R 
 
Amplification of C. longa 
4CL cDNA DY382750.1 
CGCACCGACGTCCTTTACTCTAG 
Cl4CL2_F Amplification of C. longa 
4CL cDNA DY382750.1 
CGGAGATCTCGAACCTGCG 
Cl4CL3_R Amplification of C. longa 
4CL cDNA DY391029.1 
GACATCACGGTGCGGATCG 
Cl4CL3_F 
 
Amplification of C. longa 
4CL cDNA DY391029.1 
GGAGGATGAGGAAGAGATCGTCG 
Cl4CL4_R Amplification of C. longa 
4CL cDNA DY390122.1 
GGACTTGACGATGCGGATCG 
Cl4CL4_F Amplification of C. longa 
4CL cDNA DY390122.1 
GCACCTTGTGATCACGAGCG 
Cl4CL5_R Amplification of C. longa 
4CL cDNA DY391030.1 
GGCCTCGTGCCGAATTCG 
 
Cl4CL5_F Amplification of C. longa 
4CL cDNA DY391030.1 
AACTCCCCTAAGATGGGTGGC 
Odt Amplification of cDNA TTTTTTTTTTTTTTTTTT 
Cl4CL1nest_F Nested amplification of C. 
longa 4CL cDNA 
DY382977.1 
GCAATTCGCCGGAGTTCG 
Cl4CL1nest_R Nested amplification of C. 
longa 4CL cDNA 
DY382977.1 
CGGCCCTGCTTCTGTCA 
Cl4CL2nest_F Nested amplification of C. 
longa 4CL cDNA 
DY382750.1 
CCTCTTGAAACCATATGAACATCT
CCACG 
Cl4CL3nest_F Nested amplification of C. 
longa 4CL cDNA 
DY391029.1 
ACCCCGACGACG CG 
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Cl4CL3nest_R Nested amplification of C. 
longa 4CL cDNA 
DY391029.1 
CGACAAGTCGTAGGCGTCC 
3raceCL1F1 3’ RACE PCR of C. longa 
4CL cDNA DY382977.1 
GCAATTCGCCGGAGTTCGTC 
3raceCL1F2 3’ RACE PCR of C. longa 
4CL cDNA DY382977.1 
CCGCTCTTCCACATCTACTCGC 
Haz_4CL5_int_L 4CL5 internal primer CTTCTAAAACCTAAAATATCGCCG
GAAG 
Haz_4CL5_int_L 4CL5 internal primer CCCTTGAGATCTTGCTACAAATGC
TACT 
pYESfseq Sequencing pYES2 insert CCTTATTTCTGGGGTAATTAATCA
GCGA 
pYESrseq Sequencing pYES2 insert AGAGGGTTAGGGATAGGCTTACC 
T7 forward Sequencing  TAATACGACTCACTATAGGG 
F_Infu_HisDCS 
 
R_Infu_DCS 
 
 
2A_F 
 
2AStrep_infu_R 
 
 
 
CURS1_F 
 
CURS1_infu_R 
 
pYES2_F: 
 
pYES2_Infu_R: 
In-Fusion Cloning pYES2-
DCS-F2A-CURS1 
 
In-Fusion Cloning pYES2-
DCS-F2A-CURS1 
In-Fusion Cloning pYES2-
DCS-F2A-CURS1 
In-Fusion Cloning pYES2-
DCS-F2A-CURS1 
 
In-Fusion cloning pYES2-
DCS-F2A-CURS1 
In-Fusion Cloning pYES2-
DCS-F2A-CURS1 
In-Fusion Cloning pYES2-
DCS-F2A-CURS1 
In-Fusion Cloning pYES2-
DCS-F2A-CURS1 
 
ATGCATCATCATCATCATCATGAA
GCGAACGGCTACCGCATAAC 
GTCAAAATTCAACAGCTGTACGTA
GTTCAGTCTGCAACTATGGAGGAC
GAC 
CAGCTGTTGAATTTTGACCTTCTT
AAGCTTGCG  
GTGGAGGTTGGCCATGTGGTTAAT
CAAACCTTTTTCAAATTGTGGATG
ACTCCA 
 
ATGGCCAACCTCCACGCG 
 
GCAGAATTCGCCCTTCTACAGTGG
CATACTGCGCAGTAC  
AAGGGCGAATTCTGCAGATATCC
ATCAC 
CGCTTCATGATGATGATGATGATG
CATATGCCCTATAGTGAGTCGTAT
TACAGCTGC 
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4CL52A_Gib_F Gibson assembly of pYES2- 
4CL5-F2A-DCS-F2A-
CURS1 
CTGTAATACGACTCACTATAGGGC
ATATGGCTAGCTGGAGCCACCCGC
AGTTC 
4CL52A_Gib_R Gibson assembly of pYES2- 
4CL5-F2A-DCS-F2A-
CURS1 
GCTTCATGATGATGATGATGATGC
ATGGGCCCAGGGTTGGACTCGAC
GTC 
DCS_482_F   
DCS_993_F   
CURS1_286_F  
pESC_DCS_GAF 
 
 
pESC_DCS_GAR 
Sequencing DCS 
Sequencing DCS 
Sequencing CURS1 
Gibson assembly of pESC-
DCS 
 
Gibson assembly of pESC-
DCS 
GCGTCATGCTCTACAACGTC 
GACGCGGCACGTACTCAG 
GACATCGTGGTGGAGGAGATA 
TACGACTCACTATAGGGCCCGGGC
GATGGAAGCGAACGGCTACCGCA
TAA 
TTCGGAAATCAACTTCTGTTCCAT
GTAGTTCAGTCTGCAACTATGGAG
GACGAC 
pESCseqF Sequencing pESC insert ATTTTCGGTTTGTATTACTTC 
pESCseqR Sequencing pESC insert GTTCTTAATACTAACATAACT 
pESC-CURS_F 
 
 
pESC-CURS_R 
Gibson assembly of pESC-
DCS-CURS1 
 
Gibson assembly of pESC-
DCS-CURS1 
TCGTCATCCTTGTAATCCATCGAT
AACAGTGGCATACTGCGCAGTAC
AAC 
ATGGCCAACCTCCACGCG 
Gal10F Sequencing pESC insert GGTGGTAATGCCATGTAATATG 
Gal10R Sequencing pESC insert GGCAAGGTAGACAAGCCGACAAC 
GAL1_F Sequencing pESC insert ATTTTCGGTTTGTATTACTTC 
GAL1_R Sequencing pESC insert GTTCTTAATACTAACATAACT 
ACT1_F Actin PCR control CTGAGGTTGCTGCTTTGGTT 
ACT1_R Actin PCR control CGGTGATTTCCTTTTGCATT 
F_AscI_4CL5 4CL5 primer GCGCGCGGCGCGCCATGGCTAGC
TGGAGCCAC 
R_XbaI_4CL5 4CL5 primer GCGCGCTCTAGACTATTTAGAGCA
CATGGTTTC 
F_AscI_DCS DCS primer GCGCGCGGCGCGCCATGGAAGCG
AACGGCTAC 
R_XbaI_DCS DCS primer GCGCGCTCTAGACTAGTTCAGTCT
GCAACT 
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F_PacI_CaUGT pET-CaUGT2 cloning GCGCGCTTAATTAAATGGTTAATC
AGCTC 
R_SalI_CaUGT pET-CaUGT2 cloning GAAAGCAACAAGACTAGTCTTGTT
GCTTTC 
pBEVY-
CaUGT2_GAF 
pBEVY-CaUGT2 cloning AGTCCAAAGCTTGCATGCCTGCAG
GCTAGTCTTGTTGCTTTCTTTCAAC
TTGAGAACGATATGC 
pBEVY-
CaUGT2_GAR 
pBEVY-CaUGT2 cloning CTTAGTTTCGACGGATCCTCTAGA
GATGGCTAGCTGGAGCCACCCGC
AGT 
GAP_F Sequencing CACAAGGCAATTGACCCACG 
M13_F Sequencing GTAAAACGACGGCCAGT 
M13_R Sequencing AACAGCTATGACCATG 
DCS_qPCR_F qPCR GAGAAGGCGATCAAGGAGTG 
DCS_qPCR_R qPCR GTAGAGCATGACGCGATTGA 
4CL5_qPCR_F qPCR ATCCCCTGAGACGGAGAGAT 
4CL5_qPCR_R qPCR GATCACAGTCCCACATGCAC 
CURS_qPCR_F qPCR CTCCCAACCTCTACGAGCAG 
CURS_qPCR_R qPCR ATCTCCTCCACCACGATGTC 
p19_qPCR_F qPCR TCACTGCACAGAGTCCTTGG 
p19_qPCR_R qPCR AGACCGAATTGCCATCTCAC 
3' Nb actin qPCR GATACGGGGAGCTAATGCAG 
5' Nb actin qPCR CGGGAAATTGTTAGGGATGT 
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Chapter 5. Final Discussion  
The biosynthetic production of plant secondary metabolites is a sustainable and green alternative 
to total chemical syntheses. It can also offer greater yields and simpler extraction processes than 
purifying natural products from the host plant. This is reflected in the dawn of synthetic and 
systems biology and the increase in heterologous biosyntheses using metabolic engineering of 
chassis organisms. With DNA synthesis becoming automated, cheaper and quicker, it is expected 
that the use of heterologous biosynthetic pathways to produce plant natural products will become 
ever more prevalent. 
Compared to extraction from C. longa, synthetic biology and metabolic engineering offered a 
route to individually produce the highly bioactive curcuminoids, curcumin, DMC and BDMC, 
with increased purity 245. Other polyketides synthesized by type III polyketide synthases (PKSs), 
namely naringenin and resveratrol, have been successfully biosynthesized via a multitude of 
heterologous enzyme pathways in both E. coli and S. cerevisiae, as reviewed by Lussier et al.184  
This study explored the less investigated heterologous biosynthesis of curcuminoids in S. 
cerevisiae and N. benthamiana, as well as the production of curcuminoid analogues by using non-
natural starting materials and glycosyltransferase tailoring enzymes. Before the start of the study, 
curcuminoids had been biosynthesized in E. coli by Katsuyama et al.146. A 4CL from L. 
erythrorhizon and CUS, from rice, was able to produce curcuminoids from exogenous 
phenylpropanoids giving a yield of 100 mg L-1 146. Katsuyama et al.105 then used this system to 
produce non-natural curcuminoids such as di-4-chlorocinnamoylmethane, di-2-
furylacryloylmethane and di-3-indoleaclyloylmethane. Unfortunately, this processes also yielded 
triketide pyrone derailment products. 
The current study aimed to utilise phenylpropanoic acids as feedstock due to their presence in 
bio-refinery waste 246, meaning they would be a sustainable starting material. The conversion of 
phenylpropanoic acids to curcuminoids required activation by a 4CL, then decarboxylative 
condensation with two malonyl-CoA units, as catalysed by polyketide synthase(s). Due to CUS 
allowing the production of derailment products 146 and having no known function in rice 90, two 
type III polyketide synthases involved in curcuminoid biosynthesis in C. longa, DCS and CURS1, 
were used. Before the start of this study, DCS and CURS1 had not been used to attempt the 
heterologous production of curcuminoids. However, during the project, Rodrigues et al.107 used 
DCS and CURS1, along with 4CL1 from Arabidopsis, to produce curcuminoids in E. coli from 
p-coumaric acid and ferulic acid.  
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During this study, a 4CL from C. longa was to be identified before being heterologously expressed 
in yeast and tobacco. Despite a BLAST search yielding five distinct ESTs with high homology to 
the query sequence of Os4CL3, none of the sequences were full-length (see Figure 18). 
Phylogenetic analysis identified these five potential C. longa 4CLs as type III 4CLs, involved in 
lignin biosynthesis (see Figure 17). Due to the abundance of curcuminoids in the rhizome tissue, 
it was surprising that none of the putative 4CLs identified as type IV, more commonly associated 
with secondary metabolite biosynthesis. This was thought to be due to the fact that the type III 
Os4CL3 was used as the BLAST query. However, when type IV Os4CL2 was used as a BLAST 
query, the top 5 BLAST hits were the same as identified as with Os4CL3.  To obtain a full-length 
C. longa 4CL coding sequence, multiple attempts at RACE were carried out, but this proved 
unsuccessful within the time constraints of the project. 
4CL5, from Arabidopsis was chosen as the first enzyme in the heterologous curcuminoid 
biosynthetic pathway. This was due to preliminary work within Prof Robert Edwards’ research 
group showing it exhibited better activity when expressed in yeast compared to Os4CL3 and other 
Arabidopsis 4CLs. 4CL5 also had the widest substrate specificity of the known Arabidopsis 4CLs 
166.  Since the decision was made to use 4CL5 near the beginning of this project, its ability to 
accept many different novel cinnamic acid derivatives was shown by Eudes, et al. 151. In this 
study, 4CL5 was cloned into the pYES2 vector for recombinant expression in yeast (see Figure 
21). In in vivo pYES2-4CL5 yeast assays, no phenylpropanoyl-CoA ester products were detected, 
although the phenylpropanoid substrate was consumed quicker than in the negative control (see 
Figure 22). In vitro assays confirmed that 4CL5 was catalysing the desired CoA esterification of 
the four natural phenylpropanoic acids (see Figure 25). It therefore led to the question as to what 
was happening to the phenylpropanoyl-CoA ester product within the yeast cell. As 
phenylpropanoyl-CoA esters do not naturally exist in yeast 183, it was hypothesized that they may 
be metabolised by the fatty acid β-oxidation pathway, a route that needs to be explored further 
using knock-outs of CoA ester transporters. Utilising the 4CL5 in vitro  assay, 4CL5 was shown 
to exhibit activity towards previously untested substrates 4- methoxycinnamic acid, 3,4-
dimethoxycinnamic acid, 4-dimethylaminocinnamic acid and 4-fluorocinnamic-acid chosen for 
their phenolic substitutions which could give curcuminoids synthesized from these bioactivities 
(see Figure 27) 80,181,182. The current work has developed the potential of 4CLs, including 4CL5, 
for the heterologous biosynthesis of secondary metabolites derived from the phenylpropanoid 
pathway.  
The type III polyketide synthases DCS and CURS1, chosen for curcuminoid biosynthesis, were 
correctly cloned into pESC and transformed into yeast (see Figure 28 and Figure 36). However, 
LC-MS analysis could not detect product formation by either enzyme, whether in vivo or in vitro 
analysis was performed. According to the literature, many type III PKSs are recalcitrant to 
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heterologous expression, and aggregate in insoluble inclusion bodies, requiring fusion to 
solubility tags such as maltose binding protein 247. However, expression from pESC-DCS 
appeared to yield soluble DCS, whereas CURS1 protein production was not confirmed. As DCS 
and CURS1 share 62 % amino acid homology 93, this may contribute to the fact that neither 
enzyme appeared to be functional. Work utilising these enzymes, by Katsuyama et al. 93 and 
Rodrigues et al. 107, both used E. coli  as a host, and whether codon optimised or not, they catalysed 
the desired reactions. Yeast is often considered a superior organism for heterologous protein 
expression, therefore it is interesting that DCS and CURS1 were not found to be active in the 
current work. Only a few metabolic engineering studies have integrated the subcellular 
localisation of enzymes into the heterologous production of biosynthetic pathways 41; it is 
therefore an avenue which should be explored. The work described here, offers a reminder that 
there is still much to learn when it comes to heterologous expression of biosynthetic pathways, 
and that a thorough analysis of the natural system should be carried out before attempting to re-
construct the pathway in a heterologous host. 
 It was hypothesized that, although expressed (see Figure 28), DCS may be inactive due to a codon 
mismatch between the C. longa coding sequence and S. cerevisiae translational machinery 
resulting in an incorrect amino acid sequence due to ribosomal slipping during translation. A 
comparison of the codon usage of DCS, with the tRNA abundance of S. cerevisiae gave three 
candidate tRNAs which were prevalent in DCS (15 % of the coding sequence) but only had one, 
or no, analogous S. cerevisiae tRNAs (Table 1). These tRNAs were expressed in yeast using the 
pRS426 vector to increase or introduce the desired tRNA. Addition of S. cerevisiae leucine tRNA 
allowed a doubling in the quantity of DCS protein produced (see Figure 34); however, there was 
no change in the inactivity of DCS (see Figure 35). Nonetheless, the production of a yeast strain 
that is engineered to produce tRNAs to rebalance codon bias for heterologous gene expression of 
non-optimised sequences is a very useful tool: it has the potential to allow simple expression of 
cDNA libraries and reduce the costs associated with codon optimisation. 
During this project, a 2A polypeptide from foot and mouth disease virus (F2A) was investigated 
for its ability to allow multiple protein production from one polycistron when expressed in 
Bakers’ yeast. The 2A polypeptide has been used as a synthetic biology tool in multiple 
biosynthetic productions of natural products 248, for example Thosea asigna 2A was successfully 
used in the biosynthesis of β-carotene derivatives in S. cerevisiae 198. F2A was successfully cloned 
as a linker sequence between the three curcuminoid biosynthetic genes 4CL5, DCS and CURS1 
(see Figure 38). It was envisaged that F2A could be used to modulate the stoichiometry of 
heterologous enzymes production and therefore influence the flux of chemicals through the 
curcuminoid biosynthetic pathway. When linking DCS and CURS1, F2A gave the desired 
polypeptide cleavage (see Figure 38), however, its influence on the chemical pathway could not 
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be ascertained as, alike to when singly expressed, the activities of DCS and CURS1 could not be 
detected (see Figure 39).  
In parallel to curcuminoid biosynthesis in yeast, work was carried out to transiently express the 
pathway in tobacco using Agrobacterium mediated transformation. 4CL5, DCS and CURS1 were 
successfully cloned into the pFGC5941 vector and transformed into Agrobacterium (see Figure 
45). As was found for to the heterologous expression of the three curcuminoid biosynthetic 
enzymes in yeast, 4CL5 was the only enzyme activity detected (see Figure 47). Again, there were 
difficulties with the expression/activity of DCS and CURS1, as ascertained by qPCR (see Figure 
46), highlighting the need to answer certain questions about these enzymes in C. longa. Where 
are they localised? How are they regulated? Do they need any specific modifications? Work with 
tobacco also highlighted known problems with curcumin such as its photo-degradation in light. 
Additionally, the metabolism and degradation of p-coumaric acid by the tobacco leaf tissue 
illustrates the need for an orthologous heterologous host. However, the fact that tobacco does 
contain endogenous phenylpropanoic acids and phenylpropanoyl-CoA esters means that there is 
the possibility to link the endogenous metabolic network with the  heterologous curcuminoid 
production. This would negate the need for supplying a starting material and would yield a more 
sustainable process.  
Despite the diverse range of bioactivities associated with curcuminoids, their physical properties 
hold them back for drug development. They are readily hydrolysed under basic and acidic 
conditions, degraded by light and sparingly soluble in water, meaning they are poorly bioavailable 
under physiological conditions 249–251. There have been many strategies explored to overcome the 
poor bioavailability of curcuminoids such as formulating curcumin as nanoparticles or within 
liposomes 118,252; administering with adjuvants or synthesizing structural analogues with altered 
physicochemical properties 66,112. Before this study, curcumin glucosides had been synthesized 
both chemically and enzymatically. Chemical synthesis, using tetrabutylammonium bromide, 
afforded the best yield of curcumin diglucoside, 71 % 135. Plant cell cultures of C. roseus and 
P.tricuspidata, had been shown to produce a diverse range of curcumin glucosides and 
gentiobiosides using endogenous enzymes, however, this was only performed on a small scale, 
using only around 1 g of cells  145,231. Whole cell E. coli culture, expressing CaUGT2 had been 
briefly studied for its ability to glucosylate curcumin: but, it afforded a poor yield of 4 % and only 
produced curcumin monoglucoside 1. Part of this work aimed to increase the bioavailability of 
curcuminoids, by expressing a UGT in S. cerevisiae which when fed curcuminoids could produce 
water soluble glucoside conjugates. 
LC-MS metabolite data, from 13 C. longa rhizome samples gathered from across Vietnam (Table 
2), were analysed for the presence of curcuminoid glucosides and other biological conjugates. 
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Enzymatic assays were also performed upon protein extracts from C. longa rhizomes searching 
for curcuminoid UGT activity (see Figure 53). There was no detectable evidence suggesting that 
C. longa contained any curcuminoid bioconjugates or curcuminoid UGTs. By studying  prevalent 
secondary metabolites in C. longa and literature concerning other Zingiberaceae, it is suggested 
that instead of using conjugation to sequester curcuminoids, it is likely that they are encapsulated 
within liposomes of oily compounds such as the sesquiterpenes ar-turmerone and turmerone. 
Ginger is known to utilise this method to sequester its primary bioactives, such as gingerol, within 
essential oil lipid bodies 101. Additionally, detailed metabolite analysis of C. longa by Xie at al. 
253, suggests the presence of co-regulated metabolic modules, including curcumin and ar-
turmerone, which is not observed between other pathways such as monoterpenes and caffeoyl 
derived curcuminoids.  To validate this hypothesis, further studies into the storage of 
curcuminoids within C. longa should be carried out, such as immunolabelling studies, microscopy 
and searching for evidence of pathway regulators.  
CaUGT2’s ability to glucosylate the three main curcuminoids was first tested in an E. coli in vitro 
study, as previous work had only investigated its ability to glycosylate curcumin 1: it was able to 
glucosylate both DMC and BDMC, as well as curcumin (see Figure 56). CaUGT2 was then cloned 
into the pBEVY vector and heterologously expressed in yeast (see Figure 57). Although in vitro 
studies showed only curcumin monoglucoside production, whole yeast cell assays showed both 
mono- and diglucoside production. The difference in products formed depending on in vivo or in 
vitro studies should be investigated further and potentially utilised to preferentially produce just 
one of the glucosides over the other. The glucoside conjugates produced by CaUGT2 expressing 
cells, were observed within the cell and the media (see Figure 60). The detection of the curcumin 
glucosides in the culture media is promising from a biotechnological perspective as cell lysis is 
not necessary to retrieve the products making any large scale up simpler. The CaUGT2 yeast cell 
culture was scaled up from a shake flask to a 5 L bioreactor and was able to produce 32 mg L-1 
curcumin monoglucoside (60 % yield). 
The change in colour of the culture, as the glucosides appeared in the media (see Figure 65), 
allowed spectrophotometric monitoring of the process, enabling culture parameters to be altered 
and easily monitored for optimisation. The effect of different sugars in the medium (galactose, 
glucose and raffinose) was first explored (see Figure 71 to Figure 74). Despite galactose inducing 
expression from the pBEVY vector, and glucose repressing expression 233, the addition of either 
of these sugars showed no effect upon the growth of the culture or the production of curcumin 
glucosides. Utilising RT-PCR, it was determined that expression of CaUGT2 from the pBEVY 
vector was leaky so may be the reason the different sugars had no discernible effect upon the 
promoter. Supplemental raffinose was expected to allow greater cell growth and in turn more 
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curcumin glycoside production due to an increased abundance of CaUGT2. However, there was 
an increase in curcumin glycoside production, but without the concomitant increase in cell 
density. This was unexpected as raffinose is not directly involved in CaUGT2 catalysis, therefore, 
this result needs further analysis. Addition of iron (FeSO4) to the media allowed an increase in 
cell growth, believed to be due to overcoming the iron sequestration in the yeast ER caused by 
curcumin glucosides, but did not allow an increase in curcumin glucoside production (see Figure 
75). These findings indicate that something else, such as the amount of available UDP-glucose, 
may be limiting glucosylation. A systems biology approach could play an important role in the 
optimisation of CaUGT2 mediated glucosylation of curcumin. Computational analysis should be 
used to choose and design the optimal number of experiments necessary to converge upon the 
best media components. Additionally, metabolic modelling of potentially influential yeast 
metabolic pathways and networks, would allow informed decisions to be made about which 
endogenous genes could be deleted or over-expressed to fine-tune glucoside product formation. 
Such analysis was performed in E. coli for the heterologous production of naringenin, allowing a 
600% increase in yield 20.  
As well as altering the pBEVY-CaUGT2 yeast medium to optimise favourable conditions for 
growth and catalysis, there are many synthetic biology avenues that could be explored that may 
also allow an increase in yield and greater control over the process. Many studies have been 
carried out into the effects of using different promoters for increased culture growth, strong 
protein expression and increased metabolic flux. For example, utilising constitutive promoters 
such as pTEF1 (transcriptional elongation factor EF-1α) that are regulated by glucose compared 
to galactose are preferable as yeast prefers glucose as a carbon source 254. Additionally, altering 
the terminator is also shown to have positive effects on mRNA stability and protein expression 
255. Effective terminators such as PRM9 and DIT1 should be compared to the current use of CYC1 
(Cytochrome c, isoform 1) 255,256.  
The functional expression of plant secondary metabolic enzymes in a heterologous host can be a 
challenging task. Plant natural product pathways are highly complex and each step can take place 
in a variety of subcellular locations. Although unable to biosynthesize curcuminoids from 
phenylpropanoids, the first step of the pathway, catalysed by 4CL5, was deemed active in both 
Bakers’ yeast and tobacco. Furthermore, 4CL5 was demonstrated to be a valuable enzyme for the 
production of novel CoA-esters which could be used for further biosynthesis of non-natural 
polyketides. This study also allowed the large scale production of curcumin glucosides within a 
bioreactor, via the heterologous expression of CaUGT2. The yield of curcumin monglucoside 
produced was 15 fold higher than previous microbial platforms utilising CaUGT2. With further 
work, to optimise and scale this process, the novel yeast system offers a sustainable route to 
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produce more bioavailable, medically relevant analogues of curcumin. As curcuminoids are 
abundant within C. longa, further biotechnology processes which concentrate upon their 
modification to improve solubility and stability would be beneficial to make curcuminoids more 
biologically relevant.  
160 
 
Appendices 
Appendix 1.1 DCS (AB495006.1) cDNA sequence from C. longa, 1170 bp 
ATGGAAGCGAACGGCTACCGCATAACTCACAGCGCCGACGGGCCGGCGACGATCTTGGCCATCGGCACCG
CCAACCCCACCAACGTCGTCGATCAGAACGCTTATCCCGACTTCTATTTCCGGGTCACCAACTCCGAGTA
TCTGCAGGAACTCAAAGCCAAGTTTAGGCGCATCTGTGAGAAAGCGGCCATCAGGAAGAGGCACTTGTAC
TTGACTGAGGAGATTTTGCGGGAGAATCCTAGCTTGCTGGCTCCCATGGCGCCGTCGTTCGACGCGCGGC
AGGCGATCGTGGTGGAGGCGGTGCCGAAGCTGGCGAAGGAGGCGGCGGAGAAGGCGATCAAGGAGTGGGG
CCGCCCCAAATCGGACATCACGCACCTCGTCTTCTGCTCCGCGAGCGGAATCGACATGCCCGGCTCCGAC
CTGCAGCTTCTCAAGCTGCTCGGGCTCCCGCCGAGCGTCAATCGCGTCATGCTCTACAACGTCGGGTGCC
ACGCCGGTGGCACCGCCCTCCGCGTCGCCAAGGACCTCGCGGAGAACAACCGCGGCGCGCGGGTGCTCGC
CGTCTGCTCCGAGGTCACCGTGCTCTCCTACCGCGGCCCCCACCCCGCCCACATCGAGAGCCTCTTCGTC
CAAGCTCTGTTTGGCGACGGCGCCGCCGCGCTCGTGGTCGGGTCCGACCCCGTCGATGGCGTCGAGCGCC
CCATCTTCGAAATCGCCTCGGCATCCCAAGTGATGCTTCCGGAGAGCGCAGAGGCGGTGGGCGGCCACCT
CCGCGAAATTGGGCTGACCTTCCACCTCAAGAGCCAGCTTCCGTCGATCATCGCGAGCAACATCGAGCAG
AGCCTGACGACTGCGTGCTCGCCGCTGGGGCTGTCGGACTGGAACCAGCTGTTCTGGGCGGTTCACCCCG
GCGGCCGAGCGATCCTGGACCAGGTGGAGGCGCGGCTCGGACTGGAGAAGGACCGGCTCGCCGCGACGCG
GCACGTACTCAGCGAGTACGGCAACATGCAGAGCGCCACGGTGCTGTTCATCCTGGACGAGATGCGGAAC
CGCTCGGCTGCGGAGGGCCACGCCACCACCGGCGAGGGGCTCGACTGGGGCGTGCTGTTGGGCTTCGGCC
CGGGACTCTCCATCGAGACCGTCGTCCTCCATAGTTGCAGACTGAACTAG 
Appendix 1.2 CURS1 (AB495007.1) cDNA sequence from C. longa, 1170 bp 
ATGGCCAACCTCCACGCGTTGCGCAGGGAGCAGAGGGCTCAAGGTCCTGCCACCATCATGGCCATCGGGA
CCGCCACCCCTCCCAACCTCTACGAGCAGAGCACCTTCCCGGACTTCTACTTCCGCGTCACCAACTCCGA
CGACAAGCAGGAGCTCAAGAAAAAGTTCCGCCGCATGTGCGAGAAGACGATGGTGAAGAAGCGGTACCTG
CACTTGACCGAGGAGATCCTGAAGGAGAGGCCCAAGCTCTGCTCCTACAAGGAGGCGTCGTTCGACGACC
GGCAGGACATCGTGGTGGAGGAGATACCGAGATTGGCTAAGGAAGCGGCGGAGAAGGCCATCAAGGAGTG
GGGGCGGCCCAAATCGGAGATCACCCACCTGGTCTTCTGCTCCATCAGCGGGATCGACATGCCCGGCGCC
GACTACCGCCTCGCCACGCTCCTCGGGCTCCCTCTCACCGTCAACCGCCTCATGATCTACAGCCAGGCCT
GCCACATGGGCGCCGCCATGCTCCGCATCGCCAAGGACCTCGCCGAGAACAACAGGGGCGCGCGCGTGCT
GGTGGTCGCCTGCGAGATCACCGTGCTCAGCTTCCGCGGCCCGAACGAGGGCGACTTCGAGGCGCTCGCG
GGGCAGGCCGGCTTCGGCGACGGCGCGGGGGCCGTCGTCGTCGGGGCCGACCCGCTGGAAGGAATTGAAA
AACCCATCTACGAGATCGCGGCGGCGATGCAGGAGACGGTGGCGGAGAGCCAGGGGGCGGTGGGCGGCCA
CCTGCGGGCCTTCGGCTGGACGTTCTACTTCCTGAACCAGCTGCCGGCGATCATCGCCGACAACCTCGGG
AGGAGCCTGGAGCGGGCGTTGGCGCCGCTGGGGGTGAGGGAGTGGAACGACGTCTTCTGGGTGGCGCACC
CGGGCAACTGGGCCATCATTGACGCCATCGAAGCCAAGCTGCAGCTGAGCCCGGACAAGCTCAGCACCGC
CCGCCACGTCTTCACAGAGTACGGCAACATGCAGAGCGCCACCGTGTACTTCGTGATGGATGAGCTGAGG
AAGCGGTCGGCGGTGGAGGGGCGGAGCACCACCGGCGACGGCTTGCAGTGGGGAGTTCTCCTCGGTTTTG
GGCCGGGCCTCAGCATCGAGACCGTTGTACTGCGCAGTATGCCACTGTAG 
Appendix 1.3 CaUGT2 (AB159213.1) cDNA sequence from C. roseus, 1720 bp 
CACTGTACCTCAATTCCATCTTCAATTTTTCCATTCATTTCATCATTTTGAGGTAGAAGAAGAAGAAGA 
GGCCATTAATATGGTTAATCAGCTCCATATTTTCAACTTCCCATTCATGGCACAGGGCCATATGTTACCC
GCCTTAGACATGGCCAATCTATTCACTTCTCGTGGAGTCAAAGTAACATTAATCACAACCCATCAACATG
TTCCCATGTTTACAAAATCCATAGAAAGGAGCAGAAATTCTGGATTTGATATATCCATTCAATCCATCAA
ATTCCCAGCTTCAGAAGTTGGTTTACCTGAAGGAATCGAAAGTCTAGATCAAGTTTCAGGGGACGACGAA
ATGCTTCCTAAGTTCATGAGAGGAGTTAATTTACTCCAACAACCTCTCGAACAACTATTGCAAGAATCTC
TCCTCATTGTCTTCTTTCTGATATGTTCTTCCCTTGGACTACTGAATCTGCTGCTAAATTTGGTATTCCC 
AGATTGCTTTTTCATGGGTCCTGTTCCTTTGCCCTCTCTGCAGCTGAAAGTGTGAGAAGAAATAAACCTT 
TCGAGAATGTTTCCACAGACACAGAGGAATTTGTTGTGCCTGATCTTCCCCACCAAATTAAATTAACCAG 
AACACAAATTTCAACATACGAAAGGGAAAATATTGAGTCAGATTTTACCAAAATGCTGAAGAAAGTTAGG 
GATTCAGAATCCACATCTTACGGAGTTGTAGTCAATAGTTTCTATGAACTTGAACCAGATTATGCCGATT 
ATTACATCAACGTTTTGGGAAGAAAAGCATGGCATATAGGGCCTTTTTTGCTTTGTAACAAATTACAAGC 
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TGAAGATAAAGCCCAAAGGGGGAAGAAATCAGCAATTGATGCAGACGAATGTTTAAATTGGCTTGATTCG 
AAACAACCAAATTCCGTAATTTATCTCTGTTTCGGAAGTATGGCCAATTTAAATTCTGCCCAATTACACG 
AAATTGCAACAGCCCTTGAATCCTCCGGCCAAAATTTCATCTGGGTTGTTAGAAAATGTGTGGACGAAGA 
AAACAGTTCAAAATGGTTTCCAGAAGGATTCGAAGAAAGAACAAAAGAAAAAGGGCTAATTATAAAGGGA 
TGGGCACCACAAACCCTAATTCTTGAACACGAATCAGTAGGAGCATTTGTTACCCATTGTGGTTGGAATT 
CAACTCTTGAAGGAATCTGCGCAGGGGTTCCTCTGGTGACTTGGCCTTTCTTTGCTGAGCAATTTTTCAA 
TGAGAAATTGATTACAGAGGTACTGAAAACGGGATACGGAGTTGGGGCTCGGCAATGGAGTAGAGTTTCA 
ACAGAGATTATAAAAGGAGAAGCCATAGCTAATGCTATTAATCGAGTAATGGTGGGTGATGAAGCTGTTG 
AGATGAGAAACAGAGCAAAAGATTTGAAGGAAAAGGCAAGAAAAGCTTTGGAAGAAGATGGATCTTCTTA 
TCGTGATCTTACTGCTCTTATTGAAGAATTGGGGGCATATCGTTCTCAAGTTGAAAGAAAGCAACAAGAC 
TAGGAAATAAGAAGAGAGAGAGAATTCTCATTTATATTATTTTGTCCATTTAATCAAATTACTATATTC 
TGTAAAATTTGCCATTTTTATTATGGAATCTAGAAGGCAGTCTATATATCTTCTTGCCAGGCACTAAAG 
AAATATTTGTCATTTCAAGTTTAAAAAAAAAAAAAAAAAAAA 
 
The CDS was significantly longer than other known UGTs. Alignment with other Group D UGTs, 
TOGT1, UBGT, UGT73B3, UGT73B4 and VmUFGT2 showed the AB159213.1 nucleotide 
sequence was longer than necessary (Figure 76). Therefore, the region underlined, which most 
likely corresponded to the coding sequence, was used for work in this thesis. The underlined CDS 
is 1464 bp. 
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Figure 76. Sequence alignment of CaUGT2 with Group D UGTs. 
Alignment of CaUGT2 with other Family 1 Group D UGTs from Arabidopsis, Nicotiana tabacum and Vigna mungo: NtTOGT1, UBGT, AtUGT73B3, AtUGT73B4, VmUFGT2 using 
JalView. Amino acids are shown in different colours, the conservation and consensus of amino acids is shown below. The brighter the yellow colour, the greater the homology between 
the amino acid sequences. CaUGT2 is significantly longer than the other sequences. 
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Appendix 2.1 Five potential 4CL ESTs identified from C. longa 
DY382977.1 
GCACCCTTTGACTCTGCTCCGCAATTCGCCGGAGTTCGTCTTTGCCTTCCTTGGTGCTTCCCTCTGCAGC
GCCGTGGCGACCACCGCCAACCCGTTTTATACTAGGGCGGAGATCCACAAGCAGGCGGCAGGAGCCGGCG
CGAGGGTAATCGTCACGGAGTCGTGCTACGTCGACAAAGTGAGGGACTTCGCGCGGGAGCGAGGGATTAT
AATCGTCTGTGTTGACGATCCTCTGCCGGAGGGATGCTGGCGATTCTCTGAGTTGCTGGAAGCAGAGGAG
AAAACAAAGGAGGCTGAGGAGGAGGAAGAGATCGTCGATCCCGACGACGTGGTGGCGTTGCCCTACTCGT
CCGGCACGACAGGGCTGCCGAAAGGGGTGATGCTGACTCACCGGAGCCTGATCACGAGCGTGGCGCAGCA
GGTGGACGGGGAGAACCCCAACTTGTACTTCCACCCCGACGACGTGCTCCTCTGCGTGCTGCCGCTCTTC
CACATCTACTCGCTGAACTCGGTGTTGCTATGTGGGCTCCGCGCCGGCTCTGCCATCCTCCTGGTGCGTA
AGTTCGAGATCTCCGCCGTGCTGGAGCTTGTGCAGCGATACCGCGTCACAATCGCGCCGTTTGTGCCACC
CATCGTGCTGGAGTTCGTCAAGAGCCCGCTCGTGGACGCCTACGACTTGTCGTCGATCCGCACCGTGATG
TCCGGAGCCGCCCCCATGGGCAAGGAGCTCGAGGACAAGTTCATGGCCCAGCTCCCAAACGCTACGTTGG
GCCAAGGTTACGGGATGACAGAAGCAGGGCCGGTGCTGTCGATGTGCCTGGCC 
DY391029.1 
AGAAAACGGAGGATGAGGAAGAGATCGTCGACCCCGACGACGTCGTGGCGCTGCCCTACTCGTCCGGCAC
GACGGGGCTACCGAAGGGGGTGATGCTGACTCACCGGAGCCTGATCACGAGCGTGGCGCAGCAGGTGGAC
GGGGAGAACCCCAACCTGTACTTCCACCACGACGACGTGCTCCTCTGTGTGCTGCCGCTCTTCCACATCT
ACTCGCTGAACTCGGTGTTGCTATGTGGGCTCCGCGCCGGCGCTTCCATCCTCCTGGTGCGTAAGTTCGA
GATCTCCTCCGTGCTGGAGCTTGTGCAGCGATACCGCGTCACAATCGCGCCGTTTGTGCCACCCATCGTG
CTGGAGTTCGTCAAGAGCCCGCTCGTGGACGCCTACGACTTGTCGTCGATCCGCACCGTGATGTCCGGCG
CCGCCCCCATGGGCAAGGAG 
DY382750.1 
CCAACATGGCGGAGATCTCGAACCTGCGCATGAGGAGGATGGCGGCGCCGACGCGGAGGCCGCAGAGCAG
CACCGAGTTGAGGGAGTAAATGTGGAAGAGAGGCAGGACGCAGAGCAGCACGTCTTCCTTCCGGAAGTAG
AGGTTCGGGTTGTCGCCGTCCACCTGCTGCGCCACGCTCGTGATCAGGCTCCGGTGAGTCAGCATCACCC
CCTTGGGAAGCCCCGTCGTCCCCGATGAGTACGGCAGCGCCACTACTTCGTCCGCGTCGATCTCCTCCTC
CTCCTCCTCTGTTTCCTCCGCTTCCTTCGTTAACTCCGAGAAGCTCCTGCAGCCCTCCGGCAGAGGATCG
TCCACACAGACGACCACCACCCCTCGCTCACGCGCGAACTCCCGCACCTTGTCCACGTAGCACGATTCCG
TGACGATCACCCTCGCTCCGGCGTCCGCGCCTGCTTGTGAATCTCTGCGGGGGTGTAGAACGGATTCGCC
CCTCGTGCCGAATTCGGCACGAGGCTTAATTCCTTTGGAGTCAGGATCACGTCAATAATAAGATCGTCAA
TTCTCCAAGAATTGCTTTTGTTTTAATAGCTGGAGCTGGTTTTATGAGTATGTTTCAGGAACTCGTGGAG
ATGTTCATATGGTTTCAAGAGGTTCTAGAGTAAAGGACGTCGGTGCG 
 DY391030.1 
GGNTCTTGACGAACTCCCCTAAGATGGGTGGCACAAACGGCGCGATTGTGACGCGGTATCGCTGCACAAG
CTCCAGCACGGAGGAGATCTCCAACTTACGCACCAGGAGGATGGAAGCGCCGGCGCGGAGCCCACATAGC
AACACCGAGTTCAGCGAGTAGATGTGGAAGAGCGGCAGCACACAGAGGAGCACGTCGTCGTGGTGGAAGT
ACAGGTTGGGGTTCTCCCCGTCCACCTGCTGCGCCACGCTCGTGATCAGGCTCCGGTGAGTCAGCATCAC
CCCCTTCGGTAGCCCCGTCGTGCCGGACGAGTAGGGCAGCGCCACGACGTCGTCGGGGTCGACGATCTCT
TCCTCCTCCTCCGTTTTCTCCTCGTGCCGAATTCGGCACGAGGCCTCGTGC  
DY390122.1 
GCACCTTGTGATCACGAGCGTGGCGCAGCAGGTGGACGGCGAGTACCCGAACCTGTACTTCCACTGCGAC
GACGTGCTCCTCTGCGTGCTGCCTCTCTTCCACATCTACGCGCTGAACTCGGTCCTGCTCTGCGGGCTCC
GCGCCGGCAGCTCCATCCTCTTAGTGCGCAAGTTCGAGATCTCCGCCGTGCTGCAGCTGGTGCAGCGCTT
CCGCGTCACGGTGGCCGCCTTCGTTCCGCCCATCGTGCTGGATTTCGTCAAGAGCTCGCTCATGGACGCC
TACGACCTGTCGTCGATCCGCATCGTCAAGTCCGGCGCCGCCCCCATGGGCAAGGAA 
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Appendix 2.2 4CL5 (AT3G21230) cDNA sequence from A. thaliana, 1720 bp 
ATGGTGCTCCAACAACAAACGCATTTTCTCACAAAGAAGATAGGTCAAGAAGACGAAGAAGAAGAACCTT
CTCATGATTTCATTTTCCGATCTAAGCTTCCTGATATCTTCATCCCTAACCACCTCCCTCTCACCGATTA
CGTCTTCCAAAGGTTCTCCGGCGATGGCGACGGAGATTCCTCAACAACCTGTATCATCGACGGTGCCACT
GGCCGTATTTTGACCTACGCCGATGTGCAAATCAACATGCGGAGGATAGCTACCGGAATCCACCGGCTCG
GGATCCGCCACGGTGACGTCGTAATGCTTCTCCTCCCGAACTCGCCGGAGTTTGCTCTGTCTTTTCTAGC
CGTTGCATACCTTGGAGCCGTTTCCACTACCGCGAATCCGTTCTACACTCAGCCGGAGATCGCTAAACAG
GCTAAAGCCTCCGCCGCGAAGATGATCATCACGAAGAAATGTTTAGTCGATAAACTAACAAACCTCAAAA
ACGACGGCGTTTTGATCGTTTGCCTAGACGATGACGGTGACAACGGCGTTGTTTCGTCGAGTGATGATGG
TTGCGTGAGTTTCACGGAACTGACTCAAGCGGACGAAACAGAACTTCTAAAACCTAAAATATCGCCGGAA
GACACGGTGGCGATGCCGTACTCTTCCGGAACAACGGGACTTCCAAAGGGAGTGATGATTACTCACAAGG
GTTTAGTTACAAGCATCGCTCAGAAAGTCGACGGAGAAAACCCTAACCTCAACTTCACGGCCAATGACGT
CATCCTCTGTTTTCTCCCAATGTTTCACATTTACGCTCTCGACGCGTTGATGCTTTCGGCGATGAGAACC
GGTGCAGCGTTACTGATCGTGCCGAGGTTCGAGTTAAATCTGGTGATGGAGCTGATTCAAAGGTACAAAG
TCACGGTTGTTCCGGTGGCTCCTCCGGTGGTTTTAGCATTCATTAAATCCCCTGAGACGGAGAGATACGA
CTTGAGCTCGGTGAGAATTATGCTATCAGGTGCAGCTACACTAAAGAAGGAGCTTGAAGACGCCGTGCGA
CTCAAGTTTCCTAATGCCATTTTTGGTCAGGGTTATGGAATGACCGAGTCCGGAACGGTAGCTAAGTCAT
TAGCGTTTGCAAAGAACCCATTTAAAACCAAGTCCGGTGCATGTGGGACTGTGATCAGAAACGCCGAGAT
GAAAGTGGTCGATACCGAAACCGGAATCTCCTTGCCGCGCAACAAATCTGGCGAGATCTGCGTCCGAGGT
CATCAGCTCATGAAAGGTTATTTGAATGATCCGGAAGCTACTGCACGAACCATAGACAAAGACGGGTGGT
TACATACAGGAGATATTGGGTTTGTGGATGATGATGATGAGATCTTCATTGTTGATCGGTTGAAGGAACT
GATCAAATTCAAAGGCTACCAAGTGGCTCCAGCTGAGCTTGAAGCATTGCTTATTTCTCATCCTTCTATC
GATGATGCCGCAGTTGTTGCAATGAAGGATGAAGTAGCTGATGAGGTTCCAGTAGCATTTGTAGCAAGAT
CTCAAGGGTCTCAGTTAACTGAAGATGATGTCAAGAGTTACGTAAACAAACAGGTGGTTCACTACAAGCG
GATTAAGATGGTGTTTTTCATAGAAGTTATACCAAAAGCAGTTTCGGGCAAGATTCTGAGGAAGGATCTG
CGAGCTAAATTGGAAACCATGTGCTCTAAATAG 
The cDNA sequence was amplified from Arabidopsis (unpublished work, Dr H. Housden, Prof 
Rob Edward’s Lab). Underlined bases are 10 point mutations which differ to the NCBI database. 
They cause three amino acid substitutions. 
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Appendix 2.3 p-Coumaric acid HPLC chromatogram 
 
Using phenylpropanoyl-CoA ester LC-MS analysis method 1, to analyse p-coumaric acid. HPLC 
chromatogram (260 nm), RT 2.05, UV max 306 nm. 
 
Appendix 2.4 Ferulic acid HPLC chromatogram 
 
Using phenylpropanoyl-CoA ester LC-MS analysis method 1, to analyse ferulic acid. HPLC 
chromatogram (260 nm), RT 2.75, UV max 321.0 nm. 
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Appendix 2.5 Feruloyl-CoA HPLC chromatogram and mass spectrum 
 
Using phenylpropanoyl-CoA ester LC-MS analysis method 2, to analyse feruloyl-CoA (Mr 943.70 
g mol-1). HPLC chromatogram (260 nm), RT 16.2. MS: m/z 943.9 [M]+, m/z 437.1 [M-ADP]+.  
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Appendix 2.6 Mass spectrum of cinnamoyl-CoA  
 
Using phenylpropanoyl-CoA ester LC-MS analysis method 2, to analyse caffeoyl-CoA (Mr 
897.68g mol-1). MS: m/z 897.9 [M]+, m/z 427.9 [AMP]+, m/z 391.0 [M-ADP]+. 
 
Appendix 2.7 Mass spectrum of p-coumaroyl-CoA  
 
Using phenylpropanoyl-CoA ester LC-MS analysis method 2, to analyse p-coumaroyl-CoA (Mr 
913.67 g mol-1). MS: m/z 913.9 [M]+, m/z 428.0 [AMP]+, m/z 423.0 [M-ADP]+. 
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Appendix 2.8 Mass spectrum of caffeoyl-CoA  
 
Using phenylpropanoyl-CoA ester LC-MS analysis method 2, to analyse caffeoyl-CoA (Mr 
929.68 g mol-1). MS: m/z 927.9 [M]+, m/z 767.9 [M-caffeic acid]+, m/z 529.8 [M-AMP]+, m/z 
427.7 [AMP]+, m/z 423.0 [M-ADP]+. 
 
Appendix 2.9 Mass spectra of 4-methoxycinnamoyl-CoA 
 
Using phenylpropanoyl-CoA ester LC-MS analysis method 2, to analyse 4-methoxycinnamoyl-
CoA (Mr 927.73 g mol-1). MS: m/z 927.9 [M]+. Major peaks below 300 (m/z 118.0, 264.7) are 
hypothesized to be TEA and water complexes. 
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Appendix 2.10 Mass spectrum of 3,4-dimethoxycinnamoyl-CoA 
 
Using phenylpropanoyl-CoA ester LC-MS analysis method 2, to analyse 3,4-
dimethoxycinnamoyl-CoA (Mr 957.73 g mol-1). MS: m/z 957.9 [M]+. Major peaks below 300 (m/z 
118.0, 264.7) are hypothesized to be TEA and water complexes. 
 
Appendix 2.11 Mass spectra of 4-dimethylaminocinnamoyl-CoA  
 
Using phenylpropanoyl-CoA ester LC-MS analysis method 2, to analyse 4-
dimethylaminocinnamoyl-CoA (Mr 940.74 g mol-1). MS: m/z 940.9 [M]+. Major peaks below 300 
(m/z 118.0, 264.7) are hypothesized to be TEA and water complexes. 
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Appendix 2.12 Supplemental yeast tRNA coding sequences 
 
S. pombe Alanine tRNA (Ala) 
ChrI:4796800-4797111 
TAGTCAATAAATAAAACAAATGTGGATAAAAAGGAAAAATAGTTTCTAACATTGGAGATGCCGGGAATCG 
AACCCGGGACCTTTTCAAGGTGCGAACTATGCGAATGAAACGTTATACCCCTAAACTACATCCCCAGTCG 
ATATGATGTTATAATTTAACCCATTATTAATAAAAGGTTAAAAAAAAGAACGAATGTCAAGCTATAAAAT 
AAAATAATCATCATCATCATTGATTAATTTAGCAAGGGTGCCTGCATCTAGTTTTTTTATCAGTCAATAA 
CTCATACATTAACCGCATTCATAAGAGGCTAT 
 
S. pombe Leucine tRNA (Leu1) 
ChrI:1527361-1527050  
TTTTCGTTCAATCAAGATATTTTATCACATTATTTCAAGGTTCAATGAATCATTCGAAGAATAGTAACGA 
ATTCAGATATATTAAATAAAGGCACACATAATCTCTAAAGATTACAGTTTAATGGCTCTTTCAAAGTGTT 
TAGTAATATATACACTAAATTTCTAAAATTCAGTAGTTATGGCGAAGTGGCCGAGTGGTCTATGGCGCTA 
GCTTCAGGTGAAAGCAATTGCTAGTCTACGTATGTGGGCGTGGGTTCGAACCCCACCTTCGTCAATATAA 
TTTTTTATATCATGTTAATGGAATTGAGAAAA 
 
S. cerevisiae Leucine tRNA (Leu 2) 
ChrVII:700500-700800  
TCTGCGTGGATTGCCACTTATAGGGCTTTTCAAATTAGTATTTTAAAGGAGTTAGATCGGTTTCAAAAGG
TCATGCTCCGGAGTAATTGACTTGATTTTGCAAAGCTTCACTTAAATGGCGTATCTTCCTTTTATAAATT
GCGTTTGCTTTATTCCCTTACCCAACAGATGAATTGGTACTCTGGCCGAGTGGTCTAAGGCGTCAGGTCG
AGGTCCTGATCTCTTCGGAGGCGCGGGTTCAAACCCCGCGGGTATCAATATTTTTTTGAATCTACGCACT
TCAATAAGAATTAGGCTGTT 
 
The whole nucleotide sequences above were cloned into the pRS41/26 vectors. Underlined are 
the nucleotides that correspond to the tRNA. 
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Appendix 2.13 Curcumin HPLC chromatogram and mass spectrum 
 
Using curcumin glycoside LC-MS analysis method, to analyse curcumin (Mr 368.39 g mol-1). 
HPLC chromatogram (425 nm), RT 14.4, UV max 424 nm. MS: m/z 366.9 [M-H]-, m/z 734.1 
2[M-H]-. 
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Appendix 2.14 Growth of pxa1 and pxa2 yeast gene-disruption mutants 
Growth of yeast strains on sugar containing (3 % glycerol) and 0.1 % oleic acid agar plates. 
Wildtype BY4742,  pxa1 and pxa2 grew equally as well on both types of carbon source, therefore 
were concluded to not exhibit the expected phenotype. 
 
 
Appendix 3.1 C. longa UGT BLAST hits JW777458.1 and JW773795.1 
JW777458.1  
 
CTCTGATTGTACCCAGCTTTGGATTCCCTTTCAATCACTACTGTATAATTGAATTGTGTCGTCGTGGAAA 
GCTGTGGAGAGGCTTTCTAGAAGCCCATTTTGCATTTTTTTTCGTGAGCTGGTGACAGTAATGAATCGAG 
GGAAGGAAAAAGACGTCTTTAGCTTAACAGACGTCATTGCAAAGGAGATCGAAGAAGTAAGAAACGCAAA 
CCTAGTCTTTGCTTACGCCGTCCTCAGTATTTAATGGATAGAAGCGCACACAGTTTGCAAGCCCATGCTC 
AATACCATGGCGGATGATCTGCATATACTCTTGCTGCCCTTTCTCTCCCCAGGCCACATCATCCCCATGG 
TCGACTTAGCACGGCTTTTTGCAGGTAAAGGAATCAAAGCCACCGTCGTCACCACCACCGGCAACGTGCC 
TCTCGTCAAACCTACCGTTGATCTCGCCAACACCGACGCTTCCCTCCGCAACCCTATCCAACTCCTCGCC 
CTCCGCCTCCCCTGCTCAGAAGCTGGAATCCCCGAGGGCTACGAGAACCTCGCCGCCTTCCCTAACCCCG 
ACTTGTTACGGTTGGTGGCCGCCACCGACAGGCTTGAGCCCTCCTTCTCGCTGCTGCTCAAAACCCACCG 
CCCTGACTGCGTCGTCGTCGATTTCTTCTATCCTTGGGCCACCCGCGTCGCCCAAGAAGCCTCCGTTCCT 
TCGCTCCTCTTTAGTGGAAGCAACTTCTTCAGCTCCGCGGTTATTAAAATCGTACAAGACGCCGGGCTGA 
TCCAGGGAGACTTGGAGACCGAGCGATTGATCGAGGTTCCCGGCATACCGCAGAAGATCCACCTCAAGCT 
CTCTAATCTCCCCGACACCGTCCTTCATCCCAAGGAGTTCTCCCACCGGATGGCCGAAAGCCGTCACCGG 
ATCCACGGCACGGTCGTGAACAGCTTCTACGAGCTGGAACGTGACTACGTCAATCGAATCCCCTACTCGC 
GAGACCTCAGGTTCTGGTTCGTCGGCCCAGTCTCGCTGCAGAACCGAGGCATGGATACGAAGATGGTGCG 
AGGGAGCGGCGACGCCGCTTCGGGGAGCGCCGATCATTTCTTGAGTTGGCTGGAAACCAAGAGGCCTAGG 
TCGGTCCTCTACGTATGCTTCGGGAGCATGGCCCGGTTCACGGCCACTCAGCTACGCGAGATCGCGCGAG 
GTCTCGAGGCGTCCGACCGGCCGTTCATCTGGGTCGTGCGGAACGCCGGAGAGATATCGGAATGGCTGCC 
GGACGGGTTCGAGAACAGGGTGGTCGGCGGCGGGAAGGGGATGCTGGTGCAAGGATGGGCGCCGCAGCTT 
CTCATACTGAATCACGAAGCGGTGGGAGGCTTCGTGACTCACTGCGGGTGGAACTCGTGCCTAGAAGCGA 
TTGCTGCCGGAGTTCCGGTGATCACTTGGCCGTTGTTTGCCGAGCAATTCCTGAACGAGAAGCTGTTGGT 
CGACGTGCACAGGATGGGGATCTCGATCGGCGTGATTTCCAGCTGCGATAAAGCAGAGGAGCGGACGGTG 
GTGAACGGTGAGCAACTGAAGGAGGCAGTGGATGAGCTGATGGGTAGCGGAGAGGAAGCCGAAGAGAGGA 
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GGAAGAGGGCGAGGGAGCTGGGGCAGACGGCGAGAAGGGCAATGGAAGAAGGTGGATCTTCTCAGGAAGC 
GATGACTTGCCTGATAGACGAGTTAATTCGATTGAAAACTGTTGATTAAGCAGGGAGAATGGAGACGAAG 
TGAAATAACGACAGTCTTCTTTGCACATCAATTCGAATTCATGTTGCCTTAATTATTTTACTTTATCAAT 
TAGAATCCGTGTTGCATTCATTACAATCACATGCATGTACTTTATCGAGAATGCATCCAAAGGCACACAA 
ACTAAGAACGACCTGTCTGCTTCTTCAAAAAAA 
 
JW773795.1 
 
CCAGTAGGTGTGATTGTTTAGGCACGCACGCCGACGGCACTTCGCTAGTCTGCCTCGATCCCCACCGTCC 
ATGGAGGAGGAACTTCACCGGGAACGACCGCCGGCGGCGCACTTCGCCTTGGTTCCCCTGTTGACGCAGG 
GCCACATCATCCCCATGCTCGACCTCGCCCACCAACTCGCCCTCCGCGGCGTCCTCGTCAGCTTCATCAC 
CACCCCCTTGAACGCCTCCCGCATCCGCCACACCATCGACCAAGCCGAAGCCCGCCGTCTCCCCATCCGA 
TTCGTCGAGCTCCCCTTCCCAGTCCACGAGGCTGGCCTCCCTGCCGGCTGCGAGAACTTCGACACCCTCC 
CCAAAACAGATATGTACATGACCTTCAACCAAGCCTGCTCGAAGCTCCTGGCTCCCCCGCTGGAGCTCTA 
CCTGGAGCAGCACCGATCCGATCTCATCGTCTCCGACTTCTGCCAGCCGTGGACGCGCGGGATAGCTGAG 
AGACTCGGAGTTCCGCGGCTCATCTTCTATAGCATGTGCTGCTTGGCGCTCCTCTGTACCCACAACATTT 
GGGTACACAAGATGTTGGAGAGAGCAGGCGACGAGAACGAGCCGTTCGCGGTTCCGGGATTGCCGGAGGA 
GCACGTAATCGAGGTGACGAAGGCCCAGGCGCCGGGGTTCTTCCCTGGCCCTGCTTTCGTGCAGATGGAT 
AAAGACGTGCGCGAAGCGGAGTTCACCGCCGACGGCGTGATTTTCAACACTATCTACGATTTGGAACCTT 
CCTACGTTTCCGGGTACGAAAAGGCCATGGGGAAGAAGATTTGGACGGTCGGTCCGTTGCTGTCGCACAG 
CCAGAGCGTCGCCGACTTGGCCACGAGGGGGAGGAAGGCTTCCATAGACACGGAGCGATGCTTGGCTTGG 
CTCGACGCGATGATGCCGCGGTCGGTGATCTACGTCAGCTTCGGGAGCCTCACACGCGTGGCGCCGTCGC 
AGATGATGGAGATCGGGCTGGGACTAGAGGCGTCAGGGCATCCGTTCATTTGGGTGATCAGGAGCAAGGA 
GGATTGCTCGCCGGAGGAGGAAGAATGGCTGACCGGAGGATTCGAGGCGAGAGTGAGCTCGAGGGCGCTG 
TTGATCAGAGGGTGGGCGCCGCAAGCCGTCATCCTGACTCACCATGCCGTCGGAGGAGTGATGACGCACT 
GCGGGTGGAACACGATCCTGGAGACGATCACGGTGGGGCTGCCGATGATCTCGTGGCCTCATTTTACGGA 
CCAGTTCTTTAACGAGAGGCTGGTCGTCCAAGTGCTGAAGGTTGGAGTTGCGATTGGAGTGAAGGTGCCA 
AATTACATTATTGGGATGGATGACATAGAGACGTTGGTGAAGAGGGAGCAGGTGGAGGAGCGGGTGAGGA 
CTCTCATGGGTGGAGGACCGGAAGGTGAAGAAAGGAGGAAGAGGGCCGCGGAGTTAGCGGAGATAGCGAA 
GGCCGCCATGGAAGAAGGGGGTTCGTCCCACTCCAATTTCACGCAACTGATCGAGCATTTCTCAGGGAGA 
AGATGCAAATGAAAGAAAATCGCGTGCACTTCTCTGTGGCATTCAGGTAGGCTCTGTTCTCTGAAATCGG 
ATGCACTTTTTTCCGCTTGTAATTTATTAATACTGCACTGTTCTTCAATATATATCAAAGCTCTAATGTT 
TGAAATCTTGAGAGAGAGAGAGTTTCACTTCAG 
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Appendix 3.2 Demethoxycurcumin monoglucoside mass spectrum  
 
Using curcumin glycoside LC-MS analysis method, to analyse demethoxycurcumin 
monoglucoside (Mr 500.48 g mol-1). MS: m/z 499.0 [M-H]-, m/z 337.0 [M-162]- DMC. 
 
Appendix 3.3 Bisdemethoxycurcumin monoglucoside mass spectrum  
 
Using curcumin glycoside LC-MS analysis method, to analyse bisdemethoxycurcumin 
monoglucoside (Mr 470.46 g mol-1). MS: m/z 468.9 [M-H]-, m/z 307.0 [M-162]- BDMC. 
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Appendix 3.4 Curcumin monoglucoside HPLC chromatogram and mass spectrum 
 
Using curcumin glycoside LC-MS analysis method, to analyse curcumin monoglucoside (Mr 
530.52 g mol-1). HPLC chromatogram (425 nm), RT 10.8, UV max 424 nm. MS: m/z 528.9 [M-
H]-, m/z 367.0 [M-162]- curcumin. 
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Appendix 3.5 Curcumin diglucoside HPLC chromatogram and mass spectrum  
 
Using curcumin glycoside LC-MS analysis method, to analyse curcumin diglucoside (Mr 691.61 
g mol-1). HPLC chromatogram (425 nm), RT 7.1, UV max 417 nm. MS: m/z 691.0 [M-H]-. 
 
 
 
177 
 
Abbreviations 
 
2PS 2-Pyrone synthase 
4CL 4-coumarate CoA ligase 
4CN 4-chloro-1-naphthol 
A Absorbance 
ACS Acridone synthase  
ADMET Absorption, distribution, metabolism, excretion, toxicity 
ADP Adenosine diphosphate 
Ala Schizsaccharomyces pombe, alanine tRNA 
AMP Adenosine monophosphate 
AP Alkaline phpsphatase 
APCI Atmospheric pressure chemical ionization 
ArREST Aromatic Rhizome EST 
At Arabidopsis thaliana 
ATP Adenosine triphosphate 
BAS benzalacetone synthase 
BCIP 5-bromo-4-chloro-3'-indoylphosphate 
BDMC Bisdemethoxycurcumin 
BLAST Basic Local Alignment Search Tool 
bp Base pairs 
C3H C-3 hydroxylase 
CaUGT2/3 Catharanthus roseus UGT2/3 
CCoAOMT Caffeoyl-CoA O-methyltransferase 
CDS Coding sequence 
CHS Chalcone synthase 
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Cl Curcuma longa 
CoA Coenzyme A 
COSTREL  Combinatorial supertransformation of transplastomic recipient 
lines 
CURS Curcuminoid synthase  
CUS Curcumin synthase 
CYC1 Cytochrome c, isoform 1 
DART Direct Analysis in Real Time 
DCS Diketide CoA synthase 
DMC Demethoxycurcumin 
ESI Electrospray ionisation 
EST Expressed sequence tags  
F2A 2A sequence from FMDV 
FDC1  Ferulic acid decarboxylase 1 
FMDV Foot and mouth disease virus 
HPLC High performance liquid chromatography 
HRP Horse-radish peroxidase 
kB Kilo base pairs 
kD Kilo daltons 
LC-MS Liquid chromatography- mass spectrometry 
Le Lithospermum erythrorhizon 
Leu1 Schizsaccharomyces pombe, leucine tRNA 
Leu2 Saccharomyces cerevisiae, leucine tRNA 
Mr Molecular mass 
NADPH Nicotinamide adenine dinucleotide phosphate 
NBT Nitro-blue tetrazolium 
NCBI National Center for Biotechnology Information 
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NF Nuclear factor 
Os Oryza sativa 
PAD1 Phenylacrylic acid decarboxylase 1 
PAL Phenylalanine ammonium lyase 
PCR Polymerase chain reaction 
PKS Polyketide synthase 
PSPG Plant secondary product glycosyltransferases  
Pv Prunella vulgaris 
PVPP Polyvinyl polypyrrolidone 
PXA1/2 Peroxisome ABC membrane transporter 1/2 
pYES2-4DC pYES2-4CL5-F2A-DCS-F2A-CURS1  
qPCR Quantitive PCR 
RACE Rapid amplification of cDNA ends 
RNAi RNA interference 
RPM Rotations per minute 
RT Retention time in minutes 
RT-PCR Reverse transcription PCR 
STAT3  Signal transducer and activator of transcription 3 
STS Stilbene synthase 
SUS1 Sucrose synthase 1 
TAL Tyrosine ammonium lyase 
TCP 2,4,5-trichlorophenol 
TEA Triethylamine 
TIC Total ion current  
UDP Uridine diphosphate  
UGT UDP-glycosyltransferase 
UPLC Ultra Performance Liquid Chromatography 
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UV Ultra violet  
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